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  ABSTRACT	  Daud	  Imhotep	  Cole:	  	  SHAPE	  analysis	  of	  telomerase	  RNA	  form	  and	  function	  (Under	  the	  direction	  of	  Michael	  Jarstfer)	  The	  conformation	  of	  telomerase	  changes	  as	  the	  multicomponent	  ribonucleoprotein	  complex	  is	  assembled	  and	  reverse	  transcription	  proceeds.	  	  The	  conformational	  changes	  associated	  with	  the	  RNA,	  DNA,	  and	  protein	  components	  of	  telomerase	  assembly	  and	  activity	  are	  poorly	  understood.	  	  Previously,	  even	  the	  secondary	  structure	  and	  base	  pairing	  configuration	  of	  individual	  nucleotides	  within	  the	  telomerase	  RNA	  subunit	  were	  not	  accurately	  identified.	  	  To	  overcome	  this	  limitation,	  I	  have	  used	  a	  novel	  combination	  of	  results	  from	  several	  low-­‐resolution	  structural	  techniques	  to	  generate	  models	  of	  telomerase	  during	  assemblage	  and	  catalysis.	  	  I	  have	  combined	  secondary	  structural	  constraints	  determined	  by	  SHAPE	  and	  tertiary	  constraints	  generated	  from	  reported	  FRET	  experiments	  of	  telomerase	  RNA	  with	  homology	  modeling	  of	  the	  reverse	  transcriptase.	  	  This	  combination	  of	  low-­‐resolution	  structural	  data	  enabled	  observation	  of	  major	  telomerase	  RNA	  structural	  changes	  associated	  with	  binding	  an	  accessory	  protein,	  p65,	  and	  the	  catalytic	  reverse	  transcriptase.	  	  It	  appears	  that	  binding	  of	  p65	  does	  not	  change	  the	  secondary	  structure	  of	  telomerase	  RNA	  but	  it	  does	  increase	  the	  dynamism	  of	  key	  residues	  and	  this	  facilitates	  assembly	  into	  the	  active	  complex.	  	  The	  resulting	  models	  explain	  how	  the	  assemblage	  of	  the	  telomerase	  ribonucleoprotein	  allows	  this	  molecular	  machine	  to	  perform	  its	  function.	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Chapter	  I.	  	  Literature	  Review	  A.	   Telomeres	  in	  Medicine	  The	  DNA	  repair	  enzymes	  that	  fix	  double-­‐stranded	  breaks	  within	  chromosomes	  must	  not	  recognize	  chromosome	  ends	  as	  breaks,	  or	  unwanted	  nucleolytic	  degradation	  and	  chromosome-­‐end	  fusion	  can	  occur.	  	  	  Telomeres	  are	  repeating	  structures	  flanking	  repetitive	  nuclear	  DNA	  that	  help	  eukaryotes	  discern	  the	  ends	  of	  linear	  chromosomes	  from	  double-­‐stranded	  breaks.	  	  Telomeres	  were	  recognized	  as	  a	  fundamental	  aspect	  of	  cellular	  biology	  with	  the	  awarding	  of	  the	  2009	  Nobel	  Prize	  in	  Physiology	  or	  Medicine	  to	  Elizabeth	  Blackburn,	  Carol	  Greider,	  and	  Jack	  Szostak	  for	  the	  discovery	  of	  how	  chromosomes	  are	  protected	  by	  telomeres	  and	  the	  enzyme	  telomerase.	  	  The	  essential	  role	  telomeres	  play	  in	  the	  maintenance	  of	  genomic	  integrity	  and	  cellular	  ageing	  is	  supported	  by	  several	  observations.	  	  	  	  	  
1.	   Eukaryotic	  Cellular	  Division	  Faces	  the	  End-­‐replication	  Problem	  	   The	  earliest	  functional	  description	  of	  telomeres	  was	  by	  geneticist	  Barbara	  McClintock	  when	  she	  observed	  in	  1931	  that	  chromosome	  ends	  never	  attached	  to	  one	  another	  after	  the	  chromosome	  was	  fragmented	  by	  x-­‐ray	  irradiation.1	  	  McClintock	  noted	  that	  there	  is	  a	  biochemical	  difference	  between	  the	  ends	  of	  broken	  chromosomes	  that	  translocated	  and	  fused	  with	  each	  other	  upon	  irradiation	  and	  the	  natural,	  inert	  ends	  of	  linear	  chromosomes	  found	  in	  eukaryotes	  like	  maize.	  	  In	  1938,	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Herman	  Muller	  termed	  these	  natural	  ends	  of	  linear	  chromosomes	  “telomere”	  to	  describe	  the	  lack	  of	  fusing	  between	  the	  natural	  ends	  of	  chromosomes	  when	  irradiated	  by	  x-­‐rays	  in	  Drosophila.	  	  Muller	  showed	  that	  the	  ends	  of	  the	  irradiated	  chromosomes,	  different	  from	  the	  other	  genomic	  regions,	  did	  not	  present	  alterations	  such	  as	  deletions	  or	  inversions,	  thanks	  to	  the	  presence	  of	  a	  protective	  cap.	  	  Muller	  named	  this	  cap	  the	  “terminal	  gene”	  and	  afterwards	  the	  “telomere”	  from	  the	  Greek	  terms	  -­‐telos	  for	  “end”	  and	  –meros	  for	  “part”.2	  	  	  	   Although	  McClintock	  and	  Muller	  monitored	  differences	  between	  natural	  linear	  chromosome	  ends	  and	  broken	  ends,	  they	  did	  not	  fully	  understand	  the	  molecular	  nature	  of	  the	  chromosome	  ends	  they	  observed,	  because	  several	  key	  pieces	  of	  information	  were	  missing.	  	  First,	  in	  1944,	  Avery,	  MacLeod,	  and	  McCarty	  identified	  DNA	  as	  the	  material	  that	  chromosomes	  are	  made	  of.3	  	  Next,	  the	  double	  helical	  structure	  of	  DNA	  was	  detected	  in	  1953.4	  	  	  	  And	  finally,	  Arthur	  Kornberg	  described	  the	  mechanism	  of	  DNA	  polymerase	  I	  activity	  in	  the	  1960s	  and	  70s	  to	  explain	  how	  DNA	  is	  replicated.5	  	  	  Although	  Kornberg	  had,	  in	  the	  1960s,	  observed	  that	  DNA	  polymerase	  replicated	  DNA,	  both	  Watson	  and	  Olovnikov	  predicted	  in	  the	  early	  1970s	  that	  DNA	  polymerase	  would	  be	  unable	  to	  faithfully	  replicate	  the	  very	  3’	  end	  of	  lagging	  strand	  DNA.	  	  Their	  prediction	  was	  based	  upon	  the	  astute	  observation	  that	  removing	  the	  RNA	  primer	  used	  by	  DNA	  polymerase	  should	  leave	  a	  region	  of	  unreplicated	  DNA	  at	  the	  end	  each	  time	  the	  cell	  divided.6,7	  The	  question	  of	  how	  the	  ends	  of	  chromosomes	  were	  completely	  replicated	  became	  known	  as	  the	  DNA	  end	  replication	  problem,	  which	  is	  described	  in	  Figure	  1.1.	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2.	   Telomeres	  Contribute	  to	  Cellular	  Mortality	  	   While	  the	  story	  of	  the	  fundamental	  role	  nucleic	  acid	  plays	  in	  cellular	  function	  was	  unfolding,	  a	  similar	  story	  was	  playing	  out	  in	  the	  field	  of	  replicative	  senescence.	  	  A	  paradigm	  shift	  in	  our	  understanding	  of	  the	  cellular	  life	  cycle	  occurred	  in	  the	  middle	  of	  the1960s	  when	  Leonard	  Hayflick	  found	  that	  fibroblasts	  isolated	  from	  an	  individual	  possess	  only	  a	  limited	  proliferative	  potential	  in	  vitro,	  meaning	  a	  lineage	  of	  cells	  could	  pass	  through	  only	  a	  predetermined	  number	  of	  growth	  and	  division	  cycles.8	  	  Prior	  to	  this	  discovery,	  researchers	  had	  assumed	  that	  individual	  cells	  from	  multicellular	  organisms	  could	  proliferate	  indefinitely.	  	  	  Cells	  that	  had	  reached	  the	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allowed	  limit	  of	  replication	  and	  remained	  active	  metabolically	  but	  that	  no	  longer	  divided	  were	  termed	  “senescent.”	  Hayflick’s	  seminal	  observations	  led	  to	  the	  hypothesis	  that	  cells	  possess	  a	  counting	  mechanism	  capable	  of	  both	  tracking	  the	  number	  of	  cellular	  divisions	  and	  halting	  any	  further	  division	  after	  a	  predetermined	  number	  of	  cell	  divisions	  (known	  as	  the	  “Hayflick	  limit”)	  was	  reached.	  	  The	  same	  Alexei	  Olovnikov	  who	  had	  predicted	  the	  end	  replication	  problem	  during	  the	  replication	  of	  linear	  chromosomes	  provided	  the	  link	  between	  the	  fields	  of	  replicative	  senescence	  and	  telomeres	  when	  he	  suggested	  that	  the	  gradual	  erosion	  of	  the	  ends	  of	  chromosomal	  DNA	  could	  cause	  the	  limited	  proliferative	  potential	  observed	  in	  Hayflick’s	  senescent	  fibroblasts.9	  	  	  	  In	  the	  mid-­‐1970s,	  Hayflick	  hypothesized	  that	  limited	  proliferative	  potential	  plays	  an	  important	  role	  in	  tumor	  suppression,	  after	  which	  researchers	  began	  to	  question	  whether	  the	  ends	  of	  linear	  chromosomes	  were	  important	  to	  tumor	  formation.10	  	  	  	  
3.	   Telomeres	  Overcome	  the	  End-­‐replication	  Problem	  Elizabeth	  Blackburn	  determined	  the	  DNA	  sequence	  of	  the	  ends	  of	  the	  ciliate	  
Tetrahymena	  thermophila	  chromosomes	  in	  the	  mid	  1970s	  and	  noted	  guanosine	  rich	  sequences	  at	  the	  3’	  end	  of	  the	  lagging	  strand.11	  	  Tetrahymena	  was	  chosen	  as	  a	  model	  organism	  because	  of	  its	  unique	  biology	  that	  confers	  an	  abundance	  of	  telomeres	  (Figure	  1.2).	  	  Blackburn	  went	  on	  to	  show	  that	  the	  same	  terminal,	  heterogeneous	  array	  of	  CCCCAA	  repeats	  on	  the	  leading	  strand,	  occurred	  at	  the	  ends	  of	  the	  other	  chromosomal	  DNA	  molecules	  of	  the	  somatic	  nucleus	  (the	  macronucleus)	  in	  Tetrahymena,	  but	  that	  these	  sequences	  were	  not	  present	  in	  the	  precursor	  DNAs	  in	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the	  germline	  nucleus	  (the	  micronucleus)	  from	  which	  the	  somatic	  nucleus	  is	  generated.12,13	  	  Once	  Blackburn	  found	  that	  new	  telomere	  sequences	  were	  added	  to	  the	  ends	  of	  the	  linear	  rDNA	  mini-­‐chromosomes	  by	  an	  unknown	  mechanism,	  the	  question	  then	  became,	  “How	  is	  the	  telomere	  repeat	  added”.14	  	  	  	  
	  By	  1983,	  there	  were	  two	  competing	  models	  for	  the	  molecular	  mechanism	  that	  generates	  telomere	  length	  heterogeneity	  and	  maintains	  the	  telomere	  length.	  	  In	  considering	  telomere	  formation	  in	  Tetrahymena,	  Blackburn	  wrote	  in	  1982:	  “the	  sequences	  common	  to	  the	  macronuclear	  DNA	  termini	  must	  be	  acquired	  by	  these	  subchromosomal	  segments	  during	  their	  formation.	  Two	  types	  of	  routes	  can	  be	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envisaged:	  Telomeric	  sequences	  are	  transposed	  or	  recombined	  onto	  the	  developing	  macronuclear	  DNA	  termini,	  or	  the	  simple,	  repeating	  telomeric	  sequences	  are	  synthesized	  de	  novo	  onto	  these	  termini	  by	  specific	  synthetic	  machinery.”14	  	  As	  Blackburn	  predicted,	  one	  model	  proposed	  that	  an	  unknown	  enzyme	  synthesized	  the	  ends,15	  	  while	  a	  second	  	  model	  proposed	  that	  the	  addition	  of	  telomere	  repeats	  occurred	  through	  a	  recombination-­‐mediated	  process.16,17	  The	  debate	  was	  settled	  in	  1985	  when	  Carol	  Greider	  provided	  direct	  experimental	  evidence	  of	  yeast	  telomere	  DNA	  synthesis18	  in	  Tetrahymena	  cellular	  extracts	  by	  a	  specific	  telomere	  terminal	  transferase.	  	  Observation	  of	  the	  requirement	  that	  the	  terminal	  transferase	  extend	  yeast	  telomeric	  DNA	  by	  one	  guanosine	  before	  the	  characteristic	  TTGGGG	  pattern	  endemic	  to	  Tetrahymena	  was	  repeatedly	  synthesized	  demonstrated	  compelling	  evidence	  of	  the	  terminal	  transferase’s	  activity.19	  	  The	  name	  of	  the	  transferase	  was	  shortened	  to	  “telomerase”	  in	  a	  subsequent	  paper.20	  	  	  Greider	  cloned	  and	  separated	  the	  RNAs	  that	  copurified	  with	  telomerase	  activity	  to	  eventually	  locate	  a	  nine-­‐nucleotide	  sequence	  within	  one	  of	  the	  purified	  RNAs	  that	  could	  serve	  as	  a	  template	  for	  reverse	  transcription.	  	  After	  accumulating	  evidence	  that	  oligonucleotides	  blocking	  the	  CAACCCCAA	  proposed	  template	  region	  also	  blocked	  telomerase	  activity,	  the	  implied	  reverse	  transcriptase	  mechanism	  of	  elongating	  telomeric	  DNA	  was	  proposed	  in	  1989.	  21	  	  The	  impact	  of	  our	  understanding	  of	  telomere	  function	  within	  eukaryotes	  was	  felt	  almost	  immediately,	  as	  Hayflick,	  in	  the	  previous	  decade,	  had	  hypothesized	  about	  the	  importance	  of	  the	  ends	  of	  linear	  chromosomes	  in	  tumor	  suppression.	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4.	   Telomerase	  Activity	  is	  a	  Potential	  Therapeutic	  Target	  for	  Cancer	  	   The	  discovery	  of	  the	  human	  telomerase	  ribonucleoprotein	  was	  announced	  in	  1989	  shortly	  after	  Greider	  proposed	  the	  mechanism	  by	  which	  Tetrahymena	  telomerase	  reverse	  transcribes	  an	  RNA	  template	  into	  a	  repeating	  sequence	  of	  DNA	  i.22	  In	  1990,	  Greider	  confirmed	  Olovnikov’s	  prediction	  that	  telomere	  shortening	  does	  indeed	  occur	  in	  cultured	  human	  cells	  due	  to	  a	  lack	  of	  telomerase	  expression	  and	  a	  consequent	  inability	  to	  maintain	  normal	  telomeres.23	  	  A	  critical	  link	  was	  made	  between	  cancer,	  the	  second	  leading	  cause	  of	  death	  in	  the	  United	  States,	  and	  telomeres	  when	  the	  authors	  showed	  that	  short	  telomeres	  can	  limit	  the	  ability	  of	  cells	  to	  divide.	  	  The	  link	  was	  made	  when	  the	  authors	  showed	  that	  inhibition	  of	  telomerase	  activity	  could	  potentially	  limit	  the	  growth	  of	  cancer	  cells.	  	  	   	  Later	  in	  1990,	  telomeres	  were	  shown	  to	  be	  shorter	  in	  cancer	  cells	  than	  in	  normal	  tissue	  by	  two	  independent	  groups.24,25	  Researchers	  could	  now	  speculate	  that	  for	  cancer	  cells	  to	  overcome	  the	  Hayflick	  limit	  to	  cellular	  division	  imposed	  by	  very	  short	  telomeres,	  telomerase	  reverse	  transcriptase	  activity	  would	  have	  to	  enable	  telomere	  maintenance.	  	  	  The	  subsequent	  demonstration	  that	  telomerase	  was	  active	  in	  many	  human	  tumor	  cells,	  but	  was	  undetected	  in	  most	  normal	  tissues,	  further	  strengthened	  the	  idea	  that	  telomerase	  inhibition	  might	  be	  an	  effective	  way	  to	  kill	  cancer	  cells.26	  	  Nearly	  a	  decade	  passed	  after	  Greider	  and	  Harley	  had	  initially	  proposed	  the	  link	  between	  cancer	  and	  telomeres	  before	  the	  ability	  to	  express	  telomerase	  (in	  those	  same	  cells	  tested	  at	  the	  beginning	  of	  the	  1990s)	  showed	  that	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telomerase	  maintained	  telomeres	  and	  did	  not	  allow	  them	  to	  shorten.	  	  Essentially,	  telomerase	  activity	  was	  shown	  to	  prevent	  senescence.27	  	  	  These	  initial	  findings	  stimulated	  the	  cancer	  community	  to	  begin	  to	  study	  telomerase	  activity	  in	  a	  variety	  of	  tumor	  types.	  	  Attention	  quickly	  led	  to	  a	  many	  hundred-­‐fold	  increase	  in	  the	  number	  of	  publications	  on	  telomerase	  at	  the	  turn	  of	  the	  21st	  century.28	  Work	  in	  the	  mid	  to	  late	  1990s	  that	  combined	  cultured	  human	  cells	  and	  a	  novel	  telomerase	  knockout	  mouse	  model	  confirmed	  that	  inhibition	  of	  telomerase	  expression	  could	  indeed	  limit	  cancer	  cell	  division	  and	  tumor	  production.29	  	  However,	  the	  details	  of	  the	  pathways	  that	  determine	  whether	  telomerase	  inhibition	  will	  be	  effective	  in	  fighting	  particular	  types	  of	  cancer	  have	  still	  not	  been	  fully	  worked	  out.	  	  	  It	  was	  observed	  that	  the	  loss	  of	  telomere	  function	  in	  some	  situations	  may	  lead	  to	  chromosome	  rearrangements	  that	  can	  surprisingly	  fuel	  tumor	  progression	  instead	  of	  arresting	  it.30	  Even	  though	  research	  into	  telomerase’s	  role	  in	  tumorigenesis	  continues	  to	  be	  robust,	  the	  plethora	  of	  biochemical	  information	  produced	  by	  the	  cancer	  community	  began	  to	  generate	  unforeseen	  links	  between	  telomeres	  and	  human	  disease.	  	  	  
5.	   Short	  Telomeres	  Have	  a	  Role	  in	  Genetic	  Diseases	  	   Telomeres	  have	  been	  pursued	  as	  a	  target	  in	  cancer	  treatment	  ever	  since	  telomerase	  activity	  was	  found	  to	  be	  upregulated	  in	  most	  cancers.	  31	  As	  experiments	  began	  to	  be	  aimed	  at	  understanding	  the	  mechanisms	  that	  limit	  telomere	  elongation	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telomerase	  activity	  is	  tightly	  regulated	  in	  mammals.	  	  After	  initially	  focusing	  on	  fundamental	  cellular	  mechanisms	  in	  simple	  model	  organisms,	  human	  genetic	  studies	  in	  the	  first	  decade	  of	  the	  21st	  century	  established	  a	  clear	  role	  for	  telomere	  dysfunction	  in	  diverse	  degenerative	  disease	  states.	  	  One	  key	  biochemical	  observation	  in	  the	  early	  2000s	  was	  that	  human	  telomerase	  RNA	  is	  an	  RNA	  polymerase	  II	  transcript,	  whereas	  ciliate	  telomerase	  RNA	  is	  transcribed	  by	  RNA	  polymerase	  III.32	  	  Like	  other	  small	  nucleolar	  RNAs	  (snoRNAs)	  that	  are	  Pol	  II	  transcripts,	  human	  telomerase	  RNA	  contains	  a	  consensus	  H	  box	  sequence	  (5’	  –	  ANANNA	  –	  3’)	  and	  an	  ACA	  trinucleotide	  located	  three	  nucleotides	  upstream	  of	  the	  mature	  3’	  end.	  	  The	  box	  H/ACA	  motif	  within	  telomerase	  RNA	  serves	  as	  a	  pseudouridylation	  modification	  site	  by	  a	  group	  of	  four	  small	  nucleolar	  ribonucleoproteins.	  (snoRNPs).	  	  	  Specifically,	  the	  dyskerin	  snoRNP	  is	  as	  a	  pseudouridine	  synthase	  that	  aids	  in	  the	  post-­‐transcriptional	  maturation	  of	  telomerase	  RNA,	  and	  as	  a	  result,	  the	  entire	  telomerase	  ribonucleoprotein.33	  Alterations	  in	  dyskerin	  were	  shown	  to	  reduce	  telomerase	  RNA	  concentration	  and	  shorten	  telomeres.34,35	  	  Later,	  mutations	  in	  three	  of	  the	  four	  mammalian	  snoRNPs	  were	  shown	  to	  lead	  to	  dyskeratosis	  congenita,	  a	  rare	  congenital	  disorder	  characterized	  by	  disruptions	  in	  the	  integumentary	  organ	  system,	  such	  as	  abnormal	  skin	  and	  bone	  marrow	  failure.36-­‐38	  Though	  the	  exact	  pathology	  of	  the	  disease	  is	  not	  yet	  fully	  understood,	  it	  was	  the	  initial	  association	  of	  dyskerin	  to	  telomeres	  that	  eventually	  led	  to	  most	  evidence	  pointing	  to	  dyskeratosis	  congenita	  being	  a	  disorder	  of	  poor	  telomere	  maintenance	  where	  one	  or	  more	  mutations	  affect	  the	  telomerase	  RNA	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component	  either	  directly	  or	  indirectly.	  	  Mutations	  in	  the	  human	  telomerase	  RNA	  cause	  the	  autosomal	  dominant	  form	  of	  the	  disease,	  while	  mutations	  in	  the	  gene	  encoding	  dyskerin	  result	  in	  the	  X	  chromosome	  linked	  form,	  and	  both	  display	  shortened	  telomeres.38,39	  	  	  	  	  It	  was	  not	  long	  before	  the	  progressive	  telomere	  shortening	  observed	  over	  many	  generations	  caused	  by	  mutations	  in	  both	  the	  RNA	  and	  protein	  components	  of	  the	  telomerase	  ribonucleoprotein	  was	  linked	  to	  limited	  tissue	  renewal	  capacity.40-­‐42	  Limited	  tissue	  renewal	  capacity	  due	  to	  telomere	  shortening	  manifests	  itself	  clinically	  as	  dyskeratosis	  congenita	  or	  as	  other	  syndromes,	  depending	  on	  the	  tissue	  most	  affected	  (Table	  1.1).	  	  The	  spectrum	  of	  telomere	  length	  disequilibrium	  diseases	  has	  been	  greatly	  extended	  and	  now	  encompasses	  prevalent	  disorders	  that	  have	  been	  poorly	  understood,	  such	  as	  aplastic	  anemia.43	  The	  most	  common	  manifestation	  of	  telomere-­‐mediated	  disease	  is	  idiopathic	  pulmonary	  fibrosis.	  44	  However,	  cumulative	  evidence	  is	  mounting	  to	  suggest	  that	  a	  group	  of	  disorders	  may	  be	  the	  spectrum	  of	  the	  same	  disease,	  as	  they	  share	  the	  molecular	  defect	  of	  short	  telomere	  length.	  	  Coats	  plus	  syndrome,	  Hoyeraal	  Hreidarsson	  syndrome,	  and	  Revesz	  syndrome	  have	  been	  proposed	  to	  be	  considered	  as	  a	  single	  syndrome	  spectrum	  because	  of	  their	  overlapping	  clinical	  features.45	  Interestingly,	  retinopathy,	  intracranial	  calcifications,	  and	  bone	  marrow	  abnormalities	  are	  also	  observed	  in	  all	  three	  disorders.	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  Biochemical	  observation	  of	  telomeres	  has	  yielded	  insights	  into	  the	  mechanisms	  behind	  several	  diseases	  and	  syndromes.	  	  Our	  limited	  understanding	  of	  telomere	  biology	  clearly	  suggests	  that	  proper	  telomere	  maintenance	  is	  critical	  for	  eukaryotic	  genetic	  stability.	  	  It	  is	  also	  clear	  that	  telomere	  structure	  is	  complex	  and	  dynamic.	  	  Next,	  we	  review	  the	  telomerase	  ribonucleoprotein	  structure.	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B.	   Telomerase	  ribonucleoproteins	  The	  evolution	  of	  linear	  chromosomes	  in	  the	  common	  ancestor	  of	  eukaryotes	  is	  remarkable	  because	  it	  occurred	  despite	  the	  many	  challenges	  posed	  by	  linear	  chromosomes.	  	  First,	  conventional	  primer-­‐requiring	  DNA	  polymerases	  cannot	  copy	  the	  end	  of	  a	  DNA	  template,	  leading	  to	  the	  progressive	  loss	  of	  end	  sequence	  with	  every	  round	  of	  DNA	  replication.	  Second,	  chromosome	  ends	  resemble	  double-­‐stranded	  DNA	  breaks	  whose	  recognition	  and	  repair	  can	  result	  in	  chromosome	  fusions.	  	  Finally,	  DNA	  ends	  are	  vulnerable	  to	  the	  destructive	  action	  of	  exonucleases.	  	  A	  solution	  to	  these	  challenges	  was	  to	  form	  the	  protective	  telomere	  structure.	  46	  Although	  telomere	  structure	  is	  conserved	  across	  almost	  all	  eukaryotes,	  telomere	  structure	  is	  dynamic,	  involves	  a	  number	  of	  different	  components,	  and	  changes	  as	  the	  cell	  progresses	  through	  its	  life	  cycle.47	  	  	  
	  1.	   Telomere	  Structure	  is	  Conserved	  Across	  Most	  Eukaryotes	  The	  first	  telomeric	  structure	  shown	  to	  exhibit	  conservation	  across	  most	  eukaryotic	  species	  examined	  to	  date	  is	  the	  guanosine-­‐rich	  strand	  of	  the	  telomere,	  which	  was	  revealed	  to	  be	  longer	  than	  the	  cytosine-­‐rich	  strand	  in	  the	  Oxytricha	  ciliate.48	  	  	  This	  observation	  implied	  a	  guanosine-­‐rich	  3’	  overhang	  at	  telomere	  termini.	  	  However,	  in	  vivo	  studies	  later	  demonstrated	  that	  the	  3’	  overhang	  of	  telomeric	  DNA	  termini	  could	  invade	  the	  double-­‐stranded	  region	  of	  telomeres	  to	  form	  a	  telomere	  specific	  displacement	  loop	  (known	  as	  a	  t-­‐loop)	  that	  sequesters	  the	  single-­‐stranded	  end	  from	  damage.49	  	  Single-­‐	  and	  double-­‐stranded	  DNA-­‐binding	  proteins	  can	  alter	  the	  conformational	  dynamics	  of	  the	  repeating	  telomeric	  DNA	  sequence	  to	  assemble	  an	  end-­‐capping	  structure	  (Figure	  1.3).50,51	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2.	  	   Telomerase	  Maintains	  Telomeres	  Telomere	  maintenance	  in	  most	  eukaryotes	  and	  cancer	  cells	  depends	  on	  new	  repeat	  synthesis	  of	  tandem	  GT-­‐rich	  repeats	  of	  DNA.	  	  Alternative	  mechanisms	  include	  recombination-­‐mediated	  or	  transposition-­‐mediated	  elongation,	  such	  as	  that	  observed	  in	  fruit	  flies.52,53	  Telomerase,	  the	  unique	  reverse	  transcriptase	  that	  maintains	  telomeric	  sequences	  in	  eukaryotes,28	  is	  a	  ribonucleoprotein	  enzyme	  with	  two	  catalytically	  essential	  subunits:	  the	  telomerase	  reverse	  transcriptase	  protein	  (TERT)	  and	  the	  telomerase	  RNA	  (TER).	  TERT	  copies	  a	  template	  within	  TER	  to	  synthesize	  the	  repeating	  telomeric	  sequence.	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In	  vitro,	  telomerase	  is	  capable	  of	  synthesizing	  stretches	  of	  DNA	  often	  exceeding	  100	  nucleotides	  at	  a	  time,	  despite	  the	  RNA	  template	  containing	  only	  one	  to	  two	  copies	  of	  the	  repeating	  telomeric	  sequence.54	  Several	  catalytic	  steps	  are	  required	  of	  a	  RNA-­‐dependent-­‐DNA	  polymerase:	  binding	  of	  primer	  and	  nucleotide	  substrates,	  conformational	  change(s)	  required	  for	  substrate	  discrimination	  and	  alignment,	  deoxynucleotide	  addition,	  product	  and	  template	  translocation,	  and	  eventual	  product	  release.	  	  The	  last	  three	  steps	  are	  described	  in	  Figure	  1.4	  and	  comprise	  the	  primer	  extension	  process.	  	  It	  is	  likely	  that	  the	  ability	  of	  telomerase	  to	  synthesize	  DNA	  processively	  depends	  on,	  but	  is	  not	  limited	  to,	  at	  least	  two	  sets	  of	  interactions:	  1)	  those	  between	  the	  reverse	  transcriptase	  subunit	  and	  the	  DNA	  substrate	  and	  (2)	  those	  between	  the	  reverse	  transcriptase	  subunit	  and	  the	  RNA	  template.	  	  How	  the	  physical	  work	  done	  by	  a	  single	  telomerase	  ribonucleoprotein	  is	  divided	  as	  labor	  among	  the	  RNA,	  DNA,	  and	  protein	  components	  of	  the	  telomerase	  RNP	  enzyme	  is	  an	  important	  question	  that	  requires	  a	  solution.	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3.	   Telomerase	  Reverse	  Transcriptase	  Structure	  is	  Conserved	  Across	  
Eukaryotes	  TERT	  is	  generally	  comprised	  of	  four	  domains:	  the	  reverse	  transcriptase	  domain	  (RT)	  containing	  the	  active	  site,	  the	  high-­‐affinity	  telomerase	  RNA-­‐binding	  domain	  (TRBD),	  the	  telomerase	  ‘‘essential’’	  N-­‐terminal	  (TEN)	  domain,	  and	  the	  C-­‐terminal	  extension	  (CTE).	  	  The	  TRBD	  enables	  specificity	  in	  the	  interaction	  between	  TERT	  and	  TER.55,56	  An	  intramolecular	  interaction	  brings	  together	  the	  TRBD	  and	  CTE	  of	  the	  physiologically	  folded	  TERT	  monomer	  to	  constrain	  the	  active	  site	  of	  the	  RT	  domain	  within	  a	  surface	  cavity	  of	  the	  ring-­‐like	  reverse	  transcriptase.57-­‐60	  The	  active	  site	  is	  in	  the	  RT	  domain	  where	  aspartic	  acid	  residues	  coordinate	  the	  magnesium	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ions	  necessary	  for	  catalysis	  of	  deoxynucleotide	  triphosphate	  (dNTP)	  addition.	  	  	  The	  active	  site	  is	  formed	  using	  motifs	  conserved	  across	  all	  reverse	  transcriptases,	  including	  the	  closely	  related	  retrotransposons.61,62	  The	  RT	  domain	  also	  positions	  the	  template	  and	  aligns	  the	  substrate	  3’	  end.63,64	  The	  interaction	  between	  the	  TEN	  and	  the	  RT	  domains	  simultaneously	  alters	  conformational	  equilibriums	  of	  both	  the	  single-­‐stranded	  telomeric	  DNA	  substrate	  and	  the	  nascent	  single-­‐stranded	  product.65	  The	  altering	  traps	  the	  old	  and	  new	  DNA	  strands	  in	  states	  that	  convert	  telomerases	  only	  capable	  of	  single-­‐repeat	  synthesis	  into	  highly	  processive	  enzymes.60	  	  	  The	  CTE	  may	  enhance	  nucleic	  acid	  association	  and/or	  otherwise	  contribute	  to	  RT	  domain	  function	  by	  promoting	  telomerase	  processivity	  and	  regulating	  telomerase	  localization,	  but	  does	  not	  appear	  to	  be	  essential	  to	  catalytic	  function.66,67	  	  
	  4.	   Telomerase	  RNA	  Structures	  Display	  More	  Structural	  Variety	  
Than	  TERT	  Structures	  Sequences	  and	  sizes	  of	  telomerase	  RNAs	  range	  from	  about	  150	  nucleotides	  in	  ciliates	  to	  more	  than	  1200	  nucleotides	  in	  yeast.	  	  Even	  so,	  functional	  assays	  suggest	  that	  four	  TER	  elements	  may	  be	  considered	  functionally	  homologous	  in	  ciliates,	  yeast,	  and	  vertebrate	  TERs,	  despite	  the	  disparities	  in	  sequence	  and	  size	  across	  eukaryotes.68-­‐72	  Figure	  1.5	  illustrates	  the	  disparities	  in	  telomerase	  RNA	  sequence	  and	  size	  across	  eukaryotes	  by	  showing	  specific	  base	  pairs	  as	  schematic	  representations.	  	  The	  four	  functionally	  homologous	  TER	  elements	  shared	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throughout	  eukaryotes	  are	  maintained	  in	  each	  of	  the	  three	  telomerase	  RNAs	  represented	  in	  Figure	  1.5.	  	  
	  The	  3’	  region	  of	  the	  template	  domain	  helps	  align	  the	  telomeric	  DNA	  substrate	  in	  the	  TERT	  active	  site	  while	  the	  5’	  portion	  is	  copied.	  	  The	  length	  of	  the	  single-­‐stranded	  template	  is	  typically	  about	  1.5	  repeats	  of	  the	  telomeric	  DNA	  sequence,	  except	  in	  yeasts	  with	  especially	  long	  and/or	  degenerate	  telomeric	  repeat	  sequences.73	  	  Usually,	  there	  is	  a	  hairpin	  structure	  immediately	  5’	  of	  the	  template	  to	  provide	  a	  template	  boundary	  element	  (TBE)	  that	  prevents	  copying	  TER	  sequences	  that	  are	  not	  in	  the	  template.74-­‐76	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A	  structurally	  conserved,	  triple-­‐helix	  stabilized	  pseudoknot	  is	  also	  adjacent	  to	  the	  template	  domain.	  	  A	  specific	  function	  for	  the	  pseudoknot	  domain	  has	  not	  yet	  been	  determined,	  although	  the	  conservation	  of	  the	  structure	  across	  eukaryotes	  is	  assumed	  to	  be	  important	  for	  global	  TER	  folding.	  	  One	  plausible	  model	  is	  that	  the	  pseudoknot	  aids	  in	  positioning	  the	  template	  relative	  to	  the	  active	  site	  and	  other	  TER	  and	  TERT	  domains.46	  In	  any	  event,	  the	  pseudoknot	  domain	  is	  typically	  flanked	  by	  long-­‐range	  base	  pairing	  at	  or	  near	  the	  5’	  end	  of	  TER.	  	  This	  pseudoknot	  flanking	  helix	  acts	  as	  the	  TBE	  in	  human	  TER,	  but	  not	  in	  ciliate	  or	  yeast	  TERs.	  	  	  There	  is	  at	  least	  one	  place	  other	  than	  the	  active	  site	  where	  TER	  directly	  interacts	  with	  TERT.	  	  The	  highly	  conserved	  stem	  terminus	  element	  (STE)	  stimulates	  telomerase	  activity	  at	  least	  in	  part	  through	  its	  direct	  interaction	  with	  the	  TRBD	  of	  the	  reverse	  transcriptase.56,77	  The	  STE	  is	  comprised	  of	  either	  a	  terminal	  hairpin,	  a	  hairpin	  from	  a	  three-­‐way	  junction,	  or	  a	  three-­‐way	  junction.	  	  	  Only	  TERT	  and	  TER	  are	  required	  to	  reconstitute	  telomerase	  catalytic	  activity	  
in	  vitro	  (although	  other	  rabbit	  reticulocyte	  lysate	  components	  like	  Heat	  Shock	  Protein	  90	  are	  required	  to	  properly	  assemble	  telomerase).78	  In	  vivo	  however,	  cellular	  telomerase	  holoenzymes	  are	  multiunit	  complexes	  that	  fractionate	  by	  gel	  filtration	  with	  an	  apparent	  mass	  of	  500	  kDa	  or	  more.69	  Apparently,	  telomerase	  holoenzyme	  proteins	  other	  than	  TERT	  direct	  and	  regulate	  physical	  interactions	  with	  telomeric	  chromatin	  and	  functional	  engagement	  with	  the	  chromosome	  3’	  end.	  	  	  The	  identities	  of	  telomerase	  holoenzyme	  proteins	  and	  their	  exact	  mechanisms	  of	  function	  differ	  between	  organisms,	  but	  some	  of	  their	  biochemical	  roles	  bear	  striking	  similarities.46	  	  Most	  telomerase	  holoenzyme	  studies	  have	  used	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telomerase	  isolated	  from	  Tetrahymena	  thermophila,	  Saccharomyces	  cerevisiae,	  Schizosaccharomyces	  pombe,	  mice,	  or	  cultured	  human	  cells.	  Less	  intensively	  studied,	  but	  still	  important	  additional	  model	  systems	  include	  other	  ciliates,	  yeasts,	  vertebrates,	  and	  plants.79-­‐83	  	  Figure	  1.6	  summarizes	  some	  of	  the	  structural	  and	  functional	  similarities	  between	  vertebrate	  and	  Tetrahymena	  thermophila	  telomerase	  ribonucleoprotein	  complexes.	  	  This	  thesis	  focuses	  on	  the	  study	  of	  
Tetrahymena	  thermophila	  telomerase,	  which	  is	  a	  valuable	  model	  system	  to	  study	  the	  mechanism	  and	  structure	  of	  all	  telomerases	  because	  of	  the	  abundance	  of	  telomeres	  and	  telomerase	  in	  organisms’	  macronucleus.	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5.	   Structure-­‐Function	  Relationships	  in	  Tetrahymena	  Telomerase	  
RNA	  	   The	  model	  laboratory	  ciliate	  possesses	  a	  159	  nucleotide	  TER	  that	  includes	  all	  four	  of	  the	  conserved	  motifs	  summarized	  in	  the	  previous	  section.	  	  The	  nine-­‐nucleotide	  template	  is	  flanked	  at	  its	  5’	  end	  by	  a	  TBE	  and	  at	  its	  3’	  end	  by	  a	  pseudoknot.	  	  In	  addition	  to	  defining	  the	  template	  boundary,	  the	  TBE	  and	  its	  adjacent	  single-­‐stranded	  regions	  also	  provide	  the	  high-­‐affinity	  TRBD-­‐binding	  site.74,84	  	  The	  pseudoknot	  sequence	  does	  not	  assemble	  into	  a	  pseudoknot	  structure	  in	  protein-­‐free,	  full-­‐length	  Tetrahymena	  TER,	  despite	  assembling	  into	  a	  stable	  pseudoknot	  conformation	  when	  separated	  from	  the	  rest	  of	  TER.	  	  It	  is	  only	  the	  assemblage	  with	  holoenzyme	  proteins	  p65	  and	  TERT	  that	  promotes	  proper	  folding	  of	  the	  pseudoknot.85,86	  The	  pseudoknot	  remains	  stably	  folded	  throughout	  the	  telomerase	  catalytic	  cycle	  and	  can	  form	  even	  when	  some	  of	  the	  base	  pairing	  is	  disrupted.85	  	  These	  observations,	  coupled	  with	  the	  fact	  that	  the	  only	  active	  telomerase	  complexes	  contain	  a	  properly	  folded	  pseudoknot,	  suggest	  that	  the	  pseudoknot	  topology,	  not	  the	  pseudoknot	  sequence,	  is	  critical	  for	  an	  active	  telomerase	  ribonucleoprotein.87,88	  	  The	  template,	  TBE,	  and	  the	  pseudoknot	  domains	  are	  enclosed	  by	  long-­‐range	  base	  pairing	  of	  stem	  I,	  while	  the	  STE	  is	  formed	  by	  terminal	  stem	  loop	  IV	  in	  Tetrahymena.	  	  UV-­‐dependent	  cross-­‐linking	  experiments	  support	  a	  direct	  contact	  of	  loop	  IV	  with	  an	  unknown	  domain	  in	  TERT,	  possibly	  the	  TRBD.89	  	  Studies	  in	  several	  laboratories	  have	  demonstrated	  that	  loop	  deletion	  or	  conserved	  loop	  nucleotide	  substitutions	  greatly	  inhibit	  the	  activity	  of	  the	  minimal	  recombinant	  telomerase	  
	   21	  
ribonucleoprotein	  reconstituted	  in	  rabbit	  reticulocyte	  lysate	  by	  TERT	  and	  TER.	  
56,77,88-­‐91	  Tetrahymena	  also	  has	  an	  additional	  motif	  immediately	  3’	  of	  the	  template	  termed	  the	  template	  recognition	  element	  (TRE).	  	  The	  TRE	  contributes	  to	  efficient	  copying	  through	  the	  nucleotides	  in	  the	  middle	  of	  the	  template	  positions	  as	  evidenced	  by	  the	  curiously	  longer	  than	  normal	  telomeres	  exhibited	  by	  Tetrahymena	  cells	  expressing	  a	  TER	  with	  TRE	  sequence	  substitutions.88	  	  The	  TRE	  may	  contribute	  to	  increased	  telomere	  length	  by	  adjusting	  the	  conformational	  dynamics	  of	  the	  template	  within	  the	  active	  site	  to	  alter	  the	  time	  the	  telomerase	  enzyme	  pauses	  during	  repeat	  synthesis	  equilibrium.	  TRE	  also	  improves	  the	  in	  vitro	  use	  of	  oligonucleotide	  templates	  physically	  separate	  from	  the	  rest	  of	  TER,	  strengthening	  the	  hypothesis	  that	  TRE	  alters	  the	  conformational	  states	  available	  to	  TER.92	  	  	  	  
6.	   p65	  Facilitates	  Telomerase	  Assemblage	  by	  Increasing	  Affinity	  of	  
tTERT	  to	  tTER	  	  The	  conformation	  of	  telomerase	  changes	  as	  the	  multicomponent	  ribonucleoprotein	  complex	  is	  assembled	  and	  as	  reverse	  transcription	  proceeds.	  	  Undoubtedly	  important	  to	  comprehending	  telomere	  biology	  is	  the	  understanding	  of	  the	  assembly	  mechanism	  of	  the	  telomerase	  ribonucleoprotein.	  Ciliate	  telomerase	  RNP	  assembly	  begins	  with	  TER	  transcription	  by	  RNA	  polymerase	  III.21	  	  Mature	  tTER	  retains	  the	  3’	  uridine-­‐rich	  sequence	  added	  to	  the	  primary	  transcript	  during	  Pol	  III	  transcription	  termination.	  	  The	  telomerase	  holoenzyme-­‐specific	  protein	  p65,	  required	  for	  tTERT	  and	  tTER	  accumulation	  in	  vivo,	  binds	  tTER	  at	  a	  site	  formed	  by	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the	  polyuridine	  tail,	  stem	  I,	  and	  stem	  IV.93,94	  The	  interaction	  of	  p65	  with	  TER	  stabilizes	  a	  kink	  in	  stem	  IV	  necessary	  for	  tight	  TERT	  binding	  and	  induces	  additional	  conformational	  changes	  in	  stem–loop	  IV	  and	  potentially	  elsewhere	  that	  promote	  TERT	  assembly	  and	  catalytic	  activity.95-­‐100	  	  	  p65	  is	  an	  RNA-­‐binding	  protein	  in	  the	  La-­‐family.	  	  La-­‐family	  proteins	  are	  involved	  in	  many	  aspects	  of	  RNA	  metabolism,	  including	  binding	  and	  protecting	  3’	  polyuridine	  tracts	  of	  newly	  RNA	  polymerase	  III-­‐transcribed	  RNA,	  processing	  5’	  and	  3’	  ends	  of	  pre-­‐tRNA	  precursors,	  and	  acting	  as	  an	  RNA	  chaperone.101,102	  p65	  appears	  to	  energetically	  stabilize	  telomerase	  RNP	  and	  help	  fold	  TER	  into	  a	  structure	  that	  is	  more	  favorable	  for	  TERT-­‐TER	  binding	  and	  enzyme	  function	  than	  in	  its	  absence.94,96,97,103	  	  These	  studies	  provide	  direct	  evidence	  of	  p65-­‐mediated	  conformational	  transitions	  within	  the	  telomerase	  RNP.	  	  Elongation	  of	  telomeric	  DNA	  by	  the	  enzyme	  telomerase	  plays	  an	  essential	  role	  in	  the	  cell	  life	  cycle,	  thus	  highlighting	  the	  attractiveness	  of	  telomerase	  reverse	  transcriptase	  activity	  as	  a	  therapeutic	  cancer	  target.	  	  While	  controlling	  telomerase	  enzymatic	  activity	  appears	  to	  be	  a	  promising	  strategy	  to	  inhibit	  tumorigenesis,	  structural	  studies	  to	  date	  do	  not	  adequately	  explain	  telomerase	  ribonucleoprotein	  complex	  function.	  The	  limited	  understanding	  of	  telomerase	  is	  due	  in	  part	  to	  the	  current	  inability	  to	  study	  the	  telomerase	  complex	  by	  NMR	  or	  X-­‐ray	  crystallography.	  Full-­‐length	  telomerase	  RNA	  (159	  nucleotides	  in	  T.	  thermophila)	  is	  not	  amenable	  to	  NMR	  due	  to	  structural	  fluctuations	  within	  the	  RNA	  and	  size	  limitations	  of	  the	  technique.	  	  Furthermore,	  the	  telomerase	  complex	  is	  not	  yet	  amenable	  to	  X-­‐ray	  crystallographic	  studies	  because	  the	  complex	  cannot	  be	  obtained	  in	  sufficient	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quantities	  at	  high	  purity.	  	  	  The	  ability	  to	  rationally	  target	  telomerase	  activity	  would	  be	  dramatically	  enhanced	  by	  a	  more	  detailed	  understanding	  of	  telomerase	  structure	  and	  function.	  	  However,	  the	  problem	  is	  that	  the	  structure-­‐function	  relationships	  of	  telomeres	  and	  their	  components	  are	  not	  fully	  understood.	  	  For	  example,	  the	  secondary	  structure	  of	  the	  RNA	  component	  of	  the	  telomerase	  ribonucleoprotein	  during	  each	  of	  its	  various	  stages	  of	  assembly	  and	  reverse	  transcriptase	  activity	  has	  not	  been	  determined.	  	  	  	  	  This	  dissertation	  uses	  telomerase	  derived	  from	  the	  well-­‐established	  model	  organism	  Tetrahymena	  thermophila	  to	  claim	  that	  binding	  of	  the	  accessory	  protein	  p65	  does	  not	  alter	  the	  secondary	  structure	  of	  ciliate	  telomerase	  RNA.	  	  Instead,	  p65	  increases	  the	  dynamics	  of	  the	  three	  dimensional	  conformation	  of	  the	  telomerase	  RNA	  nucleotides	  to	  facilitate	  assembly	  into	  the	  active	  telomerase	  complex.	  This	  claim	  is	  supported	  by	  evidence	  from	  several	  biochemical	  and	  biophysical	  experiments,	  including	  a	  novel	  combination	  of	  SHAPE	  structure-­‐probing	  chemistry	  and	  discrete	  molecular	  dynamics	  (DMD)	  modeling	  with	  mutations	  of	  the	  pseudoknot	  region	  of	  telomerase	  RNA	  and	  previously	  determined	  FRET-­‐derived	  tertiary	  constraints.	  	  Chapter	  II	  first	  identifies	  the	  secondary	  structural	  differences	  between	  protein	  free	  tTER	  and	  reverse	  transcriptase	  bound	  tTER.	  	  Chapter	  III	  then	  describes	  how	  the	  subtle	  differences	  among	  pseudoknot	  region	  SHAPE	  intensities	  in	  protein	  free	  tTER	  and	  p65	  bound	  tTER	  do	  not	  translate	  into	  secondary	  structural	  differences.	  	  Finally,	  Chapter	  IV	  focuses	  on	  how	  mutating	  nucleotides	  in	  the	  pseudoknot	  region	  of	  tTER	  allows	  the	  tTER	  structure	  in	  p65-­‐tTER	  and	  tTERT-­‐tTER	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to	  be	  differentiated	  by	  SHAPE.	  	  Our	  hypothesized	  model	  is	  described	  in	  Figure	  1.7	  as	  the	  progression	  from	  panels	  A	  to	  C	  to	  D	  rather	  than	  from	  A	  to	  B	  to	  D.	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Table 1.2 


















A1 CBD CBD CBD CBD CBD CBD CBD CBD CBD CBD 
U2 CBD CBD CBD CBD CBD CBD CBD CBD CBD CBD 
A3 CBD CBD CBD CBD CBD CBD CBD CBD CBD CBD 
C4 CBD CBD  CBD CBD CBD CBD CBD CBD CBD 
C5 CBD CBD  CBD CBD CBD CBD CBD CBD CBD 
C6 CBD CBD  CBD CBD CBD CBD CBD CBD CBD 
G7 CBD CBD  CBD CBD + CBD +++  CBD 
C8 CBD CBD  CBD CBD  CBD  + CBD 
U9 CBD CBD  CBD CBD  CBD   CBD 
U10 + CBD  CBD CBD  CBD   CBD 
A11 ++ CBD +++  CBD  CBD   CBD 
A12 ++ CBD +++  CBD  CBD   CBD 
U13 + CBD   CBD  CBD   CBD 
U14 ++ CBD   CBD  CBD   CBD 
C15 CBD CBD +++  CBD  CBD   CBD 
A16 + CBD +++  CBD  CBD   CBD 
U17 + CBD   CBD  CBD   CBD 
U18 - CBD   CBD  CBD   CBD 
C19 - CBD   CBD  CBD  + CBD 
A20 - CBD   CBD  CBD  ++ CBD 
G21 - CBD   CBD +++ CBD +++ +++ CBD 
A22 - CBD +  CBD  CBD + ++ CBD 
U23 - CBD   CBD  CBD +  CBD 
C24 - CBD   CBD  CBD + + CBD 
U25 - CBD   CBD  CBD  + CBD 
G26 + CBD   CBD ++ CBD   CBD 
U27 +++ CBD     CBD   CBD 
A28 +++ CBD +++ +++   CBD   CBD 
A29 ++ CBD ++ +   CBD   CBD 
U30 +++ CBD         
A31 + CBD         
G32 -    +++ ++   +  
A33 -          
A34 -  +      +  
C35 -       +   
U36 -          
G37 -     ++     
U38 ++ +++         
C39 ++ +++ +++       ++ 
A40 +++ +++ +        
U41 +++ +++         
U42 +++ +++         
C43 ++ +++ +++       ++ 
A44 +++  +++ +       
A45 +  + +       
C46 -          
C47 -          
C48 -       +   
C49 - ++ ++       ++ 

















A50 +++ ++ +++     +  ++ 
A51 + ++ +++ +       + 
A52 +++ ++ +++ +       
A53 + ++  +     +  
A54 - ++       +  
U55 - ++       +  
C56 - ++       ++  
U57 + ++       ++ ++ 
A58 + ++       + ++ 
G59 + ++   + +++     
U60 + ++         
G61 - ++   +++ +++     
C62 + ++ +++     +   
U63 - ++      + ++  
G64 - ++   +++ +++  + ++  
A65 ++ ++        ++ 
U66 ++ ++         
A67 +++ ++ + +     + ++ 
U68 +++ ++       +  
A69 +++ ++ +++ +++     ++  
A70 +++ ++ +++ +++     ++  
C71 -  +++      ++  
C72 ++  +++  +    ++  
U73 +    +    ++  
U74 + +       +  
C75 + +         
A76 +          
C77 -        ++  
C78 + +       ++  
A79 +++ + + +++     ++  
A80 +++ + +++ +       
U81 +++ +         
U82 + +         
A83 -        ++  
G84 -    + +  +   
G85 -    + +  + +  
U86 -       +   
U87 +         ++ 
C88 + +++ +++        
A89 ++ +++ +++ +++       
A90 ++ +++ +++ +++       
A91 ++ +++ ++ +++       
U92 ++ +++         
A93 ++  +++ +++       
A94 ++  + +++       
G95 +    + +++   + + 
U96 +++         + 
G97 -    + +++     
G98 -    + +++    + 
U99 + +         
A100 ++ + + +       
A101 ++ + +++ +       
U102 ++          
G103 -        +++  

















C104 -       + +++  
G105 -       + +++  
G106 -    +    +++  
G107 -    +++    +++ + 
A108 ++ +++ +++        
C109 CBD +++ +++        
A110 +++ +++ +++ +     +  
A111 +++  +++ +       
A112 ++  ++        
A113 +        +  
G114 -     +   +++  
A115 -         + 
C116 -          
U117 +++ ++         
A118 ++  +       + 
U119 +       +   
C120 -  +++        
G121 +++    +++ ++   +++  
A122 +++ ++ +++ +++       
C123 -         + 
A124 +         + 
U125 ++          
U126 ++          
U127 ++       +++ +  
G128 -       +++ +  
A129 -     CBD CBD +++ CBD CBD 
U130 -     CBD CBD + CBD CBD 
A131 +++     CBD CBD  CBD CBD 
C132 -  CBD   CBD CBD  CBD CBD 
A133 +++ +++ CBD +++  CBD CBD  CBD CBD 
C134 ++ +++ CBD   CBD CBD  CBD CBD 
U135 +++ +++ CBD   CBD CBD  CBD CBD 
A136 +++ +++ CBD +++  CBD CBD  CBD CBD 
U137 +++ +++ CBD   CBD CBD  CBD CBD 
U138 +++ +++ CBD   CBD CBD  CBD CBD 
U139 + + CBD   CBD CBD  CBD CBD 
A140 - CBD CBD   CBD CBD  CBD CBD 
U141 - CBD CBD   CBD CBD  CBD CBD 
C142 - CBD CBD   CBD CBD  CBD CBD 
A143 - CBD CBD   CBD CBD  CBD CBD 
A144 + CBD CBD   CBD CBD  CBD CBD 
U145 + CBD CBD   CBD CBD  CBD CBD 
G146 ++ CBD CBD  + CBD CBD  CBD CBD 
G147 + CBD CBD  + CBD CBD  CBD CBD 
A148 + CBD CBD   CBD CBD  CBD CBD 
U149 + CBD CBD   CBD CBD  CBD CBD 
G150 - CBD CBD  + CBD CBD  CBD CBD 
U151 - CBD CBD   CBD CBD + CBD CBD 
C152 - CBD CBD   CBD CBD +++ CBD CBD 
U153 + CBD CBD   CBD CBD + CBD CBD 
U154 +++ CBD CBD   CBD CBD +++ CBD CBD 
A155 +++ CBD CBD   CBD CBD  CBD CBD 
U156 +++ CBD CBD   CBD CBD  CBD CBD 
U157 +++ CBD CBD   CBD CBD  CBD CBD 

















U158 +++ CBD CBD   CBD CBD  CBD CBD 
U159 +++ CBD CBD   CBD CBD  CBD CBD 
 
Lack of a symbol is used for nucleotide positions that were unreactive to the 
reagent used.   
 
CBD is used for nucleotide positions whose result cannot be determined.   
 
- is used for nucleotide positions with no reactivity to the NMIA reagent. 
 
+ is used for nucleotide positions with low reactivity to the reagent used. 
 
++ is used for nucleotide positions with moderate reactivity to the reagent used. 
 




aRibonuclease ONE digestion of telomerase RNA in the absence of p65 and in 
the absence of the amino terminal half of TERT (amino acids 1-516) under 
several buffer conditions. Data is from the minus p65, minus TERT-N lane of 
Figure 4B in Berman et al104. 
 
bT7 transcripts of telomerase RNA treated with dimethyl sulfate for thirty minutes 
were subtracted from untreated RNA data from in Figure 3A of Zaug and Cech 
105. 
 
cDiethylpyrocarbonate modification of tTER folded at 30°C lanes from Figure 1 in 
Bhattacharyya and Blackburn 106. 
 
dRibonuclease T1 digestion of telomerase RNA in Tris folding buffer for 10 
minutes from Figure 2C of Bhattacharyya and Blackburn 106. 
 
eRibonuclease T1 digestion of telomerase RNA in rabbit reticulocyte lysate with 
no pET28a-TERT plasmid included from lane 5 of Figure 2A in Sperger and 
Cech 91. 
 
fRibonuclease T1 digestion of telomerase RNA in the absence of p65 and in the 
absence of the RNA binding domain of TERT (amino acids 216-516) under 
several buffer conditions.  Data is from the minus p65, minus RBD lane of Figure 
4C in Berman et al 99. 
 
gRibonuclease V1 digestion of telomerase RNA in Tris folding buffer for 30 
minutes from Figure 2A of Bhattacharyya and Blackburn 106. 
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hRibonuclease V1 digestion of telomerase RNA in rabbit reticulocyte lysate with 
no pET28a-TERT plasmid included from lane 8 of Figure 2A in Sperger and 
Cech 91. 
 
iRibonuclease V1 digestion of telomerase RNA in the absence of p65 and in the 
absence of the amino terminal half of TERT that contains the TEN and RBD 
domains.  Data is from the minus p65, minus TERT-N lane of Figure 4A in 
Berman et al 99. 
 
 	  	  	  
	   30	  
	  
Table 1.3 




NMIA RN ONEa DMSb RN T1c RN T1d RN V1e RN V1f 
A1 CBD CBD CBD CBD CBD CBD CBD 
U2 CBD CBD CBD CBD CBD CBD CBD 
A3 CBD CBD CBD CBD CBD CBD CBD 
C4 CBD CBD  CBD CBD CBD CBD 
C5 CBD CBD  CBD CBD CBD CBD 
C6 CBD CBD  CBD CBD CBD CBD 
G7 CBD CBD   CBD  CBD 
C8 CBD CBD  + CBD  CBD 
U9 CBD CBD   CBD  CBD 
U10 ++ CBD   CBD  CBD 
A11 ++ CBD +  CBD  CBD 
A12 ++ CBD +  CBD  CBD 
U13 ++ CBD   CBD  CBD 
U14 ++ CBD   CBD  CBD 
C15 - CBD   CBD  CBD 
A16 - CBD   CBD  CBD 
U17 - CBD   CBD  CBD 
U18 - CBD   CBD  CBD 
C19 - CBD   CBD + CBD 
A20 - CBD   CBD ++ CBD 
G21 - CBD  + CBD +++ CBD 
A22 - CBD +  CBD ++ CBD 
U23 - CBD   CBD ++ CBD 
C24 - CBD   CBD ++ CBD 
U25 - CBD   CBD ++ CBD 
G26 - CBD  ++ CBD  CBD 
U27 ++ CBD   CBD  CBD 
A28 +++ CBD +  CBD  CBD 
A29 + CBD   CBD  CBD 
U30 +++ CBD      
A31 - CBD      
G32 -   + +   
A33 -       
A34 -      + 
C35 -     + + 
U36 -      + 
G37 -   + + +  
U38 - ++      
C39 + ++     ++ 
A40 +++ ++ +     
U41 +++ ++      
U42 +++ ++     +++ 
C43 CBD ++ +++    ++ 
A44 ++  +++     
A45 +  +++     
C46 -  +++    + 
C47 -  +++    ++ 
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tTER 
position 
NMIA RN ONEa DMSb RN T1c RN T1d RN V1e RN V1f 
C48 -  +++   + ++ 
C49 - ++ +++   ++ ++ 
A50 +++ ++ +++   ++ ++ 
A51 + ++ +++   ++ + 
A52 ++ ++ +++   +  
A53 ++ ++ +++     
A54 ++ ++ +     
U55 ++ ++    + ++ 
C56 + ++ +   ++ ++ 
U57 ++ ++    ++ ++ 
A58 +++ ++ +   + + 
G59 +++ ++  +++ +  + 
U60 +++ ++     + 
G61 ++ ++  +++ +  ++ 
C62 + ++     ++ 
U63 ++ ++    ++ ++ 
G64 ++ ++  +++ + ++  
A65 +++ ++ +    + 
U66 CBD ++ ++     
A67 +++ ++ ++   + + 
U68 +++ ++    +  
A69 ++ ++    ++  
A70 + ++    ++  
C71 -     ++  
C72 -     ++  
U73 -     ++  
U74 + +    +  
C75 + +      
A76 +     +  
C77 -     +  
C78 - +    +  
A79 ++ +    +  
A80 ++ +    +  
U81 ++ +     + 
U82 + +     + 
A83 -    +  +++ 
G84 -   + + ++  
G85 -   +  +++  
U86 +      ++ 
U87 ++       
C88 CBD +++      
A89 ++ +++      
A90 + +++      
A91 ++ +++      
U92 ++ +++      
A93 ++       
A94 ++       
G95 +   + + + + 
U96 ++      + 
G97 -   + +   
G98 -   + +  + 
U99 + +      
A100 +++ + ++     
A101 CBD + +     
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tTER 
position 
NMIA RN ONEa DMSb RN T1c RN T1d RN V1e RN V1f 
U102 +++       
G103 -      ++ 
C104 -     +++ ++ 
G105 -     +++ + 
G106 -     ++  
G107 -      + 
A108 CBD  ++     
C109 CBD +++ ++     
A110 +++ +++ ++   +  
A111 +++  ++     
A112 +  +     
A113 -     +  
G114 -   + + +  
A115 -     + + 
C116 -     +  
U117 ++ ++    +  
A118 -     + + 
U119 CBD     +  
C120 -     +  
G121 +++   ++ +   
A122 +++ ++      
C123 -      + 
A124 +      + 
U125 CBD       
U126 +       
U127 ++     +  
G128 CBD     +  
A129 -   CBD  CBD  
U130 -   CBD  CBD  
A131 +   CBD  CBD  
C132 -  CBD CBD  CBD  
A133 ++ +++ CBD CBD  CBD  
C134 + ++ CBD CBD  CBD  
U135 ++ ++ CBD CBD  CBD  
A136 +++ ++ CBD CBD  CBD  
U137 +++ +++ CBD CBD  CBD  
U138 +++ +++ CBD CBD  CBD  
U139 - + CBD CBD  CBD  
A140 - CBD CBD CBD  CBD  
U141 - CBD CBD CBD  CBD  
C142 - CBD CBD CBD  CBD  
A143 - CBD CBD CBD  CBD  
A144 - CBD CBD CBD  CBD  
U145 CBD CBD CBD CBD  CBD  
G146 CBD CBD CBD CBD  CBD  
G147 - CBD CBD CBD CBD CBD CBD 
A148 - CBD CBD CBD CBD CBD CBD 
U149 - CBD CBD CBD CBD CBD CBD 
G150 CBD CBD CBD CBD CBD CBD CBD 
U151 CBD CBD CBD CBD CBD CBD CBD 
C152 - CBD CBD CBD CBD CBD CBD 
U153 + CBD CBD CBD CBD CBD CBD 
U154 CBD CBD CBD CBD CBD CBD CBD 
A155 +++ CBD CBD CBD CBD CBD CBD 
	   33	  
tTER 
position 
NMIA RN ONEa DMSb RN T1c RN T1d RN V1e RN V1f 
U156 +++ CBD CBD CBD CBD CBD CBD 
U157 +++ CBD CBD CBD CBD CBD CBD 
U158 +++ CBD CBD CBD CBD CBD CBD 
U159 +++ CBD CBD CBD CBD CBD CBD 
 
Lack of a symbol is used for nucleotide positions that were unreactive to the 
reagent used.   
CBD is used for nucleotide positions whose result cannot be determined.   
- is used for nucleotide positions with no reactivity to the NMIA reagent. 
+ is used for nucleotide positions with low reactivity to the reagent used. 
++ is used for nucleotide positions with moderate reactivity to the reagent used. 
+++ is used for nucleotide positions with high reactivity to the reagent used. 
 
 
aRibonuclease ONE digestion of telomerase RNA in the absence of p65 but in 
the presence of the amino terminal half of TERT (amino acids 1-516) under 
several buffer conditions. The amino terminal half of TERT contains the amino 
terminal and RNA binding domains but does not include the active site.  Data is 
from the minus p65, plus TERT-N lane of Figure 4B in Berman et al104. 
bDimethyl sulfate treatment of living Tetrahymena thermophila cells for two 
minutes were subtracted from cells where β-mercaptoethanol quench solution 
was added prior to dimethyl sulfate treatment.  The data from Figure 3A and 
isolation of the nuclear RNA can be found in Zaug and Cech 105. 
cRibonuclease T1 digestion of telomerase RNA assembled in telomerase that 
was translated in rabbit reticulocyte lysate using the pET28a-TERT plasmid from 
lane 4 of Figure 2A in Sperger and Cech 91. 
dRibonuclease T1 digestion of telomerase RNA in the absence of p65 but in the 
presence of the RNA binding domain of TERT (amino acids 216-516) under 
several buffer conditions.  Again, the reverse transcriptase active site is not 
included in the TERT portion tested.  Data is from the minus p65, plus RBD lane 
of Figure 4C in Berman et al 99. 
eRibonuclease V1 digestion of telomerase RNA assembled in telomerase that 
was translated in rabbit reticulocyte lysate using the pET28a-TERT plasmid from 
lane 8 of Figure 2A in Sperger and Cech 91. 
fRibonuclease V1 digestion of telomerase RNA in the absence of p65 but in the 
presence of the amino terminal half of TERT (amino acids 1-516) under several 
buffer conditions. Again, the amino terminal half of TERT contains the amino 
terminal and RNA binding domains but does not include the active site.  Data is 
from the minus p65, plus TERT-N lane of Figure 4B in Berman et al.104 
 
 
	   34	  
	  	  	  
	  
Chapter	  II.	  Modeling	  TERT	  induced	  telomerase	  ribonucleoprotein	  
conformational	  transitions	  1	  
	  
INTRODUCTION	   	  We	  sought	  to	  better	  understand	  the	  three-­‐dimensional	  structure	  and	  conformational	  changes	  associated	  with	  tTER	  function	  within	  the	  telomerase	  RNP.	  Therefore,	  we	  combined	  secondary	  structural	  constraints	  of	  tTER	  obtained	  using	  the	  high-­‐resolution	  footprinting	  technique	  selective	  2’-­‐hydroxyl	  acylation	  analyzed	  by	  primer	  extension	  (SHAPE),107	  distance	  constraints	  obtained	  from	  single-­‐molecule	  FRET	  data,95	  and	  biochemical	  inference	  gleaned	  from	  previous	  biochemical	  experiments	  to	  generate	  constraints.	  We	  then	  modeled	  the	  structure	  of	  tTER	  in	  the	  minimal	  complex	  using	  discrete	  molecular	  dynamics	  (DMD)	  that	  allows	  facile	  incorporation	  of	  experimental	  information.108	  In	  addition,	  we	  docked	  the	  resulting	  model	  with	  a	  homology	  model	  of	  tTERT	  based	  on	  the	  crystal	  structure	  of	  the	  T.	  Castaneum	  TERT59	  and	  the	  tTERT	  RNA	  binding	  domain76	  to	  generate	  a	  three-­‐dimensional	  model	  of	  tTER	  in	  the	  minimal	  telomerase	  complex.	  The	  results	  reveal	  conformational	  changes	  that	  occur	  during	  telomerase	  assembly	  and	  suggest	  a	  model	  for	  stem	  IV	  binding	  to	  tTERT.108	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This	  chapter	  originally	  appeared	  as	  an	  article	  in	  the	  Journal	  of	  the	  American	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MATERIALS	  AND	  METHODS	  
	  
1. Preparation	  of	  tTER	  and	  pFLAG-­‐tTERT.	  RNA	  was	  transcribed	  in	  vitro	  using	  Ampliscribe	  T7	  Transcription	  Kit	  (Epicenter	  Technologies).	  Templates	  were	  generated	  by	  PCR	  using	  the	  plasmid	  pTET-­‐telo,	  a	  pUC19-­‐based	  plasmid	  containing	  the	  tTER	  gene,	  a	  T7	  RNA	  polymerase	  promoter,	  and	  a	  self-­‐cleaving	  hammerhead	  ribozyme	  that	  processes	  the	  5′-­‐end	  of	  the	  RNA.	  Primers	  are	  listed	  in	  Table	  S4.	  PCR	  products	  were	  gel	  purified	  using	  Wizard	  PCR	  Prep	  Kits	  and	  RNAs	  gel	  purified	  and	  stored	  in	  TE	  (pH	  7.5)	  at	  −80	  °C.	  A	  sequence	  encoding	  the	  FLAG	  epitope	  was	  ligated	  into	  a	  pET-­‐28a	  plasmid	  containing	  tTERT	  cloned	  into	  the	  BamH1	  and	  Xho1	  sites.	  Oligonucleotides	  were	  gel	  purified	  and	  annealed	  before	  ligation	  into	  the	  Nco1	  and	  BamH1	  sites	  in	  pET-­‐28a-­‐tTERT.	  This	  removed	  the	  Nco1	  site	  and	  an	  Nde1	  site,	  allowing	  for	  easy	  screening	  of	  positive	  clones,	  and	  removed	  the	  N-­‐terminal	  His-­‐	  and	  T7-­‐tags.	  	  
2. Reconstitution	  and	  Affinity	  Purification	  of	  Tetrahymena	  Telomerase.	  Tetrahymena	  telomerase	  was	  reconstituted	  in	  rabbit	  reticulocyte	  lysates	  following	  standard	  protocols	  (Promega)	  and	  affinity	  purified	  using	  Anti-­‐FLAG	  M2	  Agarose	  beads	  (Sigma).	  Beads	  were	  pre-­‐washed	  with	  WB1	  (20	  mM	  Tris-­‐acetate	  pH	  7.5,	  100	  mM	  potassium	  glutamate,	  5	  mM	  MgCl2,	  1	  mM	  EDTA,	  0.1	  mM	  DTT,	  and	  10%	  glycerol)	  and	  blocked	  with	  blocking	  buffer	  (WB1	  with	  0.5	  mg/	  mL	  lysozyme,	  0.5	  mg/mL	  BSA,	  0.05	  mg/mL	  glycogen,	  and	  0.1	  mg/	  mL	  yeast	  RNA).	  400	  μL	  of	  crude	  telomerase	  complex	  in	  rabbit	  reticulocyte	  lysates	  was	  mixed	  with	  400	  μL	  of	  blocking	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buffer,	  and	  the	  mixture	  was	  centrifuged	  at	  15	  000g	  for	  10	  min	  at	  4	  °C	  to	  remove	  any	  precipitates.	  The	  supernatant	  was	  then	  added	  to	  the	  100	  μL	  of	  pre-­‐	  blocked	  Anti-­‐FLAG	  beads,	  and	  the	  resultant	  slurry	  was	  mixed	  on	  an	  orbital	  shaker	  for	  2	  h	  at	  4	  °C.	  The	  beads	  were	  washed	  four	  times	  with	  1400	  μL	  of	  WB1	  containing	  300	  mM	  potassium	  glutamate,	  two	  times	  with	  1400	  μL	  of	  TMG	  (10	  mM	  Tris-­‐Acetate	  pH	  8.0,	  1	  mM	  MgCl2,	  0.1	  mM	  DTT,	  and	  10%	  glycerol),	  and	  resuspended	  in	  100	  μL	  of	  TMG	  to	  afford	  a	  1:1	  slurry.	  The	  telomerase	  complexes	  were	  eluted	  in	  1.5	  mL	  of	  Protein	  LoBind	  Tube	  (Eppendorf).	  The	  bead	  slurry	  containing	  telomerase	  complexes	  was	  washed	  two	  times	  with	  1200	  μL	  of	  WB2	  (20	  mM	  Tris-­‐acetate	  pH	  7.5,	  5	  mM	  MgCl2,	  1	  mM	  EDTA,	  0.1	  mM	  DTT,	  and	  10%	  glycerol).	  Twelve	  microliters	  of	  10	  mg/mL	  BSA	  was	  added	  directly	  to	  the	  beads,	  followed	  by	  200	  μL	  of	  3xFLAG	  peptide	  solution	  (WB2	  with	  0.75	  mg/mL	  of	  3xFLAG	  peptide	  (Sigma)).	  This	  slurry	  was	  incubated	  on	  an	  orbital	  shaker	  for	  1	  h	  at	  4	  °C.	  The	  slurry	  was	  centrifuged	  at	  1500g	  for	  2	  min	  at	  4	  °C,	  and	  the	  supernatant	  containing	  soluble	  telomerase	  was	  gently	  removed	  and	  transferred	  to	  a	  fresh	  LoBind	  tube.	  Samples	  were	  flash	  frozen	  in	  a	  dry	  ice/ethanol	  bath	  and	  stored	  at	  −80	  °C.	  	  
3. SHAPE	  Analysis	  of	  tTER-­‐3-­‐Ext.	  	  A	  7	  μL	  solution	  of	  tTER-­‐3-­‐Ext	  (1	  pmol)	  in	  deionized	  water	  was	  snap	  annealed	  by	  heating	  at	  95	  °C	  for	  2	  min,	  then	  cooled	  on	  ice	  for	  5	  min	  before	  2	  μL	  of	  5×	  folding	  buffer	  (250	  mM	  Hepes	  pH	  8.0,	  10	  mM	  MgCl2)	  was	  added.	  The	  solution	  was	  then	  incubated	  at	  30	  °C	  for	  5	  min.	  The	  RNA	  was	  then	  treated	  with	  1	  μL	  of	  NMIA	  (100	  mM	  in	  anhydrous	  DMSO)	  or	  1	  μL	  of	  anhydrous	  DMSO	  as	  a	  control,	  incubated	  at	  30	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°C	  for	  90	  min,	  precipitated	  with	  ethanol	  in	  the	  presence	  of	  0.2	  M	  NaCl	  and	  200	  μg/mL	  glycogen,	  washed	  once	  with	  70%	  ethanol,	  speed	  vacuumed	  until	  dry,	  and	  reconstituted	  in	  5	  μL	  of	  pH	  8.0	  TE	  buffer.	  	  Sites	  of	  modification	  were	  mapped	  by	  reverse	  transcription	  using	  two	  separate	  5′-­‐[32P]-­‐labeled	  primers:	  con-­‐RT	  that	  binds	  the	  primer	  binding	  site	  in	  the	  SHAPE	  cassette,	  and	  C103	  that	  binds	  to	  tTER	  to	  begin	  reverse	  transcription	  at	  C103.	  cDNA	  extension	  products	  were	  separated	  by	  electrophoresis	  and	  compared	  to	  dideoxythymidine	  sequencing	  ladders,	  visualized	  by	  phosphorimaging	  using	  ImageQuant	  5.1,	  and	  quantified	  using	  SAFA.	  For	  greater	  detailed	  description,	  see	  the	  Supporting	  Information.	  	  
4. SHAPE	  Analysis	  of	  tTER	  in	  Complex	  with	  tTERT.	  	  Affinity	  purified	  telomerase	  (25	  μL,	  ∼125	  fmol)	  was	  incubated	  in	  folding	  buffer	  (50	  mM	  Hepes	  pH	  8.0,	  2	  mM	  MgCl2)	  (50	  μL	  total	  reaction	  volume)	  at	  30	  °C	  for	  2	  min.	  NMIA	  or	  DMSO	  was	  added	  to	  separate	  sample	  at	  a	  final	  concentration	  of	  10	  mM	  NMIA	  or	  10%	  DMSO	  and	  incubated	  for	  17.5	  min	  (1	  half-­‐life).	  The	  reaction	  was	  immediately	  quenched	  by	  the	  addition	  of	  dithiothreitol	  (5	  mM).	  The	  solution	  was	  proteolyzed	  for	  10	  min	  at	  37	  °C	  with	  160	  μg/mL	  of	  proteinase	  K	  in	  1X	  TES	  (40	  mM	  Tris	  pH	  8.0,	  4	  mM	  EDTA,	  and	  0.15%	  SDS),	  phenol/	  chloroform	  extracted,	  precipitated	  with	  ethanol,	  and	  reconstituted	  in	  5	  μL	  of	  RNase-­‐Free	  TE	  pH	  8.0	  (Ambion).	  Sites	  of	  modification	  were	  mapped	  by	  reverse	  transcription	  as	  described	  above.	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5. Structural	  Models	  of	  tTER.	  	  Secondary	  structures	  were	  modeled	  with	  SHAPE	  constraints	  using	  RNAstructure.	  Because	  RNAstructure	  could	  not	  predict	  the	  tTER	  pseudoknot,	  we	  compared	  the	  SHAPE	  reactivities	  to	  tTER	  pseudoknots	  predicted	  using	  conserved	  sequence	  analysis	  and	  heuristic	  folding	  prediction	  methods.	  	  
6. Model	  of	  tTERT.	  	  The	  tTERT	  model	  was	  generated	  with	  the	  crystal	  structure	  of	  the	  tTERT	  residues	  (the	  RNA	  binding	  domain,	  PDB	  2R4G)	  and	  homology	  modeling	  of	  the	  remaining	  tTERT	  RT	  domain	  using	  the	  T.	  castaneum	  TERT	  crystal	  structure	  with	  model	  of	  the	  primer-­‐template	  duplex	  bound	  to	  the	  active	  site	  (PDB	  3KYL).	  The	  N-­‐	  terminal	  domain	  of	  tTERT	  was	  not	  included.	  A	  large	  domain,	  D624−	  D688,	  in	  tTERT	  is	  absent	  in	  the	  T.	  castaneum	  sequence.	  This	  insertion	  was	  modeled	  using	  ab	  initio	  folding	  methods	  and	  included	  in	  the	  tTERT	  model.109	  PDB	  3KYL	  contains	  a	  RNA−DNA	  chimeric	  hairpin	  the	  mimics	  the	  template−primer	  duplex.	  Only	  the	  nucleotides	  representing	  the	  DNA	  primer	  were	  maintained	  in	  the	  tTERT	  model.	  	  
7. Discrete	  Molecular	  Dynamics	  Modeling	  of	  tTER	  Sequence	  information	  and	  base	  pairs	  established	  by	  SHAPE	  were	  subjected	  to	  one	  round	  of	  refinement	  by	  DMD108	  at	  (T)	  =	  0.3	  for	  100,000	  time	  units	  (tu),	  where	  T	  is	  the	  reduced	  temperature	  in	  units	  of	  kcal	  /	  (mol·kB).	  After	  base	  pair	  formation	  was	  visually	  confirmed,	  files	  were	  prepared	  for	  incorporation	  of	  potential	  energy	  functions	  describing	  distances	  between	  FRET	  fluorophores.	  We	  also	  modeled	  the	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base	  pairing	  between	  tTER	  and	  a	  nine-­‐nucleotide	  sequence	  complementary	  to	  the	  template,	  and	  a	  penalty	  for	  base	  pairing	  of	  nucleotides	  10−18.	  We	  estimated	  distances	  between	  four	  pairs	  of	  TER	  nucleotides	  using	  equation	  1	   FRET = !!!!!!!!          (1)  where	  R0	  is	  the	  Förster	  radius	  and	  r	  is	  the	  distance	  between	  FRET	  fluorophores.	  FRET	  values	  were	  obtained	  from	  published	  single	  molecule	  FRET	  efficiencies	  between	  four	  fluorophore-­‐labeled	  TER	  nucleotide	  pairs.95	  	  A	  Förster	  radius	  of	  50	  Å	  was	  used	  to	  estimate	  the	  distance	  between	  fluorophores	  in	  active	  telomerase	  observed	  at	  maximum	  FRET	  efficiency.	  	  Similarly,	  a	  Förster	  radius	  of	  60	  Å	  was	  used	  to	  estimate	  the	  distance	  between	  fluorophores	  in	  active	  telomerase	  observed	  at	  half-­‐maximal	  FRET	  efficiency.	  It	  is	  important	  to	  note	  that	  the	  four	  labeled	  uridines	  were	  in	  full-­‐length	  TER	  when	  the	  RNA	  was	  assembled	  in	  the	  telomerase	  complex.	  It	  is	  also	  important	  to	  note	  that	  the	  labeled	  RNAs	  were	  used	  by	  telomerase	  successfully	  as	  templates	  despite	  being	  labeled	  with	  bulky	  Cy3	  and	  Cy5	  adducts.	  We	  then	  used	  a	  potential	  function	  to	  restrict	  the	  distances	  between	  the	  four	  pairs	  of	  labeled	  TER	  uridines	  to	  within	  distances	  calculated	  from	  the	  FRET	  efficiencies	  (Figure	  S10).	  We	  introduced	  a	  nine-­‐nucleotide	  RNA	  sequence	  that	  was	  complementary	  to	  tTER	  template	  nucleotides	  43−51	  to	  mimic	  association	  of	  TER	  with	  its	  primer	  and	  to	  provide	  a	  steric	  block	  of	  the	  template	  from	  other	  tTER	  domains.	  The	  fifth	  nucleotide	  in	  the	  primer	  mimic	  was	  constrained	  to	  be	  less	  than	  10	  Å	  from	  C47.	  We	  also	  used	  a	  potential	  function	  to	  maintain	  the	  distance	  between	  nucleotides	  10−18	  and	  38−46	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to	  be	  at	  least	  10	  Å	  away	  from	  each	  other	  because	  nucleotides	  15−18	  are	  predicted	  to	  function	  as	  a	  protein-­‐binding	  site	  (see	  Figures	  S10	  and	  S11	  for	  the	  potential	  function	  and	  algorithm	  used).	  Once	  constraints	  were	  incorporated,	  the	  RNA	  was	  allowed	  to	  equilibrate	  at	  T	  =	  0.25	  for	  3	  ×	  104	  tu	  before	  confirming	  the	  primer	  mimic	  approached	  the	  template	  nucleotides.	  The	  RNA	  was	  cooled	  in	  two	  additional	  steps	  at	  T	  =	  0.15	  for	  104	  tu	  and	  T	  =	  0.15	  for	  105	  tu.	  One	  complete	  three-­‐dimensional	  refinement	  of	  the	  159	  nucleotide	  TER	  required	  <2	  h	  on	  a	  Linux	  computational	  node	  (3.2	  GHz	  Intel	  Xeon	  IBM	  BladeCenter	  node,	  Red	  Hat	  Linux	  v5,	  64-­‐bit	  OS).	  Distance-­‐based	  hierarchical	  clustering	  was	  performed	  without	  user	  intervention	  on	  4500	  predominant	  RNA	  conformations	  using	  OC	  software	  (available	  at	  http://www.compbio.dundee.ac.uk/downloads/	  oc).110	  	  Final	  conformations	  were	  divided	  into	  10	  clusters,	  subject	  to	  the	  requirement	  that	  structures	  within	  a	  cluster	  agree	  to	  better	  than	  6	  Å	  RMSD.	  From	  the	  10	  clusters,	  we	  focused	  on	  the	  most	  highly	  populated	  ensemble,	  which	  contained	  ∼65%	  of	  the	  total	  representative	  models.	  We	  focused	  our	  analysis	  on	  the	  most	  central	  structure	  in	  each	  of	  these	  final	  clusters	  because	  the	  Boltzmann	  distribution	  dictates	  that	  these	  clusters	  represent	  the	  lowest	  free	  energy	  state.	  DMD	  model	  verification	  by	  RMSD	  alignments	  was	  computed	  on	  the	  basis	  of	  superposition	  of	  backbone	  phosphate	  atoms	  at	  base	  paired	  positions	  when	  compared	  to	  stem	  II	  (PDB	  ID	  2FRL)	  and	  stem	  IV	  (PDB	  ID	  2FEY)	  NMR	  models.	  To	  model	  tTER	  bound	  to	  tTERT,	  we	  inserted	  the	  most	  populated	  tTER	  model	  from	  DMD	  simulations	  with	  the	  tTERT	  homology	  model	  described	  above.	  tTER	  was	  aligned	  with	  the	  tTERT	  active	  site	  by	  setting	  nucleotides	  51-­‐AAG-­‐49	  as	  base	  paired	  to	  the	  DNA	  primer.	  The	  molecular	  system	  then	  was	  relaxed	  with	  all-­‐atom	  DMD	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simulations,111	  where	  the	  protein	  and	  template	  are	  kept	  fixed,	  and	  the	  secondary	  structure	  and	  FRET-­‐based	  tertiary	  structure	  are	  maintained.	  The	  all-­‐atom	  relaxation	  simulations	  were	  performed	  at	  room	  temperature	  (300	  K).	  	  The	  lowest	  energy	  structure	  from	  the	  100	  ns	  simulations	  was	  used	  as	  the	  model	  structure	  of	  tTER	  bound	  to	  tTERT.	  	  
8. Data	  Analysis	  SHAPE	  intensities	  from	  SAFA	  quantified	  denaturing	  gels	  were	  scaled	  with	  a	  previously	  described	  model	  free	  box	  plot	  analysis.112	  	  Alternatively,	  we	  applied	  a	  2-­‐	  8%	  rule	  more	  appropriate	  for	  data	  sets	  smaller	  than	  300	  nucleotides	  where	  we	  discard	  the	  top	  2%	  of	  the	  most	  reactive	  peaks	  and	  divide	  by	  the	  average	  intensity	  of	  the	  next	  8%.113-­‐115	  SHAPE	  intensities	  from	  free	  in	  solution	  TER	  and	  TER	  in	  the	  presence	  of	  TERT	  were	  treated	  separately.	  The	  arithmetic	  mean	  of	  SHAPE	  intensities	  at	  each	  nucleotide	  position	  was	  calculated	  from	  data	  normalized	  with	  the	  box	  plot	  analysis	  and	  2-­‐8%	  rule.	  The	  sample	  variance	  𝑠2	  for	  each	  nucleotide	  position	  was	  calculated	  using	  equation	  2.	  	  Variances	  above	  0.01	  served	  as	  markers	  of	  nucleotide	  positions	  with	  highly	  variant	  SHAPE	  reactivities	  across	  testing	  dates.	  	    
𝑠! = !!!! !!!!!!!!!!         (2)    The  standard  deviation   𝑆𝐷   of  normalized  SHAPE  reactivities  for  each  nucleotide  position  was  calculated  using  equation  3.  Intensities  from  highly  variant  nucleotides  
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were  excluded  from  a  final  arithmetic  mean  calculation  of  all  nucleotide  positions  if  they  were  more  than  three  standard  deviations   𝑆𝐷   from  the  previously  calculated  mean.        
𝑆𝐷 = !!!! !!!!!!! !      (3)    The  arithmetic  mean  at  each  nucleotide  position  of  free  in  solution  SHAPE  intensities  was  calculated  from  both  the  box  plot  and  2-­‐8%  values  for  3  measurements  of  nucleotides  10-­‐88.    The  means  were  calculated  from  5  measurements  of  nucleotides  75-­‐159  for  each  nucleotide  position.      
9. Predicted	  Secondary	  Structure	  Models	  of	  tTER.	  	  Base	  pairing	  probabilities	  for	  base	  pairs	  in	  folded	  tTER	  were	  predicted	  with	  the	  partition	  program	  from	  RNAstructure	  5.3	  and	  the	  output	  was	  saved	  as	  binary	  files.116-­‐119	  	  We	  specified	  that	  the	  calculation	  take	  place	  at	  a	  temperature	  of	  303	  K.	  	  The	  SHAPE	  reactivities	  were	  incorporated	  in	  predictions	  as	  pseudo	  energy	  constraints	  using	  equation	  4	  for	  each	  base	  paired	  residue	  𝑖.120	  	  The	  slope	  parameter	  𝑚	  was	  varied	  from	  zero	  to	  five	  and	  the	  intercept	  parameter	  𝑏	  was	  varied	  from	  zero	  to	  negative	  three	  with	  no	  effect	  on	  predictions.	  	  We	  focused	  on	  the	  minimum	  free	  energy	  structure	  although	  a	  small	  number	  of	  similar	  structures	  were	  obtained	  because	  even	  if	  more	  accurate	  structures	  are	  predicted	  at	  higher	  folding	  free	  energies,	  there	  is	  no	  general	  way	  to	  identify	  these	  as	  improved	  structures.	  	  TER	  base	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pair	  models	  predicted	  by	  SHAPE	  and	  RNAstructure	  were	  compared	  to	  models	  developed	  by	  comparative	  sequence	  analysis,91,106	  and	  RNA	  structural	  probing	  experiments	  described	  in	  Appendices	  1.1	  and	  1.2	  before	  submission	  to	  DMD	  and	  were	  composed	  using	  the	  xrna	  software	  (http://rna.ucsc.edu/rnacenter/xrna/).	  	  	     ∆𝐺!"#$% = 𝑚 ∗ 𝑙𝑛 𝑆𝐻𝐴𝑃𝐸  𝑅𝑒𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖 + 1 + 𝑏                                                (4)    Base  pairing  probabilities  were  maximized  to  predict  the  most  accurate  structure  expected  using  the  MaxExpect  program.121    The  program  ProbKnott  was  used  in  an  attempt  to  predict  pseudoknots.122      Scorer  was  used  to  calculate  the  sensitivity  and  positive  predictive  value  (PPV)  quality  metrics  when  comparing  predictions  to  accepted  structures.118,123  Flexible  pairings  are  allowed  meaning  base  pairs  are  considered  to  be  correctly  predicted  when  one  of  the  two  indices  is  different  by  up  to  one  nucleotide.  This  better  accounts  for  RNA  dynamics  and  uncertainty  in  the  RNA  structure.  For  a  known  base  pair  a-­‐b,  all  of  the  following  predicted  pairs  are  considered  correct  with  flexible  pairings:    a   à   b  a   à   b  –  1  a   à   b  +  1  a  –  1     à   b  a  +  1   à   b  




1. A	  Recombinant	  Telomerase	  Complex	  for	  Chemical	  Probing	  
Experiments.	  	  	  Because	  accurate	  structural	  modeling	  requires	  robust	  experimental	  constraints,	  we	  generated	  quantifiable	  data	  reporting	  on	  individual	  tTER	  nucleotides	  using	  SHAPE	  chemistry.107	  SHAPE	  chemistry	  measures	  the	  reactivity	  of	  RNA	  2’-­‐hydroxyl	  groups	  with	  isatoic	  anhydride	  derivatives.	  Reactivity	  is	  primarily	  governed	  by	  nucleotide	  flexibility	  with	  more	  flexible	  nucleotides	  exhibiting	  greater	  reactivity.124	  Nucleotide	  acylation	  was	  mapped	  as	  reverse	  transcription	  stops.	  To	  maximize	  coverage	  of	  tTER	  in	  SHAPE	  experiments,	  we	  added	  a	  3’-­‐extension	  with	  a	  primer	  binding	  site	  for	  reverse	  transcription	  and	  a	  linker	  that	  separated	  the	  primer	  binding	  site	  from	  tTER	  to	  generate	  tTER-­‐3’-­‐Ext	  (Figure	  2.2).	  We	  confirmed	  that	  the	  extension	  allowed	  reconstitution	  of	  active	  telomerase	  and	  conducted	  SHAPE	  experiments	  on	  tTER-­‐3’-­‐Ext	  in	  the	  presence	  and	  absence	  of	  tTERT.	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2. In	  Vitro	  Transcribed	  Tetrahymena	  Telomerase	  RNA	  Forms	  an	  
Extended	  Stem	  III	  Instead	  of	  a	  Stem	  IIIa/IIIb	  Pseudoknot.	  	  	  We	  used	  N-­‐methylisatoic	  anhydride	  (NMIA)	  to	  generate	  the	  SHAPE	  profile	  of	  tTER-­‐3’-­‐Ext	  in	  the	  absence	  of	  tTERT	  (Figures	  2.3	  and	  S1).	  We	  quantified	  SHAPE	  reactivities	  for	  149	  of	  the	  159	  tTER	  nucleotides,	  and	  the	  data	  were	  used	  to	  constrain	  predictions	  using	  the	  program	  RNAstructure.112	  The	  secondary	  structure	  of	  tTER	  using	  SHAPE	  data	  contained	  all	  but	  four	  of	  the	  base	  pairs	  predicted	  by	  RNAstructure	  using	  only	  the	  primary	  sequence.112	  Both	  the	  SHAPE	  constrained	  and	  the	  unconstrained	  models	  of	  protein-­‐	  free	  tTER	  contained	  many	  features	  present	  in	  the	  accepted	  secondary	  structure	  model	  of	  tTER,	  including	  stems	  I,	  II,	  and	  IV.	  The	  most	  prominent	  difference	  was	  in	  the	  template	  and	  pseudoknot	  domains,	  which	  included	  a	  large	  stem	  III	  that	  encompassed	  several	  template	  residues	  instead	  of	  the	  stem	  IIIa/	  IIIb	  pseudoknot	  (Figure	  2.3).	  To	  ensure	  that	  the	  3’-­‐extension	  did	  not	  perturb	  the	  native	  tTER	  structure	  leading	  to	  the	  formation	  of	  the	  large	  stem	  III	  confirmation,	  we	  compared	  both	  the	  SHAPE	  and	  the	  RNase	  V1	  profiles	  of	  wild-­‐type	  tTER	  to	  tTER-­‐	  3’-­‐Ext.	  We	  detected	  no	  difference	  in	  the	  footprinting	  profiles	  of	  the	  RNAs,	  and	  interpretation	  of	  the	  SHAPE	  data	  by	  RNAstructure	  generated	  the	  same	  secondary	  structures	  for	  tTER	  and	  tTER-­‐3’-­‐Ext	  (Figure	  S2	  and	  data	  not	  shown).	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  We	  compared	  the	  SHAPE	  data	  to	  reported	  NMR	  structures	  and	  found	  excellent	  agreement	  (Figure	  S3).75,98,125	  The	  SHAPE	  profile	  for	  stem	  IV	  correlates	  with	  the	  generalized	  order	  parameter	  S2,	  consistent	  with	  previously	  reported	  data	  for	  a	  small	  stem	  IV	  model126	  and	  is	  consistent	  with	  the	  stem	  IV	  solution	  structure,	  as	  we	  previously	  reported.125	  SHAPE	  reactivity	  of	  stem	  II	  also	  correlated	  with	  its	  solution	  structure.	  Each	  nucleotide	  forming	  the	  predicted	  stem	  II	  helix	  was	  unreactive	  to	  NMIA,	  including	  A22	  and	  A34.	  This	  suggests	  that	  A22	  and	  A34	  are	  stacked	  within	  the	  helix	  and	  not	  bulged	  as	  is	  typically	  drawn,	  consistent	  with	  NMR	  data.75	  Interestingly,	  the	  loop	  residues	  of	  stem	  II	  exhibited	  mixed	  levels	  of	  reactivity.	  G26	  and	  A29	  were	  less	  reactive	  than	  A28	  and	  U30,	  suggesting	  that	  G26	  and	  A29	  are	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structured	  despite	  residing	  in	  a	  single-­‐	  stranded	  loop.	  Indeed,	  the	  solution	  structure	  indicates	  that	  stem	  II	  is	  capped	  by	  a	  structured	  pentaloop	  with	  G26	  stacked	  on	  top	  of	  the	  terminal	  U25-­‐A31	  base	  pair	  and	  A29	  is	  tucked	  into	  the	  pentaloop	  structure.	  We	  conclude	  that	  the	  previously	  reported	  solution	  structure	  of	  stems	  II	  and	  IV	  accurately	  represent	  these	  domains	  in	  full-­‐length	  tTER.	  Surprisingly,	  the	  SHAPE	  profiles	  of	  the	  template	  and	  pseudoknot	  nucleotides	  (nts	  45−99)	  are	  inconsistent	  with	  the	  accepted	  secondary	  structure	  of	  tTER.	  Instead,	  the	  data	  suggest	  with	  high	  probability	  that	  these	  nucleotides	  are	  involved	  in	  a	  large	  and	  stable	  stem-­‐loop	  structure.	  This	  model	  is	  remarkably	  consistent	  with	  previous	  footprinting	  data,91,104,106	  but	  the	  SHAPE	  experiment	  revealed	  sufficient	  constraints	  to	  confidently	  make	  this	  conclusion	  (Table	  S2).	  Moreover,	  recently	  reported	  FRET	  data	  also	  suggest	  that	  a	  pseudoknot	  does	  not	  form	  in	  protein-­‐free	  tTER	  due	  to	  disruptive	  interactions	  with	  other	  parts	  of	  the	  RNA.85	  These	  interactions	  now	  appear	  defined.	  Instead	  of	  a	  pseudoknot	  and	  single-­‐stranded	  template	  region,	  the	  pseudoknot	  and	  template	  nucleotides	  participate	  in	  extensive	  base	  pairing	  to	  form	  an	  extended	  stem	  III	  (Figure	  2.3c).	  	  
3. tTERT	  Induces	  a	  Conformational	  Change	  in	  tTER	  	  The	  structure	  of	  in	  vitro	  transcribed	  tTER	  we	  determined	  is	  incompatible	  with	  a	  functional	  telomerase	  RNP	  as	  it	  would	  prevent	  association	  of	  the	  template	  with	  the	  active	  site.	  We	  therefore	  predicted	  that	  binding	  to	  tTERT	  would	  result	  in	  significant	  conformational	  changes	  in	  the	  template	  and	  pseudoknot	  domains	  of	  tTER.	  To	  test	  this	  hypothesis,	  we	  assembled	  telomerase	  in	  rabbit	  reticulocyte	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lysates,	  immunopurified	  the	  complex,	  and	  analyzed	  the	  structure	  of	  tTER	  by	  SHAPE.	  We	  posited	  that	  acylation	  by	  a	  SHAPE	  reagent	  might	  destabilize	  the	  telomerase	  complex	  and	  compromise	  the	  experiments.	  This	  concern	  was	  validated	  by	  demonstrating	  that	  acylation	  with	  NMIA	  was	  destabilizing	  to	  telomerase	  complex	  (Figure	  S4).	  For	  our	  studies,	  we	  therefore	  performed	  SHAPE	  on	  the	  telomerase	  complex	  for	  1	  reagent	  half-­‐life	  to	  maximize	  signal-­‐to-­‐noise	  and	  avoid	  potential	  contribution	  of	  tTER	  that	  has	  dissociated	  from	  tTERT.	  We	  also	  confirmed	  that	  the	  SHAPE	  reactivity	  profile	  of	  tTER	  in	  the	  tTERT	  complex	  was	  not	  time	  dependent	  over	  the	  course	  of	  the	  experiments	  (Figure	  S5).	  A	  histogram	  of	  all	  SHAPE	  reactivities	  for	  free	  tTER	  as	  compared	  to	  reactivities	  of	  tTER	  bound	  to	  TERT	  shows	  no	  appreciable	  difference	  in	  the	  overall	  distribution	  of	  specific	  SHAPE	  values	  between	  the	  two	  conditions:	  an	  equal	  number	  of	  nucleotides	  became	  more	  reactive	  to	  the	  SHAPE	  reagent	  as	  became	  less	  reactive	  when	  tTER	  was	  bound	  to	  TERT.	  However,	  we	  observed	  significant	  localized	  SHAPE-­‐reactivity	  changes	  in	  TERT-­‐bound	  tTER	  when	  compared	  to	  protein-­‐free	  tTER	  (Figures	  2.2	  and	  S1).	  Remarkably,	  nucleotides	  exhibiting	  increased	  reactivity	  were	  concentrated	  from	  A53-­‐G65:	  the	  template	  recognition	  element	  and	  proposed	  tTERT	  binding	  site	  3’	  of	  the	  template.	  In	  the	  absence	  of	  tTERT,	  these	  nucleotides	  are	  resistant	  to	  NMIA.	  However,	  upon	  assembly	  they	  become	  SHAPE	  reactive,	  suggesting	  they	  become	  single	  stranded	  upon	  binding	  to	  tTERT.	  Nucleotides	  with	  decreased	  SHAPE	  reactivity	  were	  present	  in	  provocative	  locations:	  the	  residues	  flanking	  the	  base	  of	  stem	  II,	  the	  loops	  of	  stems	  II	  and	  IV,	  and	  nucleotides	  that	  constitute	  the	  presumed	  pseudoknot	  stems	  IIIa	  and	  IIIb:	  A69−C72,	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A79−	  A80,	  and	  A89−U96.	  The	  SHAPE	  profiles	  of	  stems	  II	  and	  IV	  are	  consistent	  with	  reported	  solution	  structures,	  including	  correlation	  of	  S2	  for	  stem	  IV	  nucleotides.126	  Nucleotides	  predicted	  to	  be	  base	  paired	  demonstrated	  low	  SHAPE	  reactivity	  while	  loop	  nucleotides	  displayed	  mixed	  SHAPE	  reactivity.	  Notably,	  nucleotides	  predicted	  to	  be	  ordered	  by	  NMR	  displayed	  low	  SHAPE	  reactivity.75,98,125	  These	  observations	  further	  validate	  the	  solution	  structures	  as	  accurate	  models	  of	  these	  domains	  in	  the	  functional	  telomerase	  RNP.	  	  	  
4. Predictions	  of	  tTER	  Base	  Pairing.	  	  We	  utilized	  the	  folding	  algorithm	  RNAstructure	  to	  predict	  base-­‐pairing	  probability	  for	  tTER	  nucleotides	  and	  compared	  these	  predictions	  to	  the	  tTER	  model	  based	  on	  comparative	  sequence	  analysis	  (CSA	  model).112	  	  The	  currently	  accepted	  tTER	  model	  contains	  40	  base	  pairs,	  including	  13	  in	  the	  pseudoknot	  region.106,127	  Stems	  I,	  II,	  and	  IV	  contribute	  27	  of	  these	  40	  base	  pairs.	  RNAstructure	  predicted	  the	  27	  base	  pairs	  in	  stems	  I,	  II,	  and	  IV	  without	  experimental	  constraints.	  The	  five	  base	  pairs	  in	  stem	  I	  are	  predicted	  without	  the	  aid	  of	  SHAPE	  constraints	  to	  exist	  with	  probabilities	  exceeding	  99%.	  The	  six	  base	  pairs	  in	  stem	  II	  are	  all	  predicted	  with	  probabilities	  exceeding	  95%.	  Fourteen	  of	  the	  16	  base	  pairs	  in	  stem	  4	  are	  predicted	  with	  probabilities	  exceeding	  80%.	  Both	  MaxExpect121	  and	  ProbKnot122	  predict	  U126	  and	  U127	  to	  base	  pair	  with	  A144	  and	  A143	  respectively	  instead	  of	  U126	  and	  U125.	  The	  U126−A144	  base	  pair	  is	  predicted	  with	  45%	  probability,	  while	  the	  U127−A143	  pair	  is	  predicted	  with	  86%	  (Figure	  S6).	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We	  incorporated	  the	  SHAPE	  intensities	  of	  tTER	  in	  complex	  with	  tTERT	  into	  RNAstructure	  predictions.	  RNAstructure	  predicted	  32	  of	  the	  40	  tTER	  base	  pairs	  present	  in	  the	  CSA	  model	  (sensitivity	  of	  80%),	  and	  32	  of	  the	  38	  base	  pairs	  in	  RNAstructure	  model	  are	  found	  in	  the	  CSA	  model	  (positive	  predictive	  value	  of	  84%).	  All	  of	  the	  27	  base	  pairs	  in	  stems	  I,	  II,	  and	  IV	  of	  the	  CSA	  model	  were	  predicted.	  Additionally,	  the	  five	  base	  pairs	  in	  stem	  IIIA	  of	  the	  putative	  pseudoknot	  in	  the	  CSA	  model	  were	  also	  correctly	  predicted.	  However,	  stem	  IIIb	  of	  the	  pseudoknot	  in	  the	  CSA	  model	  was	  not	  present	  in	  predictions.	  Instead,	  structures	  included	  long-­‐range	  base	  pairs	  between	  nucleotides	  94−98	  and	  14−18.	  This	  long-­‐range	  interaction	  is	  not	  consistent	  with	  the	  biochemical	  understanding	  of	  telomerase	  and	  likely	  results	  from	  the	  inability	  of	  RNAstructure	  to	  accurately	  predict	  the	  tTER	  pseudoknot	  (Figure	  S7).	  Because	  the	  pseudoknot	  domain	  was	  not	  accurately	  predicted,	  we	  compared	  the	  SHAPE	  profiles	  to	  several	  possible	  pseudoknot	  structures	  including	  the	  CSA	  model,106,127	  a	  model	  predicted	  by	  the	  Tzfati	  lab,128	  and	  models	  predicted	  by	  several	  heuristic	  algorithms	  (Figure	  S8).129-­‐132	  In	  no	  case	  was	  the	  SHAPE	  profile	  completely	  consistent	  with	  the	  predicted	  base-­‐pairing	  pattern.	  Overall,	  only	  two	  sets	  of	  base-­‐pairing	  interactions	  are	  consistently	  supported	  by	  predictions	  and	  the	  SHAPE	  data:	  70-­‐	  ACCU/83-­‐AGGU	  and	  76-­‐ACC/97-­‐GGU.	  	  
5. Test	  of	  Predicted	  Stem	  IIIa	  Base	  Pairs	  by	  SHAPE	  and	  Activity	  Analysis	  of	  
tTER	  Mutants.	  	  	  We	  designed	  three	  mutants	  to	  test	  the	  proposed	  protein-­‐free	  and	  tTERT-­‐bound	  tTER	  models	  as	  shown	  in	  figure	  2.3.	  Mutants	  were	  designed	  to	  differentially	  
	   52	  
affect	  the	  stability	  of	  stem	  III	  in	  the	  protein-­‐free	  model	  and	  stem	  IIIa	  in	  the	  tTERT-­‐bound	  model	  (Figure	  S9).	  The	  models	  predict	  that	  two	  mutants,	  MS1	  (70-­‐ACCU	  →	  70-­‐UGGA)	  and	  MS2	  (83-­‐	  AGGU	  →	  83-­‐UCCA),	  would	  alter	  several	  base-­‐pairing	  interactions	  in	  both	  protein-­‐free	  and	  tTERT-­‐bound	  tTER,	  whereas	  double	  mutant	  MS1/MS2	  is	  predicted	  to	  dramatically	  destabilize	  the	  protein-­‐free	  structure	  but	  allow	  base	  pairing	  in	  the	  tTER	  complex	  due	  to	  the	  compensatory	  mutations.	  SHAPE	  profiles	  of	  protein-­‐free	  MS1,	  MS2,	  and	  MS1/MS2	  suggest	  disruption	  of	  the	  wild-­‐type	  tTER	  stem	  III	  structure	  and	  new	  but	  poorly	  formed	  structures	  or	  mixtures	  of	  several	  structures	  (Figure	  S9).	  Importantly,	  the	  SHAPE	  profile	  of	  protein-­‐free	  MS1/MS2	  was	  distinct	  from	  wild-­‐type,	  protein-­‐free	  tTER	  consistent	  with	  the	  hypothesis	  that	  these	  residues	  are	  not	  associated	  by	  base	  pairing.	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  When	  bound	  to	  tTERT,	  MS1	  exhibited	  a	  shift	  in	  SHAPE	  reactivity,	  making	  it	  appear	  to	  have	  formed	  a	  new	  structure	  (Figure	  2.3).	  We	  examined	  possible	  secondary	  structures	  of	  the	  MS1	  pseudoknot	  using	  heuristic	  modeling	  algorithms	  and	  found	  that	  several	  stable	  pseudoknot	  structures	  are	  compatible	  with	  the	  MS1	  sequence	  and	  SHAPE	  reactivity	  of	  MS1	  bound	  to	  tTERT.	  MS2	  exhibited	  a	  much	  greater	  increase	  in	  SHAPE	  reactivity	  of	  both	  the	  mutated	  residues	  as	  well	  as	  their	  predicted	  base-­‐pairing	  partners.	  Unlike	  MS1,	  none	  of	  the	  algorithms	  we	  tested	  predicted	  a	  stable	  structure	  for	  an	  MS2	  pseudoknot.	  In	  striking	  contrast	  to	  protein-­‐free	  tTER,	  the	  SHAPE	  profile	  of	  MS1/MS2	  is	  nearly	  indistinguishable	  from	  the	  profile	  of	  wild-­‐	  type	  tTER.	  Notable	  exceptions	  include	  A70	  and	  A90,	  which	  exhibited	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increased	  reactivity	  in	  the	  MS1/MS2	  mutant	  when	  compared	  to	  wild-­‐type	  tTER.	  We	  examined	  the	  effect	  of	  disrupting	  predicted	  base-­‐pairs	  in	  stem	  IIIa	  on	  telomerase	  activity	  and	  found	  that	  both	  MS1	  and	  MS2	  exhibited	  severely	  reduced	  telomerase	  activity,	  while	  MS1/MS2	  retained	  wild-­‐type	  activity	  (Figure	  2.4).	  It	  should	  be	  pointed	  out	  that	  similar	  mutations,	  71-­‐CC	  →	  71-­‐GG	  and	  84-­‐GG	  →	  84-­‐CC,	  were	  reported	  to	  show	  decreased	  telomerase	  activity	  that	  can	  be	  rescued	  by	  p65.104	  
	  
6. DMD	  Analysis	  of	  tTER.	  	  DMD	  simulations	  have	  been	  successfully	  used	  to	  model	  the	  three-­‐dimensional	  structures	  of	  RNAs,	  and	  the	  accuracy	  of	  modeling	  can	  be	  greatly	  enhanced	  by	  experimental	  constraints.108,133-­‐135	  We	  performed	  DMD	  simulations	  to	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generate	  structural	  models	  of	  protein-­‐free	  and	  tTERT-­‐bound	  tTER	  using	  both	  SHAPE-­‐derived	  secondary	  structure	  and	  FRET-­‐derived	  distance	  constraints	  (Figure	  S10).108	  Protein-­‐free	  tTER	  formed	  the	  predicted	  pairing	  regions	  stems	  I,	  II,	  and	  IV	  present	  in	  the	  CSA	  as	  well	  as	  the	  large	  stem	  III	  predicted	  by	  SHAPE	  constrained	  RNAstructure.	  In	  exploratory	  studies,	  initial	  models	  of	  tTERT-­‐bound	  tTER	  generated	  with	  SHAPE	  and	  FRET	  data	  alone	  exhibited	  long-­‐	  range	  base	  pairing	  like	  that	  found	  using	  RNAstructure	  (see	  Figure	  S7)	  that	  would	  block	  a	  proposed	  tTERT	  binding	  site	  as	  well	  as	  seemingly	  preclude	  proper	  association	  of	  the	  template	  with	  the	  tTERT	  active	  site.	  We	  therefore	  included	  several	  constraints	  based	  on	  biochemical	  inference	  (Figure	  S11).	  First,	  we	  introduced	  a	  nine-­‐nucleotide	  RNA	  sequence	  that	  was	  complementary	  to	  tTER	  template	  nucleotides	  43−51	  to	  mimic	  association	  of	  tTER	  with	  its	  primer	  and	  provide	  a	  steric	  block	  of	  the	  template	  from	  other	  tTER	  domains.	  Because	  nucleotides	  15−18	  are	  predicted	  to	  function	  as	  a	  protein	  binding	  site,55,88	  we	  also	  restricted	  the	  distances	  between	  tTER	  nucleotides	  10−18	  and	  the	  rest	  of	  the	  RNA	  to	  no	  less	  than	  10	  Å	  to	  ensure	  these	  nucleotides	  remain	  single-­‐stranded.	  The	  resulting	  models	  recapitulate	  all	  of	  the	  established	  base	  pairs	  in	  stems	  I,	  II,	  and	  IV.	  The	  models	  also	  predicted	  the	  stacked	  adenosines	  22	  and	  34	  of	  stem	  II,	  consistent	  with	  models	  from	  NMR	  data.75	  Cluster	  analysis	  of	  tTER	  folding	  trajectories,	  which	  identifies	  distinct	  conformational	  states	  sampled	  in	  simulations,	  revealed	  three	  stable	  domains	  that	  are	  internally	  stable:	  a	  region	  encompassing	  stem	  IV	  (nucleotides	  112−159),	  a	  region	  encompassing	  the	  template	  (nucleotides	  1−107),	  and	  a	  flexible	  linker	  between	  stem	  IV	  and	  stem	  I	  (108−111).	  In	  the	  simulations,	  the	  flexible	  linker	  allows	  stem	  IV	  and	  the	  template	  domains	  of	  tTER	  to	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change	  coordinates	  with	  respect	  to	  each	  other.	  Examination	  of	  the	  representative	  structures	  from	  cluster	  analysis	  indicates	  that	  movement	  in	  the	  flexible	  linker	  region	  enables	  the	  template	  nucleotides	  43−51	  to	  rotate	  approximately	  90°	  in	  relation	  to	  stationary	  stem	  IV.	  This	  suggests	  that	  the	  template	  nucleotides	  43−51	  can	  exist	  in	  several	  discrete	  positions	  with	  respect	  to	  stem	  IV.	  One	  aspect	  of	  the	  DMD-­‐generated	  models	  that	  did	  not	  appear	  to	  allow	  tTER	  function	  in	  the	  telomerase	  complex	  was	  the	  close	  association	  of	  the	  template	  with	  the	  rest	  of	  the	  RNA	  (Figure	  2.5B	  and	  C).	  We	  therefore	  modeled	  tTER	  bound	  to	  a	  homology	  model	  of	  tTERT.	  To	  constrain	  tTER	  binding,	  we	  aligned	  the	  template	  to	  the	  coordinates	  of	  a	  DNA	  primer	  available	  from	  the	  T.	  castaneum	  TERT	  crystal	  structure,	  which	  contains	  a	  model	  of	  the	  predicted	  T.	  castaneum	  telomerase	  template	  RNA	  residues	  base	  paired	  to	  the	  complementary	  DNA	  contained	  in	  a	  chimeric	  hairpin.59	  We	  performed	  DMD	  simulations	  to	  relax	  tTER	  while	  maintaining	  the	  secondary	  and	  tertiary	  structures	  of	  tTER.	  As	  we	  expected,	  docking	  to	  the	  tTERT	  model	  as	  a	  constraint	  altered	  the	  tTER	  structure	  (Figure	  7D).	  The	  major	  change	  was	  a	  twist	  in	  the	  template-­‐	  containing	  strand	  away	  from	  the	  remainder	  of	  tTER	  commensurate	  with	  extending	  stem	  II	  away	  from	  the	  main	  body	  of	  the	  RNA.	  The	  tTER	  model	  contains	  stems	  I,	  II,	  IIIa/	  IIIb,	  and	  IV	  with	  stem	  IV	  pointed	  toward	  the	  IIIa/IIIb	  pseudoknot.	  The	  template	  recognition	  element	  and	  the	  template	  are	  positioned	  away	  from	  the	  main	  body	  of	  tTER	  to	  accommodate	  association	  with	  the	  tTERT	  active	  site.	  The	  stem	  II	  model	  aligns	  within	  1.5	  Å	  root-­‐mean-­‐square	  deviation	  (RMSD)	  of	  the	  published	  NMR	  structure,75	  and	  stem	  IV	  aligns	  to	  within	  5.4	  Å	  RMSD	  of	  the	  published	  NMR	  structure	  (Figure	  S12).98,125	  




1. Binding	  to	  tTER	  Causes	  a	  Major	  Conformational	  Change	  in	  tTER.	  	  We	  combined	  SHAPE	  chemistry,	  published	  FRET,	  and	  molecular	  modeling	  to	  examine	  the	  three-­‐	  dimensional	  structure	  of	  tTER.	  By	  comparing	  unbound	  tTER	  to	  tTER	  in	  the	  minimal	  telomerase	  complex,	  we	  revealed	  a	  dramatic	  conformational	  change	  in	  tTER	  that	  attends	  assemblage	  in	  the	  minimum	  telomerase	  complex.	  The	  most	  noteworthy	  evidence	  for	  the	  conformational	  change	  is	  indicated	  by	  the	  SHAPE	  profile	  for	  nucleotides	  A53−A100,	  which	  includes	  the	  template	  recognition	  element	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and	  presumed	  pseudoknot	  domain	  (Figure	  2.2).	  We	  interpret	  this	  change	  as	  evidence	  for	  the	  absence	  of	  a	  pseudoknot	  in	  protein-­‐free	  tTER	  and	  formation	  of	  a	  pseudoknot	  in	  tTERT-­‐bound	  tTER.	  The	  SHAPE-­‐inferred	  secondary	  structure	  of	  tTER	  in	  solution	  is	  remarkably	  different	  from	  the	  accepted	  secondary	  structure	  associated	  with	  tTER	  function	  in	  that	  the	  template	  and	  pseudoknot	  form	  a	  large	  paired	  region	  that	  we	  refer	  to	  as	  stem	  III.	  Importantly,	  this	  model	  is	  consistent	  with	  previous	  enzymatic	  and	  chemical	  footprinting	  of	  tTER	  (Table	  S1).	  It	  is	  notable	  that	  previous	  tTER	  structure	  probing	  experiments	  did	  not	  lead	  to	  the	  protein-­‐free	  structure	  of	  tTER	  we	  predict.	  In	  part,	  this	  is	  a	  result	  of	  insufficient	  data	  available	  to	  accurately	  assign	  the	  structure.	  Recent	  experiments	  using	  RNase	  One	  do	  provide	  wider	  coverage,	  and	  RNase	  One	  is	  reported	  to	  cleave	  single-­‐stranded	  RNA.104	  	  It	  is	  surprising	  then	  that	  the	  reactivity	  profile	  of	  protein-­‐free	  tTER	  using	  RNase	  One	  varies	  so	  much	  from	  SHAPE	  reactivity,	  particularly	  in	  the	  stem	  III	  domain	  of	  the	  protein-­‐free	  structure	  (residues	  A44−U102,	  see	  Table	  S1).	  This	  difference	  requires	  an	  explanation.	  One	  possibility	  for	  decreased	  RNase	  One	  reactivity	  at	  nonbase-­‐paired	  nucleotides	  is	  steric	  restriction	  on	  RNase	  One	  binding.	  Additionally,	  RNase	  One	  binding	  could	  shift	  the	  structural	  equilibrium	  from	  double-­‐	  stranded	  to	  single-­‐stranded	  RNA.	  This	  would	  result	  in	  increased	  reactivity	  at	  base-­‐paired	  residues.	  Because	  SHAPE	  is	  governed	  almost	  exclusively	  by	  flexibility,	  these	  secondary	  effectors	  of	  RNase	  One	  reactivity	  may	  explain	  the	  differences	  between	  SHAPE	  and	  RNase	  One	  and	  would	  challenge	  accurate	  structural	  interpretation	  of	  RNase	  One	  experiments	  when	  compared	  to	  SHAPE	  chemistry.	  The	  model	  proposed	  here	  for	  the	  protein-­‐free	  tTER	  structure	  also	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rationalizes	  FRET	  data	  of	  tTER	  at	  labeled	  pairs	  U63	  and	  U92	  and	  pairs	  U73	  and	  U99	  that	  are	  lower	  than	  expected	  for	  a	  folded	  pseudoknot.85	  The	  FRET	  data	  are,	  however,	  consistent	  with	  an	  extended	  stem	  III	  structure.	  The	  SHAPE-­‐inferred	  secondary	  structure	  of	  tTER	  bound	  to	  tTERT,	  in	  contrast	  to	  the	  protein-­‐free	  structure,	  is	  consistent	  with	  the	  accepted	  secondary	  structure.	  However,	  the	  specific	  base-­‐pairing	  pattern	  of	  the	  pseudoknot	  domain	  remains	  challenging	  to	  define.	  In	  an	  attempt	  to	  better	  address	  this,	  we	  compared	  the	  SHAPE	  profile	  of	  the	  pseudoknot	  residues	  with	  several	  proposed	  models	  (Figure	  S8).	  We	  found	  that	  no	  model	  was	  entirely	  consistent	  with	  the	  SHAPE	  profile;	  instead,	  each	  model	  is	  partially	  consistent	  with	  the	  data.	  The	  G−C	  rich	  regions	  are	  predicted	  by	  each	  model	  to	  be	  base-­‐paired,	  which	  is	  consistent	  with	  the	  SHAPE	  profile.	  However,	  the	  A−U-­‐rich	  regions	  do	  not	  appear	  to	  form	  a	  consistent	  base-­‐pairing	  pattern.	  It	  seems	  that	  the	  pseudoknot	  domain	  forms	  a	  triple	  helix	  with	  the	  reactive	  A−U-­‐rich	  nucleotides	  bound	  to	  the	  minor	  or	  major	  groove	  of	  stems	  IIIa	  and	  IIIb,	  similar	  to	  the	  model	  forwarded	  by	  the	  Tzfati	  lab.128	  To	  account	  for	  the	  high	  SHAPE	  reactivity	  of	  the	  A−U-­‐rich	  strands	  of	  the	  pseudoknot	  domain,	  we	  propose	  that	  either	  several	  base-­‐pairing	  configurations	  of	  the	  pseudoknot	  are	  present	  or	  the	  pseudoknot	  is	  flexible.	  One	  possibility	  is	  that	  during	  catalysis	  or	  in	  the	  presence	  of	  the	  telomerase	  holoenzyme	  component	  p65,	  the	  pseudoknot	  forms	  a	  more	  stable	  structure.	  The	  decrease	  in	  SHAPE	  reactivity	  of	  the	  apical	  loops	  of	  stem-­‐	  loops	  II	  and	  IV	  upon	  binding	  tTERT	  is	  evidence	  for	  decreased	  flexibility	  resulting	  from	  either	  increased	  stability	  of	  the	  secondary	  structure	  elements	  or	  direct	  tTERT	  interaction.	  	  Specifically,	  the	  loop	  of	  stem	  II	  that	  displayed	  decreased	  SHAPE	  reactivity	  is	  unlikely	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to	  bind	  directly	  to	  tTERT	  because	  mutating	  or	  extending	  the	  length	  of	  stem	  II	  is	  well	  tolerated.90,95,136	  Accordingly,	  we	  conclude	  that	  association	  of	  tTER	  with	  tTERT	  stabilizes	  stem	  II	  resulting	  in	  decreased	  nucleotide	  flexibility.	  The	  reduced	  reactivities	  of	  15-­‐CAUU-­‐18	  and	  39-­‐UC-­‐40	  are	  consistent	  with	  predicted	  direct	  and	  stable	  interactions	  of	  these	  nucleotides	  with	  tTERT.	  Binding	  to	  tTERT	  could	  reduce	  nucleotide	  flexibility	  or	  sterically	  block	  reaction	  with	  NMIA.	  Like	  stem-­‐loop	  II,	  stem-­‐loop	  IV	  residues	  displayed	  decreased	  SHAPE	  reactivity	  within	  the	  loop	  region.	  Several	  previous	  reports	  suggest	  a	  direct	  interaction	  between	  loop	  IV	  and	  tTERT.	  Therefore,	  direct	  interactions	  with	  tTERT	  as	  well	  as	  increased	  structural	  order	  are	  likely	  to	  contribute	  to	  the	  observed	  decrease	  in	  SHAPE	  reactivity.	  Interestingly,	  RNase	  One	  was	  reported	  to	  display	  the	  opposite	  distribution	  of	  reactivities	  in	  loop	  IV	  with	  A136,	  U137,	  and	  U138	  exhibiting	  resistance	  to	  RNase	  One	  cleavage	  but	  high	  SHAPE	  reactivity	  (Table	  S2).	  One	  model	  that	  is	  consistent	  with	  the	  data	  is	  that	  residues	  C132,	  A133,	  and	  C134	  form	  a	  rigid	  platform	  to	  constrain	  the	  range	  of	  motion	  of	  flexible	  nucleotides	  135-­‐	  UAUU-­‐138.	  Evidence	  from	  several	  mutagenesis	  studies	  suggests	  that	  stem	  IV	  binds	  tTERT	  and	  that	  this	  interaction	  is	  stabilized	  by	  p65.	  Interestingly,	  when	  the	  C132−U138	  base	  pair	  is	  mutated	  to	  an	  A−U	  base	  pair,	  SHAPE	  reactivity	  decreases	  for	  U138	  commensurate	  with	  dramatically	  reduced	  catalytic	  activity.125	  Flexibility	  in	  these	  nucleotides	  therefore	  seems	  in	  part	  related	  to	  their	  biochemical	  role	  in	  telomerase	  assembly.	  Interestingly,	  mutation	  of	  A136,	  U137,	  and	  U138	  causes	  a	  significant	  decrease	  in	  assembly	  of	  active	  telomerase	  even	  in	  the	  presence	  of	  p65,	  but	  does	  not	  appear	  to	  negatively	  affect	  activity	  of	  properly	  assembled	  complexes.	  We	  propose	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that	  the	  UAUU	  nucleotides	  are	  flexible	  to	  allow	  an	  induced	  fit	  with	  tTERT.	  In	  addition,	  we	  predict	  that	  tTERT	  binds	  tTER	  in	  the	  major	  groove	  of	  stem	  IV.	  Binding	  the	  major	  groove	  would	  likely	  protect	  A136,	  U137,	  and	  U138	  from	  RNase	  One	  cleavage	  but	  not	  block	  reaction	  of	  these	  nucleotides	  with	  NMIA,	  assuming	  RNase	  ONE	  cleavage	  is	  governed	  by	  sterics	  and	  NMIA	  by	  nucleotide	  flexibility.	  We	  were	  surprised	  that	  four	  template	  residues,	  46-­‐CCCC-­‐49,	  remained	  resistant	  to	  SHAPE	  reactivity	  after	  assembly.	  These	  nucleotides	  are	  also	  resistant	  to	  RNase	  One	  cleavage	  when	  tTER	  is	  bound	  to	  the	  N-­‐terminus	  of	  tTERT	  (amino	  acids	  1−	  516).	  Because	  a	  primer	  must	  bind	  these	  residues,	  we	  expected	  that	  they	  were	  single	  stranded	  and	  would	  exhibit	  high	  SHAPE	  reactivity.	  The	  low	  reactivity	  suggests	  that	  these	  nucleotides	  are	  directly	  bound	  to	  tTERT	  in	  a	  rigid	  conformation	  in	  the	  active	  site,	  perhaps	  providing	  a	  platform	  for	  primer	  binding.	  	  
2. A	  Three-­‐Dimensional	  Model	  of	  tTER.	  	  The	  three-­‐	  dimensional	  model	  of	  tTER	  generated	  by	  DMD	  simulations	  predicts	  all	  base	  pairs	  within	  stems	  I,	  II,	  and	  IV	  and	  displays	  relatively	  low	  RMSD	  alignments	  to	  NMR-­‐generated	  models	  of	  stems	  II	  and	  IV.	  Although	  the	  biochemical	  data	  do	  not	  allow	  assignment	  of	  a	  specific	  base-­‐pairing	  pattern	  for	  the	  pseudoknot,	  DMD	  simulation	  suggests	  a	  compact	  structure	  with	  several	  base	  triples.	  The	  DMD	  simulations	  also	  allow	  insight	  into	  tTER	  dynamics.	  Overall,	  simulations	  reveal	  that	  the	  template	  region	  is	  remarkably	  flexile	  (compare	  Figure	  6B,	  C	  to	  D).	  The	  simulations	  suggest	  that	  one	  important	  aspect	  of	  this	  flexibility	  is	  rotation	  of	  the	  single-­‐stranded	  region	  between	  stems	  I	  and	  IV.	  One	  possibility	  is	  that	  the	  lack	  of	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FRET	  constraints	  for	  any	  nucleotides	  in	  the	  distal	  loop	  of	  the	  stem	  II	  domain	  may	  account	  for	  this	  dynamic	  positioning	  of	  the	  template.	  An	  alternative	  and	  more	  interesting	  interpretation	  is	  that	  the	  observed	  motion	  captures	  necessary	  movement	  of	  the	  template	  during	  successive	  rounds	  of	  nucleotide	  addition	  and	  repeat	  addition	  processivity.	  On	  the	  basis	  of	  this	  model,	  stem	  IV	  remains	  docked	  to	  tTERT	  in	  an	  allosteric	  activating	  site	  while	  the	  template	  can	  cycle	  through	  its	  required	  positions,	  a	  motion	  allowed	  by	  rotation	  about	  the	  linker	  between	  stem	  IV	  and	  stem	  I	  (Figure	  6)	  perhaps	  coupled	  with	  scrunching	  of	  the	  template	  recognition	  element.137	  Alternatively,	  the	  motion	  may	  allow	  proper	  docking	  of	  stem	  IV	  during	  assembly.	  	  
3. A	  Biological	  Model	  for	  the	  tTER	  Structural	  Rearrangement.	  	  The	  significant	  conformational	  change	  we	  detected	  in	  tTER	  that	  attends	  telomerase	  assembly	  can	  be	  interpreted	  in	  many	  ways.	  One	  possibility	  is	  that	  the	  alternative	  structure	  is	  an	  artifact	  of	  in	  vitro	  transcription,	  and	  tTER	  does	  not	  fold	  into	  a	  biologically	  relevant	  structure	  due	  to	  the	  lack	  of	  tTER-­‐binding	  partners,	  for	  example	  p65,	  which	  may	  be	  present	  during	  its	  transcription	  in	  vivo.	  Alternatively,	  it	  can	  be	  proposed	  that	  tTER	  folds	  as	  we	  show	  for	  the	  protein-­‐free	  tTER	  in	  vivo	  prior	  to	  p65	  binding,	  which	  can	  induce	  a	  conformational	  change	  in	  tTER,95,96,104	  followed	  by	  association	  with	  tTERT.	  If	  this	  latter	  possibility	  is	  the	  case,	  does	  the	  misfolded	  tTER	  structure	  serve	  a	  purpose?	  We	  propose	  a	  model	  that	  protein-­‐free	  tTER	  folds	  with	  a	  large	  stem	  III	  to	  sequester	  the	  template	  cytosine	  residues	  in	  a	  double	  stranded	  helix	  until	  assembly	  to	  protect	  the	  integrity	  of	  the	  telomere	  sequence	  and	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may	  serve	  other	  purposes	  as	  well.	  Because	  tTER	  codes	  for	  the	  DNA	  sequence	  at	  chromosome	  termini,	  damage	  to	  the	  templating	  residues	  could	  have	  significant	  negative	  consequences.	  For	  example,	  mutation	  of	  the	  human	  TER	  templating	  residues	  results	  in	  cell	  death.138	  Because	  the	  deamination	  rate	  of	  cytosine	  in	  single-­‐stranded	  oligonucleotides	  is	  faster	  than	  that	  of	  cytosine	  in	  double-­‐	  stranded	  duplexes,139	  the	  misfolded	  tTER	  would	  protect	  the	  coding	  cytosine	  residues.	  	  
CONCLUSIONS	  	  In	  summary,	  high-­‐resolution	  footprinting	  of	  protein-­‐free	  and	  tTERT-­‐bound	  tTER	  revealed	  a	  significant	  conformational	  change	  in	  tTER.	  In	  the	  absence	  of	  tTERT,	  tTER	  does	  not	  form	  a	  pseudoknot	  but	  instead	  forms	  a	  large	  stem	  that	  encompasses	  the	  pseudoknot	  and	  template	  nucleotides.	  Importantly,	  the	  data	  provide	  critical	  evidence	  that	  the	  previous	  solution	  structure	  models	  of	  stem	  II	  and	  IV	  derived	  from	  NMR	  constraints	  are	  consistent	  with	  the	  structure	  of	  tTERT-­‐bound	  tTER,	  offer	  robust	  evidence	  for	  the	  pseudoknot	  structure	  in	  tTERT-­‐bound	  tTER,	  and	  provide	  new	  hypotheses	  for	  telomerase	  RNA	  function	  during	  assembly	  and	  catalysis.	  	  	  	  	  	  	  	  




Chapter	  III.	  Modeling	  p65-­‐induced	  telomerase	  ribonucleoprotein	  
conformational	  transitions	  	  
INTRODUCTION	  
	   Understanding	  the	  mechanisms	  by	  which	  RNA	  forms	  three-­‐dimensional	  (3-­‐D)	  structures	  endowed	  with	  properties	  such	  as	  catalysis,	  ligand	  binding,	  and	  recognition	  of	  proteins	  is	  important	  given	  the	  central	  roles	  of	  RNA	  in	  cellular	  biochemistry.	  tTER	  is	  159	  nucleotides	  and	  is	  predicted	  by	  phylogenetic	  covariation	  to	  form	  extensive	  base	  pairing,	  as	  described	  in	  Figure	  3.1a.127,140,141	  Four	  base	  pair	  regions	  are	  predicted	  and	  denoted	  by	  Roman	  numerals	  I-­‐IV	  in	  most	  tetrahymenine	  ciliates.	  	  However,	  only	  three	  of	  the	  four	  predicted	  base	  pair	  regions	  form	  when	  tTER	  is	  free	  in	  solution.86	  	  The	  one	  base	  pair	  region	  that	  does	  not	  form	  when	  in	  vitro	  tTER	  is	  transcribed	  in	  the	  absence	  of	  protein	  is	  predicted	  to	  form	  a	  pseudoknot	  in	  active	  telomerase.	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  The	  3D	  structure	  of	  the	  tTER	  pseudoknot	  region	  is	  of	  interest	  to	  us	  because	  it	  controls	  mechanisms	  of	  catalysis	  and	  recognition	  of	  proteins	  in	  the	  telomerase	  ribonucleoprotein.	  	  The	  first	  time	  that	  the	  pseudoknot	  region	  of	  tTER	  was	  mentioned	  in	  the	  literature	  was	  in	  1994,106	  That	  paper	  described	  equilibrium	  between	  the	  pseudoknot	  and	  the	  two	  helices	  in	  the	  pseudoknot.	  Stem	  IIIa	  of	  the	  pseudoknot	  was	  predicted	  to	  predominate.	  	  The	  authors	  found	  that	  folding	  interactions	  with	  other	  parts	  of	  a	  full	  length	  RNA	  specifically	  prevents	  pseudoknot	  formation,	  which	  had	  not	  been	  reported	  previously.	  	  	  Two	  papers	  published	  in	  1999	  contrasted	  the	  catalytic	  behavior	  of	  the	  telomerase	  pseudoknot	  when	  reconstituted	  in	  vitro	  as	  opposed	  to	  when	  expressed	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in	  vivo.	  	  	  The	  first	  article	  showed	  that	  in	  vitro	  RRL	  reconstituted	  telomerase	  was	  still	  active,	  although	  at	  only	  30%	  activity,	  when	  either	  of	  the	  two	  component	  stems	  of	  the	  pseudoknot	  were	  deleted.90	  	  The	  second	  article	  showed	  in	  vivo	  that	  it	  was	  the	  topology	  of	  the	  pseudoknot	  that	  was	  important,	  rather	  than	  the	  specific	  sequence	  of	  stem	  IIIa.87	  	  Importantly,	  disrupting	  the	  structure	  of	  pseudoknot	  stem	  IIIa	  in	  vivo	  prevents	  formation	  of	  functional	  telomerase.	  	  	  Also,	  the	  RNA	  pseudoknot	  may	  provide	  a	  conformation	  that	  allows	  telomerase	  assembly.87	  	  Finally,	  in	  vitro	  pseudoknot	  mutations	  in	  ciliates	  are	  more	  detrimental	  to	  activity	  than	  in	  vivo	  mutations.	  	  	  Biochemical	  experiments	  implicated	  tTER	  pseudoknot	  equilibrium	  in	  telomerase	  protein	  recognition	  in	  the	  early	  2000s.	  	  In	  2001,	  pseudoknot	  folding	  was	  shown	  to	  be	  TERT-­‐dependent	  and	  that	  loop	  IV	  may	  be	  involved	  in	  correctly	  positioning	  the	  protein	  to	  direct	  folding	  of	  the	  pseudoknot.91	  	  Shortly	  thereafter,	  an	  article	  suggested	  that	  base	  pairing	  in	  ciliate	  in	  vitro	  assembled	  telomerase	  pseudoknots	  as	  well	  as	  the	  sequences	  of	  the	  two	  stems	  both	  contribute	  to	  activity.89	  	  That	  same	  article	  also	  showed	  that	  the	  potential	  to	  form	  base	  pairs,	  but	  not	  necessarily	  the	  sequence	  of	  both	  stems	  of	  the	  pseudoknot	  region,	  is	  required	  for	  optimal	  repeat	  addition	  processivity.89	  	  We	  now	  better	  understand	  how	  the	  conformational	  state	  of	  the	  telomerase	  RNA	  pseudoknot	  region	  is	  linked	  to	  both	  catalytic	  activity	  and	  protein	  recognition	  within	  the	  ribonucleoprotein.	  	  	  Structural	  equilibrium	  in	  the	  pseudoknot	  region	  of	  telomerase	  RNA	  was	  linked	  to	  disease	  later	  in	  2003,	  when	  it	  was	  observed	  that	  mutations	  found	  in	  the	  pseudoknot	  region	  of	  telomerase	  RNA	  of	  dyskeratosis	  congenita	  patients	  altered	  the	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equilibrium	  between	  the	  folded	  pseudoknot	  and	  its	  component	  helices.142	  	  Thermal	  melting	  experiments	  showed	  that	  thermodynamically,	  but	  not	  kinetically,	  the	  tertiary	  (3°)	  structure	  of	  hTER	  pseudoknot	  unfolds	  first,	  followed	  by	  secondary	  structural	  (2°)	  unfolding	  of	  component	  stems	  2	  and	  then	  1	  (corresponding	  to	  stems	  IIIb	  and	  IIIa,	  respectively,	  in	  ciliates	  as	  shown	  in	  panels	  B	  and	  C	  of	  figure	  3.1).	  	  NMR	  predicted	  that	  the	  GC	  rich	  (50%)	  stem	  1	  of	  the	  construct	  was	  in	  equilibrium	  with	  the	  predominant	  pseudoknot	  form.	  	  Mutations	  to	  the	  pseudoknot	  sequence	  within	  the	  construct	  did	  not	  change	  structure,	  only	  the	  equilibrium	  between	  populations.142	  	  From	  2004	  through	  2007,	  more	  progress	  was	  made	  in	  characterizing	  both	  in	  vitro	  and	  in	  vivo	  hTER	  pseudoknot	  states.	  	  	  Biophysical	  studies	  have	  contributed	  much	  to	  our	  understanding	  of	  telomerase	  pseudoknot	  equilibrium.	  	  One	  such	  study	  in	  2007	  computationally	  modeled	  base	  triples	  predicted	  in	  the	  tTER	  pseudoknot.128	  	  Kinetic	  FRET	  studies	  were	  done	  on	  the	  tTER	  pseudoknot	  both	  in	  the	  context	  of	  the	  full	  length	  tTER	  and	  in	  isolation	  in	  2011.85	  	  These	  key	  kinetic	  studies	  demonstrated	  that	  the	  tTER	  pseudoknot	  does	  not	  fold	  in	  protein-­‐free	  RNA,	  but	  that	  the	  core	  telomerase	  proteins	  play	  a	  critical	  role	  in	  stably	  forming	  the	  pseudoknot	  throughout	  catalysis	  in	  the	  active	  telomerase	  RNP.	  	  The	  reverse	  transcriptase	  portion	  is	  just	  one	  of	  the	  two	  core	  telomerase	  proteins	  in	  Tetrahymena	  contributing	  to	  tTER	  conformational	  state	  transitions;	  p65	  is	  the	  other.97	  	  FRET	  data	  shows	  unique	  conformational	  states	  for	  free	  in	  solution	  tTER,	  p65-­‐bound	  tTER,	  and	  tTERT-­‐bound	  tTER,	  suggesting	  unique	  secondary	  structural	  states.95	  	  The	  individual	  base	  pairs	  of	  free	  in	  solution	  tTER	  and	  tTERT-­‐
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bound	  tTER	  were	  only	  recently	  determined	  experimentally	  and	  are	  summarized	  in	  Figure	  3.2	  (compare	  Figure	  3.2	  to	  	  3.1).86	  	  However,	  one	  aspect	  of	  telomerase	  assembly	  that	  is	  not	  yet	  fully	  understood	  is	  how	  p65	  helps	  coordinate	  the	  changes	  from	  the	  protein-­‐free	  to	  the	  tTERT-­‐bound	  tTER	  structure.	  	  	  The	  base	  pair	  pattern	  of	  p65	  bound	  tTER	  must	  first	  be	  determined	  in	  order	  to	  resolve	  this	  gap	  in	  knowledge.	  	  	  
	  	  Until	  we	  first	  define	  secondary	  structural	  changes	  associated	  with	  assembly	  and	  catalysis,	  understanding	  the	  tertiary	  and	  quaternary	  structures	  of	  RNP	  macromolecular	  machines	  and	  any	  dynamic	  changes	  the	  machines	  may	  undergo	  during	  assemblage	  and	  catalysis	  will	  be	  difficult.	  	  Previous	  FRET	  studies	  and	  our	  own	  SHAPE	  studies	  led	  us	  to	  hypothesize	  that	  p65	  binding	  of	  tTER	  in	  the	  absence	  of	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tTERT	  alters	  the	  energy	  landscape	  of	  tTER	  to	  more	  closely	  resemble	  holoenzyme	  state	  (described	  in	  the	  right	  panel	  of	  Figure	  3.2)	  than	  the	  protein-­‐free,	  in	  solution	  state	  (described	  in	  the	  left	  panel).	  	  Our	  hypothesized	  model	  is	  presented	  in	  Figure	  3.3	  as	  the	  progression	  from	  panels	  B	  to	  C	  to	  E	  rather	  than	  from	  panels	  B	  to	  D	  to	  E.	  	  	  	  
To	  further	  understanding	  of	  the	  structural	  changes	  tTER	  undergoes	  during	  telomerase	  assemblage	  and	  catalysis,	  we	  compared	  the	  SHAPE	  reactivities	  of	  wildtype	  free	  in	  solution	  tTER	  to	  tTER	  in	  the	  presence	  of	  p65	  to	  compare	  the	  secondary	  structural	  changes	  induced	  by	  tTERT	  to	  those	  induced	  by	  p65.	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MATERIAL	  AND	  METHODS	  	  
1. p65	  Expression	  and	  Purification	  The	  gene	  expressing	  full-­‐length	  p65	  used	  in	  these	  studies	  was	  cloned	  into	  a	  high	  copy	  pET-­‐15b	  plasmid	  vector	  and	  purchased	  from	  addgene.org	  (#27661).	  	  The	  p65	  plasmid	  that	  was	  originally	  developed	  by	  the	  Collins	  lab	  encodes	  a	  His6	  tag	  immediately	  upstream	  of	  the	  p65	  DNA.97	  	  The	  plasmid	  arrived	  within	  a	  stab	  culture	  of	  DH5αTM	  Escherichia	  coli	  cells	  in	  LB	  agar,	  which	  was	  streaked	  on	  ampicillin	  -­‐	  LB	  agar	  plates	  (100	  μg·mL-­‐1)	  to	  produce	  single	  colonies.	  	  A	  single	  colony	  of	  cells	  was	  amplified	  overnight	  in	  500	  mL	  of	  ampicillin-­‐containing	  LB	  before	  a	  MaxiPrep	  plasmid	  purification	  kit	  was	  used	  to	  purify	  the	  His6pET15p65	  plasmid	  DNA	  (Qiagen),	  which	  was	  stored	  inT10E1	  (Tris	  HCl	  10	  mM	  pH	  8.0	  and	  EDTA	  1	  mM).	  	  DNA	  integrity	  was	  checked	  with	  Nanodrop	  spectrophotometry	  (Thermo	  Scientific)	  and	  by	  electrophoresing	  His6pET15p65	  plasmid	  digested	  with	  BamHI	  and	  Nde1	  to	  release	  the	  1,630	  base	  pair	  insert	  of	  p65	  DNA	  from	  the	  pET	  15b	  plasmid.	  	  	  
Escherichia	  coli	  BL21(DE3)	  cells	  transformed	  with	  His6pET15p65	  were	  grown	  in	  LB	  supplemented	  with	  100	  μg·mL-­‐1	  ampicillin	  at	  37°C	  until	  an	  optical	  density	  at	  600	  nm	  of	  0.4-­‐0.6	  was	  reached.	  	  The	  temperature	  then	  was	  decreased	  to	  16°C	  for	  30	  min	  prior	  to	  induction	  with	  a	  final	  concentration	  of	  1	  mM	  isopropyl-­‐D-­‐thiogalactopyranoside	  (IPTG)	  for	  6-­‐8	  hrs.	  Cells	  were	  harvested	  and	  stored	  at	  -­‐80	  °C.	  Cells	  were	  suspended	  in	  T20Mg1	  lysis	  buffer	  (20	  mM	  Tris-­‐HCl,	  pH	  7.5,	  1	  mM	  MgCl2,	  300	  mM	  NaCl,	  10%	  glycerol,	  20	  mM	  imidazole)	  with	  cOmplete™,	  EDTA-­‐free	  protease	  inhibitor	  tablets	  (Roche).	  	  Following	  lysis	  by	  sonication,	  lysate	  was	  clarified	  by	  centrifuging	  lysate	  at	  10,000	  ×	  g	  for	  30	  min	  at	  4°C	  to	  pellet	  the	  cellular	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debris.	  	  Once	  clarified,	  lysate	  was	  incubated	  with	  TALON	  immobilized	  metal	  affinity	  (Clontech	  Laboratories)	  chromatography	  resin	  that	  was	  equilibrated	  with	  a	  very	  low	  concentration	  of	  imidazole	  (10	  mM).	  	  Protein	  was	  washed	  with	  a	  low	  concentration	  of	  imidazole	  (20	  mM	  in	  10	  bed	  volumes)	  before	  p65	  was	  eluted	  with	  a	  high	  concentration	  of	  imidazole	  (500	  mM	  in	  5	  bed	  volumes)	  to	  collect	  p65.	  	  The	  p65	  fractions	  were	  dialyzed	  overnight	  against	  T20Mg1	  buffer	  (20	  mM	  Tris-­‐HCl,	  pH	  7.5,	  1	  mM	  MgCl2)	  to	  remove	  imidazole.	  	  Spectra/Por®	  6	  regenerated	  cellulose	  semipermeable	  membranes	  of	  molecular	  weight	  cutoff	  25	  kDa	  were	  used	  for	  dialysis	  (Spectrum	  Labs).	  	  Purified	  p65	  was	  stored	  in	  the	  presence	  of	  25%	  glycerol	  at	  -80	  °C.	  	  Concentration	  was	  determined	  by	  Bradford	  assay	  and	  the	  purity	  judged	  by	  electrophoresis	  on	  a	  1.5	  mM	  thick	  Tris	  glycine	  SDS	  gel	  containing	  an	  8%	  resolving	  gel	  (pH	  8.8)	  and	  a	  5%	  stacking	  gel	  (pH	  6.8)	  followed	  by	  staining	  with	  Coomasie	  Blue.	  	  
2. RNA	  Preparation	  RNA	  was	  synthesized	  in	  vitro	  using	  Ampliscribe	  T7	  Transcription	  kit	  (Epicentre	  Technologies).	  	  The	  template	  for	  runoff	  transcription	  was	  EarI-­‐digested	  plasmids	  (ptetTELO)	  containing	  a	  hammerhead	  ribozyme	  at	  the	  5’	  end,	  the	  template	  for	  TER,	  and	  a	  3’	  SHAPE	  extension.86,105,107	  After	  transcription	  at	  37	  °C,	  the	  reactions	  were	  diluted	  four-­‐fold	  into	  20	  mM	  MgCl2	  to	  activate	  hammerhead	  ribozyme	  cleavage.	  Following	  ribozyme	  cleavage,	  the	  RNAs	  were	  concentrated	  by	  ethanol	  precipitation	  and	  reconstituted	  in	  denaturing	  loading	  buffer	  (formamide	  80%,	  44.5	  mM	  Tris/borate,	  1	  mM	  EDTA,	  0.01%	  xylene	  cyanol	  FF,	  0.01%	  bromophenol	  blue).	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RNA	  was	  purified	  on	  a	  denaturing	  gel	  containing	  8%	  polyacrylamide,	  7	  M	  urea,	  and	  1X	  Tris-­‐borate-­‐EDTA	  .	  Transcripts	  were	  visualized	  by	  UV	  shadowing	  and	  gel	  slices	  were	  removed	  and	  crushed	  by	  passing	  through	  the	  tip	  of	  a	  sterile	  plastic	  syringe,	  before	  the	  transcripts	  were	  extracted	  from	  the	  polyacrylamide	  matrix	  into	  TEN	  buffer	  (10	  mM	  Tris	  pH	  7.5,	  1	  mM	  EDTA,	  250	  mM	  NaCl).	  Transcripts	  were	  concentrated	  by	  ethanol	  precipitation	  and	  suspended	  in	  T10E1	  low	  ionic	  strength	  buffer	  (10	  mM	  Tris-­‐Cl	  pH	  8.0,	  1	  mM	  EDTA).	  	  	  
3. Electrophoretic	  Mobility	  Shift	  Assay	  tTER	  was	  first	  heated	  to	  95	  °C	  for	  3	  min	  before	  being	  snap-­‐cooled	  on	  ice	  for	  3	  min	  to	  fold	  the	  RNA.	  	  EMSA	  reactions	  for	  p65	  contained	  tTER	  EMSA	  Buffer	  (20	  mM	  Tris	  HCl	  pH	  8.0,	  100	  mM	  NaCl,	  1	  mM	  MgCl2,	  5	  mM	  DTT,	  50	  ng·μL-­‐1	  BSA,	  1	  U·μL-­‐1	  RNasin,	  and	  10%	  glycerol)	  and	  a	  20	  nM	  final	  concentration	  of	  tTER.	  	  Samples	  were	  mixed	  on	  ice	  in	  a	  20	  μL	  final	  volume	  then	  incubated	  at	  30	  °C	  for	  10	  min	  before	  electrophoresis	  in	  a	  5%	  (v/v)	  non-­‐denaturing	  polyacrylamide	  gel	  (37.5:1	  acrylamide/bisacrylamide,	  0.5X	  TBE)	  in	  0.5X	  TBE	  at	  200	  volts	  for	  2.5	  hours	  at	  4	  °C.	  	  A	  heat	  denatured	  Low	  Range	  ssRNA	  ladder	  (New	  England	  Biolabs)	  was	  used	  as	  a	  marker.	  	  Bands	  were	  stained	  with	  SYBR®	  Green	  II	  RNA	  gel	  stain	  (Molecular	  Probes)	  and	  visualized	  on	  a	  Storm™	  860	  molecular	  imager	  (GE	  Life	  Sciences).	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4. 1M7	  Acylation	  of	  tTER	  	  RNA	  (1	  pmol)	  was	  first	  heated	  to	  95	  °C	  for	  3	  min	  before	  being	  snap-­‐cooled	  on	  ice	  for	  3	  min	  in	  15	  μL	  of	  low	  ionic	  strength	  buffer	  (Tris	  10	  mM	  EDTA	  1	  mM	  pH	  8.0).	  	  The	  solution	  was	  then	  incubated	  at	  30	  °C	  for	  10	  min	  with	  tTER	  EMSA	  Buffer	  (20	  mM	  Tris	  HCl	  pH	  8.0,	  100	  mM	  NaCl,	  1	  mM	  MgCl2,	  5	  mM	  DTT,	  50	  ng·μL-­‐1	  BSA,	  1	  U·μL-­‐1	  RNasin,	  and	  10%	  glycerol)	  either	  in	  the	  absence	  or	  presence	  of	  four	  picomoles	  of	  purified	  p65	  in	  a	  total	  volume	  of	  27	  μL.	  	  The	  RNA	  was	  immediately	  treated	  with	  3	  μL	  of	  1M7	  (80	  mM	  in	  anhydrous	  DMSO)	  or	  anhydrous	  DMSO	  as	  a	  control	  and	  incubated	  at	  30	  °C	  for	  5	  min	  (five	  1M7	  half	  lives).	  	  The	  solution	  was	  proteolyzed	  for	  60	  min	  at	  37	  °C	  with	  125	  μg/mL	  of	  proteinase	  K	  in	  5x	  tTER	  Hit	  Buffer.	  	  tTER	  was	  precipitated	  with	  ethanol	  in	  the	  presence	  of	  200	  mM	  RNase-­‐free	  NaCl	  (Ambion),	  1	  mM	  EDTA	  (pH	  8.0	  Ambion)	  and	  100	  μg/mL	  of	  RNase-­‐free	  glycogen	  (Ambion).	  	  The	  RNA	  was	  washed	  once	  in	  70%	  ethanol,	  speed	  vacuumed	  until	  dry,	  and	  reconstituted	  in	  9	  μL	  of	  RNase	  free	  water.	  	  	  	  
5. Superscript	  III	  Reverse	  Transcription	  Reaction	  Sites	  of	  1M7-­‐modification	  RNA	  (9	  μl)	  were	  mapped	  by	  adding	  1	  μL	  of	  5'-­‐[32P]-­‐	  labeled	  DNA	  primer.	  	  The	  primer	  used	  for	  targeting	  the	  3’SHAPE	  extension	  was	  5'-­‐GAACCGGACCGAAGCCCG,	  while	  the	  primer	  used	  to	  target	  upstream	  of	  the	  pseudoknot	  was	  5’-­‐GATAGTCTTTTGTCCCGC.	  	  The	  reverse	  transcription	  DNA	  primer	  was	  annealed	  to	  the	  RNA	  by	  heating	  the	  mixture	  to	  95	  °C	  for	  1	  min,	  65	  °C	  for	  6	  min,	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35	  °C	  for	  10	  min,	  and	  on	  ice	  for	  2	  min	  before	  the	  immediate	  addition	  of	  4	  μL	  of	  5X	  First-­‐Strand	  Buffer	  (Invitrogen)	  reverse	  transcription	  buffer	  (250	  mM	  Tris-­‐Cl	  pH	  8.3,	  375	  mM	  KCl,	  15	  mM	  MgCl2),	  1	  μL	  of	  100	  mM	  DTT,	  1	  μL	  of	  10	  mM	  dNTPs,	  and	  0.5	  μL	  of	  Superscript	  III	  reverse	  transcriptase	  (100	  units;	  Invitrogen).	  	  	  Reactions	  were	  pipette	  mixed,	  spun	  down	  to	  collect	  all	  condensation,	  incubated	  at	  45	  °C	  for	  2	  min	  to	  ensure	  proper	  primer	  binding,	  52	  °C	  for	  35	  min	  to	  allow	  elongation,	  and	  65	  °C	  for	  5	  min	  to	  heat	  denature	  the	  enzyme.	  	  All	  reactions	  were	  then	  placed	  on	  ice	  for	  at	  least	  5	  min.	  	  The	  reactions	  were	  quenched	  by	  adding	  16.5	  μL	  of	  400	  mM	  NaOH	  and	  heated	  at	  95	  °C	  for	  5	  min	  before	  being	  neutralized	  by	  adding	  16.5	  μL	  of	  400	  mM	  HCl.	  	  	  Next,	  the	  reactions	  were	  ethanol	  precipitated	  in	  the	  presence	  of	  4.95	  μL	  of	  3	  molar	  sodium	  acetate	  (pH	  5.5)	  and	  4.4	  μL	  of	  500	  mM	  EDTA	  (pH	  8.0)	  and	  suspended	  in	  10	  μL	  of	  formamide	  loading	  buffer	  (94.2	  %	  formamide,	  44.5	  mM	  Tris/borate,	  1	  mM	  EDTA,	  0.01%	  xylene	  cyanol	  FF,	  0.01%	  bromophenol	  blue).	  	  Dideoxythymidine	  sequencing	  ladders	  were	  generated	  by	  the	  adding	  of	  1	  μL	  of	  5	  mM	  ddTTP	  to	  the	  reverse	  transcription	  reaction	  of	  unmodified	  RNAs.	  	  
6. Sequencing	  Gel	  Electrophoresis	  The	  radiolabeled	  extension	  products	  generated	  by	  reverse	  transcription	  of	  1M7	  acylated	  RNAs	  were	  separated	  by	  electrophoresis	  on	  40	  cm	  x	  0.4	  cm	  8%	  denaturing	  sequencing	  gels	  (29:1	  acrylamide:	  bisacrylamide/7M	  urea,	  89	  mM	  Tris/borate,	  2	  mM	  EDTA)	  run	  at	  65	  W	  for	  ~1.5	  h	  and	  visualized	  by	  phosphorimaging	  using	  ImageQuant	  5.1.	  
	   75	  
	  
7. SHAPE	  Data	  Standardization	  The	  first	  step	  in	  analyzing	  quantitative	  footprint	  data	  is	  the	  standardization	  procedure	  to	  correct	  for	  differences	  in	  loading	  amounts	  in	  the	  quantified	  footprinting	  data.143	  Standardization	  determines	  ratios	  among	  the	  fitted	  peak	  areas	  to	  a	  selected	  peak	  or	  peaks	  within	  the	  same	  lane.	  	  The	  fully	  reverse	  transcribed	  bands	  in	  each	  lane	  were	  selected	  as	  references.	  	  The	  ratio	  between	  the	  intensity	  of	  the	  faintest	  full-­‐length	  band	  in	  the	  experiment	  that	  was	  performed	  in	  triplicate	  and	  all	  other	  full	  length	  bands	  was	  calculated	  using	  ImageQuant	  TL	  version	  5.0	  (Molecular	  Dynamics).	  	  All	  bands	  within	  a	  lane	  were	  divided	  by	  the	  ratio	  found.	  	  	  	  
8. SHAPE	  Data	  Normalization	  There	  is	  no	  standard	  method	  for	  normalizing	  SHAPE	  data,	  but	  a	  consistent	  approach	  to	  normalization	  is	  important	  for	  comparing	  data	  sets	  and	  making	  accurate	  secondary	  structure	  predictions.	  	  Individual	  band	  intensities	  of	  1M7	  and	  DMSO	  lanes	  were	  integrated	  using	  the	  Semi-­‐automated	  footprint	  analysis	  software	  (SAFA).	  	  	  SAFA	  deconvolutes	  bands	  with	  an	  optimized	  algorithm	  to	  enable	  fast	  lane	  and	  band	  assignments.144	  Hit	  intensities	  were	  normalized	  in	  the	  following	  way.	  	  Band	  intensity	  was	  corrected	  for	  background	  by	  subtracting	  the	  density	  of	  the	  corresponding	  band	  in	  the	  DMSO	  control	  lane.	  	  After	  this	  subtraction,	  any	  negative	  values	  were	  altered	  to	  zero,	  since	  negative	  densities	  tell	  us	  only	  that	  there	  is	  no	  modification	  at	  that	  position.	  	  The	  most	  reactive	  2%	  of	  peaks	  within	  a	  lane	  are	  taken	  to	  be	  outliers.	  	  The	  mean	  reactivity	  of	  the	  same	  lane’s	  next	  8%	  most	  reactive	  nucleotides	  was	  averaged	  and	  used	  to	  divide	  all	  intensities	  within	  that	  lane	  by	  the	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calculated	  value.114,115	  The	  resulting	  reactivities	  typically	  spanned	  a	  scale	  from	  0	  to	  2.	  	  A	  model-­‐free	  box-­‐plot	  normalization	  scheme	  was	  not	  implemented	  where	  reactivities	  greater	  than	  1.5	  times	  the	  interquartile	  range	  are	  considered	  outliers	  and	  were	  removed	  from	  the	  data	  set.	  All	  remaining	  values	  were	  divided	  by	  the	  mean	  of	  the	  next	  highest	  10%	  of	  outlier-­‐subtracted	  data.113	  	  	  This	  decision	  was	  made	  because	  the	  159	  nucleotides	  of	  tTER	  are	  presumed	  to	  be	  too	  short	  to	  implement	  the	  commonly	  used	  model	  free	  box	  plot	  normalization	  scheme	  of	  removing	  outlier	  data	  (typically	  ≥	  300	  reactivity	  measurements).145	  	  	  	  
9. Secondary	  Structural	  Predictions	  Secondary	  structural	  predictions	  on	  the	  stability	  of	  partially	  folded	  pseudoknot	  conformations	  were	  made	  using	  the	  partition	  program	  without	  the	  aid	  of	  SHAPE	  pseudo	  energy	  constraints	  to	  predict	  base	  pair	  probabilities	  using	  a	  partition	  function	  set	  to	  303	  K	  (30	  °C	  of	  SHAPE	  experiment	  and	  not	  the	  default	  temperature	  of	  37	  °C).117-­‐119	  	  Three	  folding	  constraints	  files	  assigning	  base	  pairs	  in	  the	  pseudoknot	  component	  helices	  were	  input	  to	  restrict	  folding.	  	  We	  then	  used	  the	  
Fold	  program	  to	  predict	  the	  lowest	  free	  energy	  structure	  and	  a	  set	  of	  suboptimal	  structures	  at	  303	  K.	  	  	  Finally,	  we	  used	  the	  draw	  program	  to	  make	  a	  postscript	  graph	  of	  the	  RNA	  base	  pairs	  of	  each	  tTER	  sequence.	  	  We	  used	  as	  input	  the	  .pfs	  partition	  function	  save	  file	  generated	  by	  the	  partition	  interface	  from	  which	  base	  pairing	  probability	  data	  was	  read	  for	  annotation.	  	  	  The	  RNA	  backbone	  of	  each	  sequence	  was	  rendered	  as	  a	  
	   77	  
circle	  plot	  in	  which	  base	  pairs	  are	  drawn	  as	  arcs	  between	  nucleotides	  plotted	  around	  the	  circle	  and	  a	  series	  of	  parallel	  arcs	  indicate	  a	  helix.	  	  	  	  Secondary	  structural	  predictions	  that	  did	  use	  SHAPE	  pseudo	  energy	  restraints	  were	  made	  one	  of	  three	  ways.	  	  One	  method	  used	  the	  ShapeKnots	  program	  with	  a	  SHAPE	  data	  file	  containing	  quantified	  intensities	  from	  the	  free	  in	  solution	  or	  the	  p65-­‐bound	  state.146	  	  The	  other	  two	  SHAPE	  directed	  methods	  both	  used	  the	  partition	  program	  set	  to	  303	  K,	  but	  with	  a	  SHAPE	  data	  file.112	  	  	  As	  with	  the	  pseudoknot	  component	  helix	  predictions	  that	  were	  not	  restrained	  by	  SHAPE	  intensities,	  both	  remaining	  methods	  used	  the	  draw	  program	  to	  render	  predictions.	  	  In	  one	  instance,	  the	  lowest	  free	  energy	  structure	  and	  a	  set	  of	  suboptimal	  structures	  were	  predicted	  using	  the	  Fold	  program.121	  	  The	  third	  and	  final	  method	  used	  the	  partition	  function	  save	  file	  as	  input	  into	  the	  ProbKnot	  program	  instead	  of	  the	  Fold	  program.	  	  Again,	  the	  
draw	  program	  was	  used	  to	  render	  circular	  structural	  predictions.	  	  When	  probability	  data	  were	  not	  used	  to	  annotate	  predictions,	  unreactive	  nucleotides	  (SHAPE	  reactivities	  <0.4)	  were	  colored	  black,	  moderately	  reactive	  nucleotides	  (0.4–0.85)	  were	  yellow,	  and	  highly	  reactive	  nucleotides	  (>0.85)	  were	  red.	  	  The	  0.4	  point	  represents	  the	  value	  at	  which	  the	  ΔG°SHAPE	  term	  (Eq.	  1)	  for	  base	  pairing	  transitions	  from	  favorable	  (negative)	  to	  unfavorable	  (positive)	  and	  0.85	  represents	  a	  net	  thermodynamic	  penalty	  of	  0.5	  kcal/mol	  or	  1.0	  kcal/mol	  per	  internal	  dinucleotide	  stack.	  146	  ∆𝐺°!"#$% = m ∗   ln 𝑆𝐻𝐴𝑃𝐸 + 1 + 𝑏        (1)  	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When	  SHAPE	  pseudo	  energy	  restraints	  did	  not	  predict	  a	  pseudoknotted	  tTER	  state,	  folding	  constraints	  were	  input	  into	  the	  partition	  program	  along	  with	  SHAPE	  restraints.	  	  Specifically,	  the	  folding	  constraints	  file	  made	  nucleotides	  from	  positions	  43	  –	  68	  to	  be	  single	  stranded,	  while	  base	  pairs	  between	  positions	  10	  –	  18	  and	  100	  –	  94	  were	  restricted	  from	  forming.	  	  No	  base	  pairs	  were	  assigned	  anywhere	  throughout	  the	  sequence,	  including	  in	  the	  pseudoknot	  region.	  	  Again,	  the	  temperature	  was	  set	  to	  303	  K.	  	  	  	  The	  resulting	  partition	  function	  save	  file	  containing	  SHAPE	  restrained,	  and	  manually	  constrained	  data,	  was	  input	  into	  the	  ProbKnot	  program	  before	  being	  rendered	  with	  the	  draw	  program	  using	  either	  probability	  or	  SHAPE	  data	  annotation.	  Secondary	  structural	  predictions	  were	  evaluated	  using	  the	  scorer	  program	  by	  “sensitivity”	  or	  by	  “positive	  predictive	  value”	  (ppv)	  when	  comparing	  predicted	  structures	  to	  a	  known	  or	  accepted	  secondary	  structure	  of	  tTER.118,147,117,123	  Sensitivity	  is	  the	  percentage	  of	  known	  base	  pairs	  contained	  in	  the	  predicted	  secondary	  structure	  while	  positive	  predictive	  value	  is	  the	  percentage	  of	  predicted	  pairs	  that	  are	  in	  the	  known	  structure.	  	  The	  “accuracy”	  was	  calculated	  as	  the	  geometric	  mean	  of	  both	  the	  sensitivity	  and	  ppv	  for	  the	  test	  set	  using	  each	  algorithm.146	  	  This	  geometric	  mean	  was	  initially	  referred	  to	  as	  “accuracy”	  in	  the	  initial	  description	  of	  the	  ShapeKnots	  algorithm.146	  	  The	  average	  of	  sensitivities	  and	  ppv	  for	  each	  test	  case	  was	  referred	  to	  as	  “mean”	  to	  quantify	  comparisons	  of	  accuracies	  using	  one	  statistical	  measure.	  The	  test	  sets	  were	  defined	  as:	  	  1)	  unconstrained,	  2)	  free	  in	  solution	  SHAPE	  directed,	  3)	  p65-­‐bound	  SHAPE	  directed,	  and	  4)	  tTERT-­‐bound	  SHAPE	  directed	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predictions.	  	  Data	  set	  sensitivities	  and	  ppv’s	  were	  compared	  using	  the	  paired,	  two	  tailed	  Student’s	  t-­‐test	  where	  the	  null	  hypothesis	  was	  that	  the	  use	  of	  different	  SHAPE	  intensities	  had	  no	  effect	  on	  prediction	  accuracy.	  	  Probabilities	  exceeding	  0.05	  were	  considered	  to	  not	  be	  statistically	  significant.	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RESULTS	  
1. EMSA	  	  We	  expressed	  and	  purified	  recombinant	  p65	  bearing	  an	  N-­‐terminal	  His6-­‐tag.	  	  The	  recombinant	  p65	  protein	  was	  expected	  to	  run	  between	  50	  and	  90	  kDa.97	  	  As	  shown	  in	  figure	  3.4a,	  p65	  ran	  just	  above	  the	  70	  kDa	  red	  reference	  band.	  	  Other	  protein	  bands	  present	  in	  the	  lane	  denote	  release	  of	  His6-­‐tagged	  p65	  from	  nickel	  containing	  agarose	  beads	  using	  increasing	  imidazole	  concentration.	  	  Remaining	  imidazole	  was	  eliminated	  from	  p65	  in	  subsequent	  dialysis	  against	  a	  permeable	  membrane	  (data	  not	  shown)	  to	  yield	  p65	  at	  approximately	  2	  mg·mL-­‐1.	  	  	  This	  was	  more	  than	  concentrated	  enough	  to	  perform	  subsequent	  experiments	  with.	  	  	  tTER	  was	  snap-­‐cooled	  before	  performing	  electrophoretic	  mobility	  shift	  assays	  to	  avoid	  misfolded	  RNAs	  and	  to	  generate	  the	  most	  thermodynamically	  stable	  structures.148	  A	  titration	  of	  p65	  with	  tTER	  showed	  that	  the	  protein-­‐bound	  tTER	  in	  a	  ratio	  of	  1:1,	  as	  expected	  (see	  Figure	  3.4b).97	  	  We	  estimated	  the	  binding	  affinity	  to	  be	  ~	  7	  nM,	  in	  agreement	  with	  single	  digit	  affinities	  observed	  in	  previous	  studies.94,97	  Increasing	  ratios	  of	  p65	  to	  tTER	  resulted	  in	  higher	  order	  complexes	  with	  p65	  bound	  to	  multiple	  copies	  of	  tTER	  or	  tTER	  bound	  to	  multiple	  copies	  of	  p65.	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2. SHAPE	  of	  tTER	  Bound	  to	  p65	  We	  required	  two	  primers	  to	  fully	  map	  all	  159	  tTER-­‐C	  nucleotides,	  due	  to	  our	  inability	  to	  resolve	  some	  of	  the	  longer	  tTER	  reverse	  transcripts.	  	  Bands	  that	  were	  5’	  of	  the	  template	  could	  not	  be	  separated	  well	  enough	  to	  be	  quantified	  by	  SAFA	  software	  using	  the	  primer	  that	  annealed	  to	  the	  3'	  extension	  of	  tTER-­‐C.	  	  A	  second	  primer	  whose	  3’	  end	  was	  complementary	  to	  residue	  G103	  was	  employed	  to	  increase	  resolution	  of	  cDNAs	  copied	  from	  the	  5’	  end	  of	  tTER-­‐C.	  	  Figure	  3.5	  depicts	  representative	  gels	  of	  SHAPE	  assays	  whose	  bands	  were	  quantified	  using	  SAFA	  software.	  Bands	  were	  next	  standardized	  and	  normalized	  following	  SAFA	  quantification.	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  While	  there	  is	  no	  general	  protocol	  for	  standardizing	  and	  normalizing	  quantified	  footprint	  data,	  common	  practice	  in	  data	  analysis	  is	  to	  eliminate	  data	  points	  that	  fall	  outside	  the	  95%	  confidence	  interval	  of	  the	  average.	  	  	  That	  is,	  data	  that	  is	  greater	  than	  or	  less	  than	  two	  times	  the	  standard	  error	  from	  the	  mean	  are	  ignored.	  	  We	  refer	  to	  this	  criterion	  as	  the	  “2S”	  test.	  	  Section	  8	  of	  the	  “Materials	  and	  Methods”	  section	  discusses	  the	  inability	  to	  calculate	  meaningful	  statistics	  from	  a	  data	  set	  as	  small	  as	  the	  159	  nucleotide	  tTER.145	  	  Data	  rejection	  is	  not	  necessarily	  more	  scientifically	  or	  methodologically	  sound	  than	  retaining	  data,	  although	  mathematical	  criteria	  like	  the	  2S	  test	  may	  provide	  an	  objective	  and	  quantitative	  method	  for	  data	  rejection.	  	  SHAPE	  intensities	  can	  be	  lost	  at	  individual	  nucleotide	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positions	  when	  ignoring	  data	  more	  than	  two	  standard	  errors	  outside	  of	  the	  arithmetic	  mean.	  	  Ignoring	  data	  can	  drastically	  alter	  the	  arithmetic	  mean	  of	  a	  given	  data	  set	  and	  may	  alter	  confidence	  in	  our	  secondary	  structural	  prediction	  and	  subsequent	  model	  of	  the	  telomerase	  RNP.	  	  SHAPE	  observations	  must	  be	  ignored	  when	  the	  two	  standard	  error	  criterion	  is	  applied	  to	  our	  p65-­‐bound	  tTER	  data,	  as	  demonstrated	  in	  Figure	  3.6.	  	  No	  observed	  SHAPE	  intensities	  fell	  within	  the	  two	  standard	  error	  range	  for	  a	  small	  percentage	  of	  nucleotide	  positions	  (~30/160).	  	  Lost	  observations	  came	  almost	  exclusively	  from	  the	  pseudoknot	  region	  at	  nucleotide	  positions	  54-­‐	  104.	  Predictably,	  the	  standard	  error	  decreased	  significantly	  at	  many	  nucleotide	  positions	  of	  outlier-­‐removed	  SHAPE	  data	  sets	  when	  the	  2S	  test	  was	  applied	  (to	  prevent	  confusion,	  the	  error	  bars	  are	  not	  displayed	  in	  Figure	  3.6).	  Figure	  3.6	  also	  illustrates	  that	  there	  does	  not	  appear	  to	  be	  an	  appreciable	  difference	  between	  the	  protocols	  used	  to	  standardize	  and	  normalize	  quantified	  SHAPE	  sequencing	  gel	  bands.	  	  There	  was	  no	  appreciable	  difference	  in	  the	  trends	  of	  1M7	  modification	  between	  the	  two	  procedures,	  despite	  the	  loss	  of	  some	  data	  points	  at	  key	  pseudoknot	  positions	  when	  outliers	  are	  ignored	  and	  the	  arithmetic	  mean	  of	  SHAPE	  intensities	  is	  recalculated.	  	  Therefore,	  we	  did	  not	  apply	  the	  two	  standard	  error	  criteria	  when	  evaluating	  SHAPE	  data	  so	  that	  data	  on	  all	  nucleotide	  positions	  could	  be	  retained.	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3. SHAPE	  Reactivity	  Profile	  of	  p65	  Bound	  Wildtype	  tTER	  The	  RNA	  structural	  changes	  that	  differentiate	  two	  states	  can	  be	  identified	  rapidly	  by	  simply	  subtracting	  one	  reactivity	  profile	  from	  another	  because	  SHAPE	  data	  is	  quantitative	  and	  normalized	  similarly	  for	  all	  data	  sets.113	  	  	  Subtracting	  protein-­‐free	  SHAPE	  intensities	  from	  tTERT-­‐bound	  values	  proved	  to	  be	  effective	  to	  distinguish	  protein	  free	  in	  vitro	  transcribed	  tTER	  conformational	  states	  from	  tTERT-­‐bound	  ones.86	  	  	  This	  profile	  subtraction	  method	  was	  repeated	  here	  with	  p65.	  	  The	  difference	  plot	  emphasizing	  changes	  in	  1M7	  modification	  of	  protein-­‐free	  tTER	  and	  p65-­‐bound	  states	  is	  shown	  in	  Figure	  3.7.	  	  tTER	  was	  divided	  into	  seven	  named	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regions	  designated	  with	  the	  letters	  “a”	  through	  “g”	  in	  the	  following	  sub-­‐sections	  where	  the	  results	  of	  SHAPE	  analysis	  of	  each	  region	  are	  discussed	  separately.	  	  
	  
a. Helix	  I	  The	  SHAPE	  reactivities	  of	  helix	  I	  nucleotides	  shown	  in	  Figure	  3.8	  predicted	  a	  secondary	  structure	  that	  was	  in	  strong	  agreement	  with	  the	  accepted	  structure.127	  	  Nucleotides	  103	  –	  107	  were	  generally	  not	  modified.	  	  The	  trend	  observed	  in	  helix	  I	  was	  slightly	  increased	  1M7	  reactivity	  in	  p65-­‐bound	  tTER	  as	  compared	  to	  protein-­‐free	  tTER.	  	  Statistically	  different	  reactivities	  were	  generally	  not	  observed	  in	  helix	  I	  though,	  as	  only	  G103	  exhibited	  a	  mean	  absolute	  reactivity	  difference	  of	  ≥	  0.3	  SHAPE	  units	  and	  a	  p-­‐value	  <	  0.05	  (data	  not	  shown).149	  	  Despite	  using	  an	  internal	  primer,	  we	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were	  still	  unable	  to	  resolve	  nucleotides	  5’	  of	  nucleotide	  U10.	  	  Therefore,	  bands	  corresponding	  to	  nucleotides	  4-­‐8	  that	  are	  predicted	  to	  form	  one-­‐half	  of	  the	  base	  pairs	  in	  helix	  I	  could	  not	  be	  quantified.	  	  The	  nucleotides	  108	  -­‐	  111	  were	  predicted	  to	  separate	  helices	  I	  and	  IV	  and	  showed	  moderate	  protection	  upon	  binding.	  	  Nucleotides	  108	  and	  109	  were	  unreactive	  (19%	  and	  27%,	  respectively)	  while	  110	  and	  111	  were	  moderately	  reactive	  (49%	  and	  64%,	  respectively).	  	  Although	  the	  nucleotides	  still	  exhibited	  reactivities	  higher	  than	  well-­‐formed	  helices	  such	  as	  103-­‐107,	  only	  A110	  was	  significantly	  lower	  when	  bound	  to	  p65.	  	  	  The	  moderate	  protection	  in	  nucleotide	  A110	  in	  the	  presence	  of	  p65	  was	  not	  repeated	  as	  tTERT	  bound	  tTER.	  	  Positions	  108-­‐111	  were	  protected	  during	  tTERT	  binding	  whereas	  only	  position	  A110	  was	  protected	  from	  1M7	  modification	  when	  p65	  bound	  tTER.	  	  	  Although	  the	  diminished	  1M7	  modification	  at	  position	  A110	  could	  be	  reporting	  on	  decreased	  flexibility	  in	  this	  single	  stranded	  region	  upon	  protein	  binding,86	  it	  is	  likely	  that	  p65	  does	  not	  induce	  the	  same	  changes	  as	  tTERT	  does	  in	  tTER	  nucleotides	  separating	  helices	  I	  and	  IV.	  	  	  Nucleotide	  U102,	  just	  upstream	  of	  helix	  I,	  was	  the	  most	  reactive	  in	  p65-­‐bound	  tTER.	  	  The	  intensity	  of	  1.9	  SHAPE	  units	  fell	  just	  below	  the	  2-­‐10	  range	  seen	  in	  hyper-­‐reactive	  nucleotides.124	  	  The	  difference	  in	  protein-­‐bound	  and	  free	  in	  solution	  U102	  was	  significant	  (nearly	  1.4	  absolute	  SHAPE	  units),	  with	  much	  more	  modification	  observed	  in	  the	  p65-­‐bound	  tTER.	  	  Nucleotide	  A101	  (65%)	  was	  also	  shown	  to	  be	  significantly	  more	  reactive	  to	  1M7	  in	  the	  p65-­‐bound	  state	  than	  when	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free	  in	  solution.	  	  The	  lack	  of	  modification	  of	  nucleotide	  A100	  was	  virtually	  unchanged	  from	  free	  in	  solution	  to	  p65-­‐bound	  states.	  Nucleotides	  10-­‐19	  that	  were	  predicted	  to	  separate	  helices	  I	  and	  II	  were	  unreactive	  to1M7	  modification	  in	  the	  presence	  of	  p65.	  	  Despite	  the	  variable	  levels	  of	  1M7	  acylation	  within	  this	  region,	  the	  region	  as	  a	  whole	  demonstrated	  significantly	  less	  1M7	  modification	  in	  the	  p65	  state	  than	  in	  the	  free	  state.	  	  	  Nucleotides	  U10-­‐U14	  in	  particular	  were	  protected	  the	  most	  from	  1M7	  in	  the	  region,	  as	  only	  A11	  did	  not	  decrease	  SHAPE	  intensity	  0.3	  units	  or	  more.	  	  	  Nucleotides	  15-­‐CAUU-­‐18,	  which	  were	  predicted	  to	  form	  a	  tTERT-­‐binding	  site	  that	  acts	  in	  conjunction	  with	  the	  base	  of	  helix	  II	  and	  the	  template	  boundary	  element	  further	  downstream,55	  all	  became	  protected	  from	  1M7	  modification	  when	  p65	  was	  bound	  to	  tTER.	  	  The	  lack	  of	  moderate	  SHAPE	  intensities	  of	  nucleotides	  15-­‐CA-­‐16,	  which	  when	  mutated	  prevent	  tTERT	  binding,	  is	  inconsistent	  with	  1M7	  reporting	  on	  both	  reactive	  and	  unreactive	  tTER	  populations.	  	  We	  would	  expect	  to	  see	  moderate	  intensities	  in	  nucleotides	  15-­‐CAUU-­‐18,	  but	  not	  the	  unreactive	  intensities	  observed,	  if	  the	  tTERT-­‐binding	  site	  oscillated	  between	  base-­‐paired	  and	  single-­‐stranded	  states	  as	  tTER-­‐bound	  p65.	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b. Helix	  II	  As	  Figure	  3.9	  shows,	  helix	  II	  appeared	  to	  be	  well	  formed	  in	  p65-­‐bound	  tTER	  as	  the	  base	  of	  helix	  II	  and	  all	  of	  the	  other	  predicted	  helix	  II	  base	  pairs	  remained	  largely	  unmodified.	  Nucleotides	  19	  –	  25	  and	  31-­‐37,	  including	  the	  two	  adenine	  nucleotides	  A22	  and	  A34	  that	  were	  predicted	  to	  be	  unpaired,	  showed	  no	  significant	  changes	  in	  1M7	  intensities	  as	  the	  p65	  protein	  bound	  tTER.	  	  Stem	  loop	  II	  nucleotides	  26	  -­‐	  30	  were	  unreactive	  in	  the	  presence	  of	  p65	  but	  highly	  reactive	  when	  free	  in	  solution.	  	  The	  p65	  protein	  reduced	  1M7	  acylation	  of	  stem	  loop	  II	  more	  than	  tTERT	  had	  reduced	  NMIA	  acylation	  of	  the	  same	  region	  in	  our	  previous	  studies.86	  	  Nucleotide	  A28	  showed	  the	  absolute	  largest	  decrease	  in	  SHAPE	  reactivity	  of	  any	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other	  tTER	  nucleotide	  when	  bound	  to	  p65,	  while	  U30	  showed	  the	  second-­‐largest	  decrease.	  	  	  
	  
c. Template	  Boundary	  Element	  SHAPE	  intensities	  in	  the	  TBE	  region	  (positions	  38-­‐42)	  of	  p65-­‐bound	  tTER	  were	  consistent	  with	  a	  well-­‐structured	  region,	  as	  all	  of	  the	  nucleotides	  were	  unreactive	  (Figure	  3.10).	  When	  bound	  to	  p65,	  nucleotides	  upstream	  of	  the	  template	  became	  increasingly	  protected	  from	  1M7	  as	  the	  sequence	  approached	  the	  5’	  end	  of	  the	  template.	  	  The	  absolute	  change	  in	  protection	  from	  1M7	  modification	  of	  nucleotides	  38-­‐42	  was	  more	  than	  that	  observed	  in	  the	  same	  nucleotides	  when	  bound	  to	  tTERT.	  	  Similarly,	  SHAPE	  intensities	  decreased	  in	  the	  TBE	  region	  more	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than	  in	  the	  high-­‐affinity	  tTERT	  binding	  site	  region	  of	  15-­‐CAUU-­‐18	  as	  when	  protein	  free	  and	  p65-­‐tTER	  are	  compared.	  	  	  
d. Template	  Region	  The	  template	  region,	  which	  includes	  nucleotides	  43-­‐51,	  displayed	  SHAPE	  intensities	  consistent	  with	  a	  mostly	  structured	  state.	  	  As	  Figure	  3.10	  shows,	  alongside	  TBE	  nucleotides,	  only	  position	  C43	  was	  moderately	  reactive	  while	  all	  other	  nucleotides	  were	  unreactive	  to	  1M7.	  	  Long-­‐range	  base	  pairs	  predicted	  to	  form	  between	  the	  template	  and	  nucleotides	  99-­‐97	  are	  in	  the	  free	  in	  solution	  structure	  change	  when	  in	  the	  p65-­‐bound	  state,	  as	  U99	  was	  highly	  reactive	  and	  U96	  was	  moderately	  reactive	  in	  p65-­‐bound	  tTER.	  	  The	  higher	  intensities	  of	  positions	  99-­‐97	  when	  p65	  was	  present	  was	  inconsistent	  with	  them	  participating	  in	  base	  pairing	  interactions	  with	  positions	  45-­‐47	  like	  in	  the	  protein	  free	  state	  (Figure	  2.2).	  	  The	  entire	  nine-­‐nucleotide	  template	  region	  became	  protected	  from	  1M7	  acylation	  when	  in	  the	  presence	  of	  p65.	  	  	  Nucleotides	  50	  and	  52,	  moderately	  reactive	  when	  free	  in	  solution,	  became	  protected	  from	  1M7	  in	  the	  presence	  of	  p65	  but	  remained	  moderately	  reactive	  when	  bound	  to	  tTERT.86	  	  The	  SHAPE	  intensities	  of	  the	  template	  nucleotides	  appeared	  to	  differ	  from	  both	  the	  protein	  free	  and	  tTERT	  bound	  states.	  	  The	  intensities	  of	  positions	  A44	  and	  A50	  remained	  moderate	  (0.4	  –	  0.8)	  as	  tTERT-­‐bound	  tTER,	  while	  both	  positions	  were	  unmodified	  in	  the	  presence	  of	  p65.	  Template	  nucleotides	  were	  probably	  in	  a	  different	  conformation	  when	  bound	  to	  p65	  as	  compared	  to	  when	  free	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in	  solution.	  	  As	  evidenced	  by	  the	  decreased	  SHAPE	  intensities	  illustrated	  in	  Figure	  3.10,	  the	  template	  may	  sample	  more	  structured	  conformations	  upon	  binding	  p65.	  	  	  
	  
e. Template	  Recognition	  Element	  As	  Figure	  3.11	  shows,	  SHAPE	  intensities	  of	  nucleotides	  53	  -­‐	  65	  were	  all	  below	  0.2	  SHAPE	  units,	  consistent	  with	  the	  elongated	  helix	  III	  formed	  in	  free	  in	  solution	  tTER.	  	  This	  contrasts	  the	  effect	  of	  tTERT	  on	  SHAPE	  intensities	  of	  the	  TRE	  residues.	  	  SHAPE	  intensities	  of	  nucleotide	  positions	  65	  –	  68	  were,	  however,	  moderately	  reactive	  to	  1M7	  and	  could	  be	  consistent	  with	  either	  protein-­‐free	  or	  tTERT-­‐bound	  tTER	  states.	  	  In	  the	  presence	  of	  tTERT,	  the	  TRE	  showed	  increased	  SHAPE	  intensities	  when	  compared	  to	  protein-­‐free	  tTER,	  consistent	  with	  rearrangement	  during	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telomerase	  assembly	  and	  placement	  of	  the	  template	  nucleotides	  within	  the	  reverse	  transcriptase	  active	  site.	  	  In	  the	  presence	  of	  p65	  however,	  the	  TRE	  SHAPE	  intensities	  either	  went	  unchanged	  or	  decreased	  at	  positions	  65	  –	  68.	  	  Despite	  being	  consistent	  with	  the	  solution	  state	  misfolded	  helix	  III,	  nucleotides	  in	  the	  p65-­‐bound	  template	  recognition	  element	  were	  probably	  not	  in	  the	  same	  conformational	  state	  as	  tTERT-­‐bound	  TRE	  nucleotides,	  as	  evidenced	  by	  the	  opposite	  trends	  in	  conformational	  flexibility	  in	  this	  region	  depending	  on	  which	  protein	  was	  bound.	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f. Helix	  IV	  The	  SHAPE	  reactivity	  profile	  of	  helix	  IV	  nucleotides	  in	  p65-­‐bound	  tTER	  is	  consistent	  with	  the	  previously	  determined	  structure	  (Figure	  3.12).125	  	  The	  3’	  poly-­‐U	  tail	  nucleotides	  159-­‐155	  were	  highly	  reactive	  to	  1M7	  in	  the	  presence	  of	  p65,	  suggesting	  that	  they	  remained	  conformationally	  unconstrained.	  	  In	  fact,	  nucleotides	  from	  the	  3’	  terminal	  nucleotide	  U159	  to	  U153	  were	  highly	  reactive	  in	  the	  presence	  of	  p65.	  	  As	  when	  tTERT	  binds	  tTER,	  these	  nucleotides	  also	  displayed	  increased	  reactivities	  when	  compared	  to	  protein-­‐free	  tTER.	  	  Nucleotides	  139-­‐152	  on	  the	  3’	  side	  of	  helix	  IV	  all	  displayed	  low	  reactivities	  consistent	  with	  predicted	  base	  pairing.	  	  	  	  However,	  nucleotide	  138	  –	  132	  intensities	  were	  high	  yet	  consistent	  with	  the	  highly	  structured	  seven-­‐nucleotide	  loop	  reported	  extensively	  elsewhere.86,125,126	  	  The	  loop	  residues	  appeared	  to	  be	  stabilized	  by	  p65,	  as	  they	  were	  less	  reactive	  to	  1M7	  in	  the	  presence	  of	  the	  protein	  than	  when	  free	  in	  solution.	  	  This	  is	  consistent	  with	  the	  reduced	  number	  of	  folding	  states	  available	  to	  tTER,	  similar	  to	  the	  effect	  of	  tTERT.	  	  Unlike	  tTERT-­‐bound	  tTER,	  almost	  the	  entire	  5’	  side	  of	  helix	  IV	  was	  protected	  from	  SHAPE	  modification	  in	  the	  presence	  of	  p65,	  consistent	  with	  this	  being	  a	  primary	  binding	  site	  for	  p65.94,96,100	  Despite	  the	  existence	  of	  three	  bulges	  on	  the	  5’	  side	  of	  the	  helix,	  there	  were	  no	  reactive	  nucleotides	  from	  positions	  112	  -­‐	  131.	  	  The	  SHAPE	  intensities	  of	  the	  5’	  side	  of	  helix	  IV	  were	  consistent	  with	  protection	  from	  modification	  due	  to	  p65	  binding.	  	  	  Interestingly,	  nucleotides	  in	  the	  predicted	  bulge	  regions	  of	  helix	  IV	  populated	  states	  that	  were	  protected	  from	  1M7	  modification	  in	  the	  presence	  of	  p65.	  	  Therefore	  it	  was	  surprising	  to	  observe	  dynamic	  flexibility	  in	  helix	  IV	  bulges	  because	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electrophoretic	  mobility	  and	  transient	  electric	  birefringence	  analyses	  indicate	  that	  bulges	  are	  not	  points	  of	  flexibility,	  but	  rather	  are	  rigid.150-­‐153	  Helix	  IV	  bulges	  included	  positions	  117,	  U125-­‐U127,	  and	  the	  conserved	  GA	  bulge	  at	  positions	  121	  and	  122.	  	  	  The	  decrease	  in	  121-­‐GA-­‐122	  bulge	  activity	  was	  predicted	  based	  on	  a	  recent	  structure	  of	  the	  stem	  IV-­‐binding	  domain	  of	  p65-­‐bound	  to	  stem	  IV.96	  	  The	  two	  GA	  bulge	  purine	  rings	  interact	  with	  Y407	  of	  p65,	  presumably	  preventing	  1M7	  acylation	  of	  their	  associated	  ribose	  2’	  hydroxyls	  via	  steric	  clashes	  or	  decreased	  flexibility.	  	  Although	  the	  bulged	  U117	  decreased	  SHAPE	  reactivities	  in	  both	  the	  p65-­‐	  and	  tTERT-­‐bound	  states,	  the	  GA	  bulge	  was	  not	  protected	  from	  NMIA	  modification	  in	  reverse	  transcriptase-­‐bound	  tTER,	  in	  contrast	  to	  the	  p65-­‐bound	  tTER	  state.86	  	  	  Decreased	  detection	  of	  2’-­‐O-­‐adducts	  in	  the	  other	  bulges	  on	  the	  5’	  side	  of	  helix	  IV	  was	  consistent	  with	  decreased	  conformational	  flexibility	  in	  the	  helix,	  as	  helix	  IV	  was	  reported	  to	  populate	  a	  specific	  kinked	  state	  when	  bound	  to	  p65.95,96	  The	  only	  other	  nucleotide	  on	  the	  5’	  side	  of	  helix	  IV	  that	  was	  significantly	  lower	  in	  intensity	  when	  bound	  by	  p65	  was	  A131.	  	  None	  of	  the	  other	  nucleotides	  on	  the	  5’	  side	  of	  helix	  IV	  changed	  intensities	  in	  the	  presence	  of	  p65.	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g. Helix	  III	  The	  most	  intriguing	  question	  is	  whether	  p65	  alter	  helix	  III	  from	  the	  elongated	  protein	  free	  state	  to	  the	  pseudoknotted	  state	  associated	  with	  TERT	  binding.	  The	  pseudoknot	  region	  begins	  at	  position	  A69	  and	  ends	  at	  position	  U99.	  	  As	  shown	  in	  Figure	  3.13,	  nucleotides	  in	  the	  pseudoknot	  structure	  are	  altered	  to	  an	  intermediate	  conformation	  when	  bound	  by	  p65.	  	  Positions	  99	  –	  92	  are	  predicted	  to	  form	  the	  3’	  half	  of	  pseudoknot	  stem	  IIIb	  and	  should	  be	  unmodified	  by	  1M7	  in	  the	  presence	  of	  p65,	  if	  p65	  induces	  tTER	  to	  populate	  states	  more	  like	  the	  functional	  pseudoknot.	  	  Only	  G98	  and	  G97	  were	  unreactive	  to	  1M7,	  while	  U99	  was	  moderately	  reactive	  (44%).	  	  Positions	  96	  through	  92	  were	  mostly	  moderately	  reactive,	  as	  only	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positions	  U92	  and	  U96	  had	  reactivities	  exceeding	  85%.	  	  If	  the	  misfolded	  helix	  that	  is	  populated	  by	  protein-­‐free	  tTER	  persisted	  in	  the	  presence	  of	  p65,	  we	  would	  expect	  to	  observe	  high	  intensities	  in	  nucleotide	  positions	  88	  through	  94	  and	  in	  96.	  	  We	  recorded	  high	  intensities	  only	  at	  positions	  88,	  92,	  and	  96.	  	  The	  moderate	  reactivities	  seen	  in	  A94,	  A93	  may	  be	  consistent	  with	  triple-­‐base	  pair	  formation	  that	  is	  predicted	  here,	  but	  the	  high	  reactivity	  of	  U92	  is	  not	  consistent	  with	  forming	  the	  terminal	  base	  pair	  of	  stem	  IIIb.	  	  Positions	  88	  -­‐	  91	  are	  predicted	  to	  form	  loop	  3	  of	  the	  folded	  pseudoknot.	  	  High	  levels	  of	  1M7	  modification	  were	  to	  be	  expected	  of	  a	  single	  stranded	  loop	  3	  if	  p65	  induces	  tTER	  to	  a	  state	  more	  like	  the	  native	  folded	  pseudoknot	  structure.	  	  Position	  C88	  was	  the	  most	  reactive	  nucleotide	  in	  p65	  bound	  tTER.	  	  Positions	  89-­‐90	  were	  only	  moderately	  reactive.	  	  Positions	  87	  –	  76	  are	  predicted	  to	  be	  base	  paired	  in	  pseudoknotted	  tTER	  and	  should	  be	  unmodified	  by	  1M7	  if	  tTER	  populates	  this	  state,	  as	  again,	  we	  would	  expect	  to	  find	  a	  reactive	  loop	  at	  positions	  78	  –	  81	  if	  the	  misfolded	  helix	  3	  state	  was	  populated	  instead.	  	  	  	  	  Only	  U85	  and	  G86	  and	  positions	  78	  and	  79	  displayed	  moderate	  reactivities	  in	  this	  region;	  the	  others	  were	  unreactive.	  	  	  The	  moderate	  reactivities	  in	  A79	  and	  C78	  do	  not	  support	  formation	  of	  base	  pairs	  at	  the	  proximal	  end	  of	  the	  5’	  side	  of	  helix	  IIIb,	  but	  probably	  reflect	  reporting	  on	  the	  elongated	  helix	  as	  well	  as	  the	  folded	  AU-­‐rich	  helix	  IIIb	  of	  the	  pseudoknot.	  	  The	  proposed	  base-­‐pairing	  partners	  to	  A79	  and	  C78	  in	  the	  folded	  pseudoknot	  of	  positions	  U96	  and	  G97	  were	  not	  protected	  from	  1M7	  modification	  as	  would	  be	  expected	  if	  the	  base	  pairs	  were	  made.	  	  In	  the	  presence	  of	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p65,	  U96	  was	  the	  second	  most	  reactive	  position	  while	  G97	  exhibited	  moderate	  modification	  (~30%).	  	  	  Nucleotides	  C71	  to	  A76	  were	  unreactive	  and	  U73	  and	  U74	  are	  predicted	  to	  form	  a	  minor	  groove	  triplex	  with	  U81	  and	  U82.128	  	  The	  low	  reactivities	  noted	  in	  tTER	  positions	  81	  and	  82	  are	  consistent	  with	  triplex	  formation.	  	  The	  moderate	  intensities	  could	  be	  indicative	  of	  U73	  and	  U74	  populating	  states	  in	  which	  hydrogen	  bonds	  form	  between	  the	  N1	  position	  of	  uracils	  73	  and	  74	  and	  the	  2’-­‐hydroxyl	  groups	  of	  U81	  and	  U82.	  	  States	  containing	  an	  AUU	  minor	  groove	  triplex-­‐base	  triple	  would	  presumably	  protect	  the	  2’	  hydroxyls	  of	  U81	  and	  U82	  from	  1M7	  modification.	  	  	  The	  secondary	  structure	  of	  the	  human	  telomerase	  RNA	  triplex	  was	  robustly	  modeled	  with	  100%	  accuracy	  using	  ShapeKnots	  software.146	  	  Positions	  69	  and	  70,	  which	  are	  predicted	  to	  participate	  in	  stem	  1	  base	  pairs	  of	  the	  putative	  pseudoknot,	  were	  unreactive	  and	  indicative	  of	  a	  base	  paired	  state.	  	  A69	  and	  A70	  would	  be	  expected	  to	  be	  highly	  reactive	  if	  the	  misfolded	  protein-­‐free	  state	  persisted	  in	  the	  presence	  of	  p65.	  	  	   If	  states	  containing	  the	  loop	  predicted	  to	  form	  in	  protein-­‐free	  misfolded	  tTER	  were	  populated	  in	  the	  presence	  of	  p65,	  we	  would	  predict	  high	  reactivities	  in	  nucleotides	  65	  through	  70	  because	  they	  form	  a	  loop	  in	  the	  misfolded	  structure.	  	  Instead,	  we	  observed	  moderate	  intensities	  in	  nucleotide	  positions	  65	  –	  68,	  and	  low	  intensities	  in	  69	  and	  70.	  	  U68,	  A69,	  and	  A70	  were	  highly	  reactive	  to	  NMIA	  in	  the	  protein	  free	  state.	  	  The	  p65-­‐bound	  SHAPE	  values	  in	  the	  predicted	  loop	  region	  were	  also	  less	  intense	  than	  the	  free	  in	  solution	  values,	  suggesting	  restriction	  by	  p65	  of	  some	  sort.	  	  The	  SHAPE	  characteristics	  of	  nucleotides	  65	  –	  70	  were	  inconsistent	  with	  
	   98	  
misfolded	  helix	  3	  and	  were	  perhaps	  more	  consistent	  with	  base	  pairs	  formed	  from	  helix	  IIIa	  of	  the	  pseudoknot.	  	  This	  hypothesis	  is	  further	  bolstered	  by	  the	  unreactivity	  of	  positions	  71	  and	  72	  that	  are	  predicted	  to	  complete	  the	  5’	  side	  of	  helix	  IIIa	  in	  the	  folded	  pseudoknot.	  
	  
4. Pseudoknot	  Component	  Helix	  Energy	  Predictions	  This	  thesis	  concentrates	  on	  four	  possible	  base	  pair	  configurations	  of	  the	  pseudoknot	  region	  in	  the	  context	  of	  the	  full-­‐length	  tTER	  sequence.	  	  The	  first	  configuration	  is	  the	  elongated	  helix	  that	  forms	  in	  the	  protein-­‐free	  state.	  	  The	  next	  configuration	  is	  the	  folded	  pseudoknot	  that	  forms	  in	  the	  active	  telomerase	  complex	  when	  both	  p65	  and	  TERT	  are	  bound	  to	  tTER.	  	  The	  third	  is	  the	  formation	  of	  the	  GC	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rich	  component	  helix	  of	  the	  pseudoknot,	  and	  the	  fourth	  is	  the	  formation	  of	  the	  AU-­‐rich	  component	  helix	  of	  the	  pseudoknot.	  	  	  As	  Figure	  3.14	  illustrates,	  base	  pair	  probabilities	  of	  the	  four	  pseudoknot	  region	  conformations	  were	  estimated	  using	  the	  partition	  and	  EnsembleEnergy	  software	  interfaces	  in	  conjunction	  with	  folding	  constraints	  designed	  to	  recapitulate	  the	  desired	  helices.	  	  Predictably,	  the	  helix	  III	  conformation	  of	  tTER	  assumed	  to	  exist	  in	  the	  protein-­‐free	  state	  was	  found	  to	  be	  the	  most	  stable	  base	  pair	  configuration,	  as	  it	  had	  the	  lowest	  Gibbs	  free	  energy	  of	  unfolding	  with	  a	  value	  of	  -­‐87.7	  kcal·mol-­‐1.	  	  The	  conformation	  of	  tTER,	  in	  which	  only	  the	  GC	  rich	  helix	  IIIa	  forms,	  was	  shown	  to	  be	  the	  least	  stable	  of	  the	  configurations,	  as	  it	  was	  predicted	  to	  have	  the	  highest	  Gibbs	  free	  energy	  of	  unfolding	  of	  -­‐30.9	  kcal·mol-­‐1.	  	  Both	  the	  folded	  pseudoknot	  and	  the	  AU-­‐rich	  component	  helix	  IIIb	  were	  predicted	  to	  have	  nearly	  identical	  unfolding	  energies	  of	  -­‐32.3	  and	  -­‐32.1	  kcal·mol-­‐1,	  respectively.	  	  Helices	  IIIa	  and	  IIIb	  are	  separated	  by	  less	  energy	  than	  the	  typical	  hydrogen	  bond	  seen	  in	  the	  context	  of	  a	  base	  pair.	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  As	  might	  be	  expected	  based	  upon	  the	  having	  the	  most	  predicted	  base	  pairs,	  the	  EnsembleEnergy-­‐determined	  probabilities	  associated	  with	  forming	  the	  elongated	  protein	  free	  helix	  were	  the	  highest.	  	  All	  of	  the	  base	  pairs	  except	  for	  two	  were	  predicted	  to	  form	  with	  probabilities	  exceeding	  99%.	  	  Only	  the	  base	  pairs	  formed	  by	  U60	  (80-­‐90%)	  and	  G61	  (60-­‐70%)	  were	  below	  99%	  confidence.	  	  Similarly,	  the	  base	  pair	  probabilities	  associated	  with	  forming	  the	  folded	  pseudoknot	  were	  the	  lowest.	  	  None	  of	  the	  base	  pair	  probabilities	  in	  the	  folded	  pseudoknot	  configuration	  exceeded	  90%	  confidence.	  	  It	  is	  interesting	  to	  note	  that	  the	  GC	  rich	  helix	  base	  pairs	  had	  substantially	  lower	  probabilities	  associated	  with	  their	  formation	  than	  the	  AU	  rich	  helix	  did	  in	  the	  context	  of	  the	  fully	  formed	  pseudoknot.	  	  This	  difference	  in	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probabilities	  may	  indicate	  that	  the	  AU	  rich	  helix	  is	  more	  likely	  to	  exist	  than	  the	  GC	  rich	  helix.	  	  All	  four	  base	  pairs	  formed	  in	  the	  GC-­‐rich	  component	  helix	  had	  associated	  probabilities	  of	  below	  50%.	  	  The	  base	  pairs	  in	  the	  AU-­‐rich	  helix	  of	  the	  fully	  formed	  pseudoknot	  were	  either	  50-­‐60%	  or	  80-­‐90%	  probable.	  The	  component	  helices	  outside	  the	  context	  of	  the	  fully	  folded	  pseudoknot	  both	  had	  reasonably	  high	  probabilities	  associated	  with	  their	  formation	  as	  none	  of	  the	  base	  pairs	  in	  either	  component	  helix	  exhibited	  probabilities	  below	  80%.	  	  However,	  it	  is	  interesting	  to	  note	  that	  the	  four	  base	  pairs	  associated	  with	  the	  GC-­‐rich	  helix	  were	  predicted	  to	  have	  a	  significantly	  higher	  probability	  of	  formation	  when	  the	  helix	  formed	  by	  itself	  outside	  of	  the	  context	  of	  the	  fully	  formed	  pseudoknot	  than	  when	  in	  the	  pseudoknot	  (compare	  ≥	  95%	  in	  isolation	  as	  opposed	  to	  ≤	  50%	  in	  the	  pseudoknot).	  	  This	  probability	  data	  suggests	  equilibrium	  between	  helix	  IIIa	  in	  isolation	  and	  when	  in	  the	  context	  of	  the	  pseudoknot	  as	  the	  isolated	  helix	  is	  predicted	  to	  be	  more	  likely	  to	  exist	  than	  the	  pseudoknot.	  	  	  Also	  of	  note	  was	  the	  inversion	  of	  base-­‐pair	  probabilities	  for	  the	  two	  helices	  when	  they	  are	  folded	  on	  their	  own	  and	  not	  in	  the	  context	  of	  the	  pseudoknot.	  	  The	  AU-­‐rich	  helix	  had	  a	  much	  higher	  probability	  of	  forming	  than	  the	  GC-­‐rich	  helix	  when	  the	  pseudoknot	  was	  folded	  (compare	  ≤	  90%	  for	  the	  AU	  rich	  as	  opposed	  to	  ≤	  50%	  in	  the	  GC	  rich).	  	  But	  when	  each	  helix	  formed	  separately	  in	  isolation,	  the	  GC-­‐rich	  helix	  was	  more	  likely	  to	  form	  than	  the	  AU-­‐rich	  helix	  (compare	  all	  base	  pairs	  forming	  with	  ≥	  95%	  certainty	  in	  the	  GC	  rich	  helix	  to	  the	  ≥	  80%	  in	  the	  AU	  rich	  helix).	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5. SHAPE-­‐directed	  RNAstructure	  Predictions	  The	  standard	  RNAstructure	  algorithm	  Fold	  program	  was	  first	  used	  to	  fold	  tTER	  even	  though	  the	  program	  does	  not	  allow	  pseudoknots.146	  	  There	  was	  no	  difference	  in	  structural	  predictions	  between	  free	  in	  solution	  and	  p65-­‐bound	  state,	  as	  both	  reproduced	  the	  protein-­‐free	  structure.	  	  The	  secondary	  structure	  did	  not	  change	  when	  the	  ProbKnot	  program	  was	  used	  as,	  again,	  the	  protein-­‐free	  helix	  3	  was	  predicted.	  	  Finally,	  the	  ShapeKnots	  program	  again	  predicted	  the	  protein-­‐free	  state	  as	  shown	  in	  Figure	  3.15.	  	  SHAPE	  intensities	  did	  not	  cause	  any	  of	  the	  RNAstructure	  suite	  of	  programs	  to	  predict	  a	  pseudoknotted	  tTER	  state	  in	  the	  presence	  of	  p65.	  	  The	  
ShapeKnots	  program	  also	  did	  not	  predict	  a	  pseudoknotted	  structure	  for	  tTERT	  bound	  tTER	  either	  (data	  not	  shown).	  	  Only	  the	  GC-­‐rich	  helix	  or	  stem	  IIIa	  of	  the	  pseudoknotted	  tTER	  structure	  was	  predicted	  when	  p65	  bound	  SHAPE	  restraints	  were	  combined	  with	  a	  folding	  constraints	  file	  that	  made	  nucleotides	  from	  positions	  43	  –	  68	  to	  be	  single-­‐stranded	  and	  restricted	  base	  pairs	  between	  positions	  10	  –	  18	  and	  100	  –	  94.	  	  In	  no	  case	  of	  SHAPE-­‐directed	  structural	  prediction	  was	  the	  AU-­‐rich	  helix,	  or	  stem	  helix	  IIIb	  of	  the	  pseudoknot,	  predicted.	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  Table	  3.1	  describes	  the	  accuracy	  of	  secondary	  structural	  predictions	  calculated	  by	  the	  scorer	  program	  when	  the	  base	  pair	  configurations	  of	  tTER	  shown	  in	  Figure	  3.2	  were	  used	  as	  accepted	  structures.	  	  The	  paired,	  two-­‐tailed	  Student’s	  t-­‐test	  was	  first	  used	  to	  test	  the	  null	  hypothesis	  that	  SHAPE	  data	  did	  not	  alter	  base-­‐pair	  predictions	  made	  with	  RNAstructure	  software.	  	  Two	  tTER	  base-­‐pair	  configurations	  served	  as	  accepted	  structures.	  	  The	  first	  configuration	  was	  the	  protein-­‐free	  tTER	  secondary	  structure	  displayed	  in	  panel	  A	  of	  Figure	  3.2	  and	  predicted	  in	  chapter	  III	  of	  this	  thesis.86	  	  The	  second	  configuration	  was	  the	  pseudoknot	  structure	  displayed	  in	  panel	  B	  based	  upon	  comparative	  sequence	  analyses	  of	  tTER.127	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  The	  methods	  described	  in	  this	  thesis	  rendered	  highly	  accurate	  predictions	  of	  the	  free	  in	  solution	  tTER	  structure	  from	  panel	  A	  of	  Figure	  3.2.	  	  The	  averages	  of	  sensitivity	  and	  positive	  predictive	  value	  were	  calculated	  in	  Table	  3.1	  and	  show	  that	  SHAPE	  data	  was	  not	  even	  required	  to	  accurately	  predict	  the	  protein	  free	  structure	  in	  panel	  A	  of	  Figure	  3.2	  as	  evidenced	  by	  the	  90%	  “mean”.	  Three	  out	  of	  the	  four	  SHAPE	  data	  sets	  tested	  exceeded	  90%	  in	  accurately	  predicting	  the	  free	  in	  solution	  structure	  as	  only	  the	  tTERT	  bound	  SHAPE	  data	  average	  failed	  to	  surpass	  the	  90th	  percentile.	  	  The	  Student’s	  t-­‐test	  was	  used	  to	  determine	  if	  tTERT	  bound	  SHAPE	  intensities	  significantly	  differed	  from	  the	  other	  three	  sets	  of	  predictions.	  	  A	  p-­‐value	  of	  4.9%	  quantified	  the	  probability	  that	  predictions	  directed	  by	  p65	  bound	  SHAPE	  intensities	  were	  unaffected	  by	  replacing	  SHAPE	  data	  with	  tTERT	  bound	  intensities.	  	  This	  low	  probability	  is	  evidence	  that	  tTERT	  bound	  SHAPE	  data	  alters	  predictions	  made	  with	  RNAstructure	  to	  differ	  from	  the	  elongated	  helix	  III	  characteristic	  of	  protein	  free	  tTER.	  	  The	  decreased	  accuracy	  in	  tTERT	  SHAPE	  intensity	  directed	  predictions	  as	  measured	  by	  the	  “means”	  in	  Table	  3.1	  indicated	  that	  tTERT	  bound	  tTER	  predictions	  were	  not	  the	  same	  as	  those	  directed	  by	  free	  in	  solution	  SHAPE	  intensities.	  	  The	  p-­‐values	  of	  all	  other	  data	  set	  comparisons	  exceeded	  the	  fifth	  percentile,	  indicating	  no	  significant	  difference	  in	  accurately	  predicting	  the	  protein	  free	  tTER	  secondary	  structure.	  	  	  Only	  tTERT	  SHAPE	  intensities	  rendered	  secondary	  structural	  models	  that	  significantly	  differed	  from	  the	  protein	  free	  tTER	  configuration.	  	  Table	  3.1	  also	  shows	  that	  SHAPE	  intensities	  from	  tTERT	  bound	  tTER	  yielded	  the	  most	  accurate	  predictions	  of	  the	  pseudoknot	  conformation	  of	  tTER	  displayed	  in	  panel	  B	  of	  Figure	  3.2.	  	  The	  78%	  mean	  of	  sensitivity	  and	  ppv	  from	  tTERT	  bound	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SHAPE	  data	  was	  the	  highest	  of	  the	  four	  test	  cases.	  	  The	  lack	  of	  SHAPE	  data	  as	  well	  as	  the	  free	  in	  solution	  and	  p65	  bound	  tTER	  SHAPE	  intensities	  all	  rendered	  accuracies	  around	  63%.	  	  Models	  of	  tTER	  secondary	  structure	  directed	  by	  tTERT	  bound	  SHAPE	  data	  significantly	  differed	  from	  the	  other	  three	  aforementioned	  test	  cases	  as	  evidenced	  by	  the	  sub	  5%	  p-­‐values	  for	  each	  comparisons	  made.	  	  Only	  comparisons	  of	  accuracies	  among	  unconstrained,	  free	  in	  solution,	  and	  p65	  bound	  SHAPE	  intensities	  were	  found	  to	  not	  differ	  significantly	  as	  measured	  by	  all	  three	  p-­‐values	  exceeding	  5%.	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DISCUSSION	  
	   	  Previous	  FRET	  studies	  and	  SHAPE	  studies	  described	  in	  Chapter	  II	  led	  to	  the	  hypothesis	  that	  p65	  binding	  changes	  the	  secondary	  structure	  of	  tTER	  to	  disrupt	  base	  pairs	  in	  template	  residues	  in	  the	  protein	  free	  tTER	  structure	  allowing	  the	  elongated	  helix	  III	  regions	  to	  form	  the	  pseudoknotted	  required	  for	  telomerase	  activity.	  	  Our	  hypothesized	  model	  was	  presented	  in	  Figure	  3.3,	  as	  the	  progression	  from	  panels	  B	  to	  C	  to	  E	  rather	  than	  from	  panels	  B	  to	  D	  to	  E	  where	  p65	  alters	  the	  secondary	  structure	  of	  tTER	  pseudoknot	  nucleotides.	  	  We	  generated	  models	  of	  the	  tTER	  secondary	  structure	  when	  bound	  to	  p65	  by	  combining	  SHAPE	  chemistry,	  native	  gel	  electrophoresis,	  and	  secondary	  structural	  prediction.	  	  	  We	  revealed	  a	  drastic	  conformational	  change	  in	  helix	  IV	  bulged	  nucleotides	  consistent	  with	  FRET	  and	  x-­‐ray	  crystallography	  studies.	  	  We	  also	  revealed	  a	  more	  moderate	  conformational	  change	  in	  the	  tTER	  pseudoknot	  region	  that	  we	  predict	  attends	  assemblage	  in	  the	  core	  telomerase	  complex.	  Secondary	  structural	  predictions	  used	  to	  compare	  the	  stability	  of	  the	  pseudoknot	  component	  helices	  to	  the	  stability	  of	  the	  free,	  in	  solution	  helix	  III	  structure	  and	  the	  pseudoknot	  demonstrate	  a	  rugged	  energy	  landscape	  for	  tTER.	  	  The	  solution	  state	  helix	  III	  is	  predicted	  to	  be	  some	  30	  kcal·mol-­‐1	  more	  stable	  than	  the	  pseudoknot	  or	  component	  helices.	  	  The	  similar	  energies	  calculated	  for	  the	  component	  helices	  and	  pseudoknotted	  states	  predict	  a	  native	  basin	  of	  attraction	  for	  tTER	  where	  the	  stability	  of	  the	  component	  helices	  is	  comparable	  to	  the	  final	  native	  structure.	  	  The	  ability	  for	  tTER	  to	  fold	  one	  of	  the	  component	  pseudoknot	  helices	  at	  a	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time	  suggests	  competing	  basins	  of	  attraction	  in	  close	  proximity	  to	  the	  native	  basin.	  	  These	  competing	  basins	  might	  be	  kinetic	  traps	  to	  prevent	  an	  unwanted	  pseudoknot	  from	  forming.	  	  	  Another	  attractive	  possibility	  is	  that	  a	  variety	  of	  interconverting	  structures,	  including	  the	  pseudoknot	  and	  long	  helix	  III,	  form	  as	  tTER	  folds.	  	  Although	  we	  do	  not	  have	  kinetic	  data	  to	  support	  our	  hypothesis,	  perhaps	  equilibrium	  exists	  between	  the	  component	  helices	  and	  the	  pseudoknot	  that	  is	  altered	  by	  p65	  and	  tTERT	  binding.	  	  Single	  molecule	  FRET	  studies	  show	  that	  it	  is	  possible	  for	  misfolded	  or	  misassembled	  telomerase	  complexes	  to	  assemble,	  however,	  active	  telomerase	  containing	  both	  p65	  and	  tTERT	  adopts	  a	  single	  active	  conformation.154	  	  	  Thermodynamically,	  SHAPE	  reactivities	  described	  a	  state	  in	  which	  stem	  IIIa	  of	  the	  pseudoknot	  and	  the	  5’	  half	  of	  stem	  IIIb	  were	  well	  formed,	  while	  the	  3’	  half	  of	  stem	  IIIb	  did	  not	  appear	  to	  dock	  with	  the	  well	  formed	  5’	  half	  as	  shown	  in	  Figure	  3.15.	  	  This	  could	  be	  a	  state	  in	  which	  bases	  on	  the	  5’	  unreactive	  side	  of	  stem	  IIIb	  are	  stacked	  upon	  each	  other,	  while	  the	  3’	  half	  is	  still	  unstructured.	  	  Perhaps	  it	  is	  the	  presence	  of	  tTERT	  that	  is	  needed	  to	  stabilize	  stem	  IIIb	  as	  tTERT-­‐bound	  tTER	  displayed	  unreactive	  nucleotides	  in	  this	  region.86	  	  tTERT	  may	  provide	  the	  interactions	  missing	  in	  the	  p65-­‐bound	  state	  to	  prevent	  tTER	  from	  entering	  competing	  basins	  of	  attraction	  to	  mostly	  populate	  the	  fully	  folded	  pseudoknot	  state.	  	  	  That	  none	  of	  the	  structural	  prediction	  programs	  predicted	  a	  pseudoknot	  state	  is	  telling:	  either	  p65	  bound	  tTER	  does	  not	  populate	  the	  pseudoknot	  states	  or	  our	  method	  was	  unable	  to	  predict	  the	  correct	  structure.	  The	  Weeks	  lab	  has	  previously	  observed	  that	  the	  overall	  accuracy	  of	  ProbKnot	  improves	  with	  SHAPE	  data,	  but	  that	  the	  performance	  at	  predicting	  pseudoknots	  decreases	  when	  SHAPE	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data	  are	  included.	  This	  diminished	  performance	  can	  be	  explained	  by	  ProbKnot	  reliance	  on	  a	  partition	  function	  calculation	  over	  pseudoknot-­‐free	  structures	  to	  identify	  the	  two	  helices	  that	  minimally	  define	  a	  pseudoknot.	  SHAPE	  data	  cause	  the	  pseudoknot-­‐free	  partition	  function	  to	  strongly	  favor	  one	  of	  the	  two	  helices	  that	  define	  the	  pseudoknot.146	  The	  ShapeKnots	  program	  did	  not	  predict	  a	  pseudoknotted	  structure	  for	  tTERT	  bound	  tTER	  either	  (data	  not	  shown).	  The	  accuracy	  of	  predicting	  the	  tTER	  pseudoknot	  was	  dependent	  on	  the	  use	  of	  tTERT	  bound	  SHAPE	  data	  and	  not	  p65-­‐bound	  values,	  suggesting	  that	  the	  pseudoknot	  is	  stabilized	  by	  tTERT	  and	  not	  p65.	  	  	  RNAstructure	  predicts	  the	  pseudoknot	  region	  of	  p65-­‐bound	  wildtype	  tTER	  to	  remain	  in	  the	  solution	  state	  base	  pair	  configuration	  despite	  the	  increased	  entropy	  in	  nucleotide	  positions	  83-­‐99	  as	  measured	  by	  SHAPE.	  	  Based	  on	  the	  data	  explained	  in	  this	  chapter,	  we	  revised	  our	  prior	  hypothesis	  because	  it	  is	  now	  evident	  that	  p65	  does	  not	  alter	  the	  secondary	  structure	  of	  tTER	  to	  facilitate	  telomerase	  assemblage;	  rather,	  the	  energy	  landscape	  of	  p65-­‐bound	  wildtype	  tTER	  appears	  to	  be	  dominated	  by	  significant	  bending	  of	  helix	  IV	  and	  the	  pseudoknot	  regions,	  as	  evidenced	  by	  their	  altered	  SHAPE	  intensities	  and	  prior	  x-­‐ray	  crystal	  structures.96	  	  Our	  hypothesized	  model	  of	  telomerase	  assemblage	  progressing	  from	  panels	  3.3B	  to	  3.3C	  to	  3.3E	  has	  been	  replaced	  by	  a	  model	  that	  progresses	  from	  panels	  3.3B	  to	  3.3D	  to	  3.3E.	  	  	  While	  it	  may	  be	  exciting	  to	  speculate	  if	  p65	  catalyzes	  an	  unknown	  reaction	  in	  ciliates	  unrelated	  to	  telomere	  biology,	  it	  is	  clear	  that	  the	  p65	  protein	  distorts	  helix	  IV	  of	  tTER.	  	  Distortion	  of	  helix	  IV	  may	  potentially	  apply	  torque	  to	  the	  elongated	  helix	  III	  region	  of	  tTER	  nucleotides.	  	  The	  applied	  force,	  stabilized	  by	  the	  bending	  of	  the	  GA	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bulge	  in	  helix	  IV,	  might	  then	  rearrange	  the	  torsion	  angles	  of	  Helix	  III	  nucleotides	  to	  more	  often	  sample	  conformations	  that	  promote	  hierarchical	  assembly	  of	  telomerase	  RNPs.	  Helix	  III	  rotamer	  angle	  alteration	  stabilized	  by	  p65	  binding	  could	  serve	  as	  a	  logic	  gate	  or	  sensor	  of	  tTERT	  concentration	  so	  that	  telomerase	  assembly	  and	  activity	  might	  be	  more	  tightly	  regulated.155-­‐157	  	  The	  decreased	  activity	  of	  p65-­‐less	  telomerase	  complexes104	  may	  explain	  why	  the	  pseudoknot	  nucleotides	  must	  first	  be	  altered	  by	  p65	  to	  a	  conditional	  torsional	  state	  before	  assembly	  proceeds	  	  
CONCLUSIONS	  	  In	  summary,	  high-­‐resolution	  footprinting	  of	  protein-­‐free	  and	  p65-­‐bound	  tTER	  did	  not	  reveal	  a	  secondary	  structural	  transition	  in	  tTER	  when	  bound	  to	  p65.	  	  Bulged	  nucleotides	  in	  helix	  IV	  are	  conformationally	  restricted	  in	  the	  presence	  of	  p65,	  whereas	  the	  pseudoknot	  region	  gains	  conformational	  flexibility.	  	  Importantly,	  the	  data	  provide	  critical	  evidence	  that	  the	  secondary	  structure	  of	  p65-­‐bound	  wildtype	  tTER	  is	  the	  same	  as	  protein-­‐free	  tTER	  and	  provide	  new	  hypotheses	  for	  telomerase	  assemblage.	  	  It	  is	  imperative	  to	  understand	  how	  telomerase	  complex	  conformational	  changes	  contribute	  to	  cellular	  health	  if	  targeted	  therapies	  to	  the	  diseases	  listed	  in	  Table	  1.1	  are	  to	  be	  developed.	  	  Therefore,	  the	  MS1,	  MS2,	  and	  MS1	  /	  MS2	  mutant	  tTERs	  from	  Chapter	  II	  were	  used	  in	  Chapter	  IV	  to	  test	  how	  primary	  structural	  changes	  to	  the	  pseudoknot	  region	  might	  affect	  the	  secondary	  structural	  states	  of	  p65-­‐bound	  tTER.	  	  Mutations	  in	  helix	  III	  were	  made	  with	  the	  intent	  of	  preventing	  docking	  between	  the	  two	  component	  helices	  to	  compare	  the	  stability	  of	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each	  pseudoknot	  component	  helix	  in	  the	  presence	  of	  p65.	  	  The	  next	  chapter	  of	  this	  dissertation	  will	  attempt	  to	  record	  Tetrahymena	  thermophila’s	  choice	  of	  pseudoknot	  conformations	  as	  it	  assembles	  into	  the	  telomerase	  ribonucleoprotein.	  	  We	  will	  attempt	  to	  predict	  the	  secondary	  structure	  of	  tTER	  in	  the	  presence	  of	  the	  p65	  binding	  protein	  that	  has	  been	  shown	  to	  be	  necessary	  for	  in	  vivo	  assemblage	  of	  the	  telomerase	  ribonucleoprotein.	  	  	  





Chapter	  IV.	  Modeling	  p65	  induced	  telomerase	  ribonucleoprotein	  
conformational	  transitions	  	  
INTRODUCTION	  There	  have	  been	  two	  models	  predicted	  of	  the	  tTER	  pseudoknot	  domain.	  	  One	  model	  is	  based	  upon	  comparative	  sequence	  analysis106,127,158	  and	  the	  other	  is	  based	  upon	  biophysical	  molecular	  modeling.128	  	  The	  only	  difference	  between	  the	  two	  is	  that	  the	  computational	  model	  predicts	  AUU	  base	  triples	  between	  loop	  1	  and	  stem	  2	  of	  ciliate	  telomerase	  RNA	  pseudoknots	  (see	  figure	  1).	  	  	  Three	  mutant	  tTER	  sequences	  have	  been	  used	  to	  discern	  protein-­‐free	  tTER	  states	  from	  tTERT-­‐bound	  states.86	  The	  mutants	  were	  designed	  to	  preferentially	  affect	  the	  stability	  of	  helix	  III	  in	  the	  protein-­‐free	  model	  and	  stem	  IIIa	  of	  the	  pseudoknot	  	  	  Both	  pseudoknot	  models	  predict	  that	  two	  mutants,	  MS1	  (70-­‐ACCU	  →	  70-­‐UGGA)	  and	  MS2	  (83-­‐	  AGGU	  →	  83-­‐UCCA),	  would	  alter	  several	  base-­‐pairing	  interactions	  in	  both	  protein-­‐free	  and	  pseudoknotted	  tTER,	  whereas	  double	  mutant	  MS1/MS2	  is	  predicted	  to	  dramatically	  destabilize	  the	  protein-­‐free	  structure	  but	  allow	  base	  pairing	  in	  the	  telomerase	  RNP	  complex	  due	  to	  the	  compensatory	  mutations.	  The	  effect	  of	  disrupting	  predicted	  base	  pairs	  in	  pseudoknot	  stem	  IIIa	  on	  telomerase	  activity	  was	  examined	  and	  it	  was	  found	  that	  both	  MS1	  and	  MS2	  exhibited	  severely	  reduced	  telomerase	  activity,	  while	  MS1/MS2	  retained	  wild-­‐type	  activity	  (see	  figure	  2.4).	  	  SHAPE	  profiles	  of	  protein-­‐free	  MS1,	  MS2,	  and	  MS1/MS2	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suggested	  disruption	  of	  the	  wild-­‐type	  tTER	  stem	  III	  structure	  and	  new,	  but	  poorly	  formed	  structures	  or	  mixtures	  of	  several	  structures	  (see	  figure	  2.3).	  	  When	  bound	  to	  tTERT,	  MS1	  exhibited	  a	  shift	  in	  SHAPE	  reactivity,	  making	  it	  appear	  to	  have	  formed	  a	  new	  structure.	  	  MS2	  exhibited	  a	  much	  greater	  increase	  in	  SHAPE	  reactivity	  of	  both	  the	  mutated	  residues	  as	  well	  as	  their	  predicted	  base-­‐pairing	  partners.	  Unlike	  MS1,	  none	  of	  the	  algorithms	  tested	  predicted	  a	  stable	  structure	  for	  an	  MS2	  pseudoknot.	  In	  striking	  contrast	  to	  protein-­‐free	  tTER,	  the	  SHAPE	  profile	  of	  tTERT	  bound	  MS1/MS2	  was	  nearly	  indistinguishable	  from	  the	  profile	  of	  tTERT	  bound	  wild	  type	  tTER.	  Notable	  exceptions	  include	  A70	  and	  A90,	  which	  exhibited	  increased	  reactivity	  in	  the	  MS1/MS2	  mutant	  when	  compared	  to	  wild-­‐type	  tTER.	  In	  order	  to	  better	  understand	  the	  contributions	  of	  both	  tTERT	  and	  p65	  on	  telomerase	  assemblage,	  we	  compared	  tTERT	  bound	  tTER	  states	  from	  p65-­‐bound	  states	  using	  the	  MS1,	  MS2,	  and	  MS1/MS2	  mutations	  to	  trap	  p65-­‐bound	  tTER	  in	  states	  where	  only	  one	  of	  the	  two	  pseudoknot	  component	  helices	  could	  form.	  	  We	  used	  SHAPE	  technology,	  native	  gel	  electrophoresis,	  and	  secondary	  structural	  prediction	  algorithms	  to	  test	  for	  differences	  in	  secondary	  and	  tertiary	  structure	  of	  the	  altered	  RNAs	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MATERIAL	  AND	  METHODS	  	  See	  chapter	  II,	  section	  D	  for	  methods	  on	  p65	  protein	  expression,	  EMSA,	  1M7	  hit	  reactions,	  Superscript	  III	  reverse	  transcription	  reactions,	  sequencing	  gel	  electrophoresis,	  SHAPE	  data	  standardization	  and	  normalization,	  and	  secondary	  structural	  predictions.	  
1. RNA	  Preparation	  tTER	  mutated	  within	  the	  putative	  pseudoknot	  and	  template	  region	  was	  a	  gift	  from	  Laura	  Bonifacio.	  	  Briefly,	  RNA	  was	  transcribed	  in	  vitro	  using	  Ampliscribe	  T7	  Transcription	  Kit	  (Epicenter	  Technologies).	  	  Templates	  were	  generated	  by	  PCR	  using	  the	  plasmid	  pTET-­‐telo,	  a	  pUC19-­‐based	  plasmid	  containing	  the	  tTER	  gene,	  a	  T7	  RNA	  polymerase	  promoter,	  and	  a	  self-­‐cleaving	  hammerhead	  ribozyme	  that	  processes	  the	  5’-­‐end	  of	  the	  RNA.	  Primers	  are	  listed	  in	  Table	  ____.	  	  	  PCR	  products	  were	  gel	  purified	  using	  Wizard	  PCR	  Prep	  Kits	  and	  RNAs	  gel	  purified	  and	  stored	  in	  T10E1	  low	  ionic	  strength	  buffer	  (pH	  7.5)	  at	  −80	  °C.	  	  Transcription	  of	  DNA	  templates	  was	  carried	  out	  as	  described	  in	  section	  D	  of	  chapter	  2.	  	  	  
2. Non-­‐Denaturing	  Gel	  Electrophoresis	  Sample	  Preparation	  	   RNA	  (1	  pmol)	  was	  first	  heated	  to	  95°C	  for	  three	  minutes	  before	  being	  snap	  cooled	  on	  ice	  for	  three	  minutes.	  	  Folding	  buffer	  for	  reactions	  was	  identical	  to	  tTER	  EMSA	  Buffer	  used	  for	  EMSA	  and	  SHAPE	  experiments	  (20	  mM	  Tris	  HCl	  pH	  8.0,	  100	  mM	  NaCl,	  1	  mM	  MgCl2,	  5	  mM	  DTT,	  50	  ng·μL-­‐1	  BSA,	  1	  U·μL-­‐1	  RNasin,	  and	  10%	  glycerol).	  	  The	  solution	  was	  incubated	  at	  30	  °C	  for	  ten	  minutes	  either	  in	  the	  absence	  or	  presence	  of	  four	  picomoles	  of	  purified	  p65	  in	  a	  total	  volume	  of	  27	  μL.	  	  The	  RNA	  was	  immediately	  mock-­‐treated	  with	  3	  μL	  of	  RNase	  free	  water	  instead	  of	  DMSO	  or	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1M7	  and	  incubated	  at	  30	  °C	  for	  five	  minutes	  (five	  1M7	  half	  lives)	  to	  simulate	  SHAPE	  experiments.	  	  Next,	  3	  μL	  of	  75%	  glycerol	  was	  added	  to	  ensure	  sample	  layering	  at	  the	  bottom	  of	  gel	  wells.	  	  All	  33	  μL	  of	  sample	  were	  loaded	  on	  5%	  (v/v)	  non-­‐denaturing	  polyacrylamide	  gels	  (200	  x	  200	  x	  1.5	  mM,	  37.5:1	  acrylamide/bisacrylamide,	  0.5X	  TBE).	  	  Samples	  were	  run	  along	  side	  10	  μL	  of	  heat	  denatured	  Low	  Range	  ssRNA	  ladder	  in	  separate	  wells	  to	  act	  as	  an	  estimate	  of	  tTER	  length	  (New	  England	  Biolabs)	  in	  0.5X	  TBE	  at	  200	  volts	  for	  2.5	  hours	  at	  4°C.	  	  	  Bands	  were	  stained	  with	  SYBR®	  Green	  II	  RNA	  gel	  stain	  (Molecular	  Probes)	  and	  visualized	  on	  a	  Storm™	  860	  molecular	  imager	  (GE	  Life	  Sciences).	  	  	  
RESULTS	  
1. Native	  Gel	  Electrophoresis	  	   We	  used	  native	  gel	  electrophoresis	  to	  assess	  the	  folding	  integrity	  of	  tTER	  and	  tTER	  mutants	  as	  well	  as	  to	  determine	  if	  65	  bound	  the	  RNA.	  	  Wildtype	  tTER	  and	  MS1	  ran	  at	  the	  same	  rate	  as	  the	  5’GUU	  sequence.	  MS2	  ran	  the	  slowest	  while	  MS1_2	  ran	  slightly	  faster	  than	  MS2	  but	  slower	  than	  both	  wildtype	  and	  MS1	  tTER.	  	  	  Chapters	  II	  and	  III	  of	  this	  thesis	  compel	  us	  to	  hypothesize	  that	  all	  tTER	  secondary	  structural	  changes	  occur	  in	  nucleotides	  between	  the	  template	  and	  helix	  IV	  (43-­‐103).	  	  It	  appears	  that	  wildtype	  and	  MS1	  tTER	  have	  similar	  conformations.	  MS2	  has	  the	  conformation	  that	  is	  most	  retarded	  by	  the	  gel	  matrix.	  	  MS1_2	  has	  a	  conformation	  that	  is	  retarded	  but	  not	  as	  badly	  as	  MS2.	  	  	  At	  least	  three	  conformations	  were	  represented	  by	  the	  migration	  rates	  of	  tTER	  mutants.	  	  Wildtype	  and	  MS1	  may	  share	  a	  similar	  topology	  while	  MS2	  and	  MS1_2	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probably	  have	  their	  own	  unique	  topologies.	  	  	  We	  used	  RNAstructure	  to	  predict	  the	  secondary	  structures	  to	  see	  if	  three	  conformations	  are	  represented.	  	  All	  tTER	  sequences	  bound	  p65	  equally	  as	  there	  are	  no	  bands	  indicative	  of	  free	  in	  solution	  RNA	  in	  the	  p65	  bound	  lanes.	  	  We	  used	  EMSA	  in	  order	  to	  verify	  suspected	  retention	  of	  binding	  affinities	  despite	  mutation	  to	  tTER.	  	  
	  	  
2. EMSA	  	  The	  specificity	  of	  p65-­‐tTER	  interaction	  was	  verified	  by	  electrophoretic	  mobility	  shift	  assay.	  	  Notably,	  substitutions	  that	  altered	  the	  stem	  IIIa	  pseudoknot	  sequence	  did	  not	  increase	  nor	  decrease	  the	  ability	  of	  p65	  to	  bind	  tTER.	  A	  titration	  of	  p65	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showed	  that	  the	  protein	  bound	  mutant	  tTERs	  in	  a	  ratio	  of	  1:1	  as	  expected.97	  We	  estimated	  the	  binding	  affinity	  to	  be	  ~	  7	  nM,	  in	  agreement	  with	  single	  digit	  affinities	  observed	  in	  chapter	  III	  as	  well	  as	  in	  previous	  studies.94,97	  As	  we	  observed	  previously	  in	  panel	  B	  of	  Figure	  3.4,	  increasing	  ratios	  of	  p65	  to	  tTER	  demonstrated	  higher	  order	  binding	  states.	  	  
3. MS1	  SHAPE	  Reactivities	  
	  
a. Helix	  I	  The	  SHAPE	  reactivities	  of	  helix	  I	  nucleotides	  were	  in	  agreement	  with	  the	  predicted	  structure	  of	  wild	  type	  tTER	  in	  both	  bound	  and	  protein	  free	  MS1	  as	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nucleotides	  103	  –	  107	  were	  generally	  not	  modified	  by	  1M7	  at	  all.	  	  Positions	  were	  negligibly	  more	  flexible	  in	  the	  presence	  of	  p65.	  	  Despite	  using	  an	  internal	  primer,	  we	  were	  unable	  to	  resolve	  nucleotides	  5’	  of	  nucleotide	  C39	  instead	  of	  U10	  as	  in	  wild	  type	  tTER.	  	  Therefore,	  we	  did	  not	  quantify	  bands	  corresponding	  to	  nucleotides	  4-­‐8	  that	  are	  predicted	  to	  form	  one	  half	  of	  the	  base	  pairs	  in	  helix	  I.	  	  The	  nucleotides	  108	  -­‐	  111	  that	  are	  predicted	  to	  separate	  helices	  I	  and	  IV	  in	  the	  wildtype	  sequence	  showed	  diminished	  1M7	  modification	  upon	  binding	  p65	  in	  positions	  A110	  and	  A111.	  	  The	  other	  nucleotides	  that	  separate	  helix	  I	  from	  helix	  IV	  did	  not	  change	  much	  upon	  binding	  p65.	  	  Nucleotide	  A108	  was	  unmodified	  in	  both	  free	  in	  solution	  and	  tTERT	  bound	  wildtype	  tTER	  as	  well	  as	  when	  wild	  type	  tTER	  was	  bound	  by	  p65.	  	  A108	  remained	  unmodified	  in	  both	  free	  in	  solution	  and	  p65	  bound	  MS1	  tTER.	  	  	  Like	  A108,	  G109	  was	  unreactive	  in	  all	  tested	  wild	  type	  conditions.	  	  Although	  G109	  in	  MS1	  was	  not	  modified	  by	  1M7	  in	  the	  presence	  of	  p65,	  G109	  was	  moderately	  modified	  (~0.7)	  when	  free	  in	  solution.	  	  Position	  A110	  was	  very	  reactive	  in	  both	  free	  in	  solution	  and	  tTERT-­‐bound	  wildtype	  tTER	  while	  only	  displaying	  moderate	  reactivity	  in	  p65	  bound	  states.	  	  A110	  went	  from	  very	  reactive	  in	  free	  in	  solution	  MS1	  (~1.2)	  but	  was	  unreactive	  in	  p65	  bound	  states	  (~0.3).	  	  	  	  Position	  A111	  presented	  moderate	  1M7	  modification	  under	  all	  experimental	  conditions	  used	  for	  wildtype	  tTER	  and	  continued	  to	  present	  moderate	  modification	  under	  both	  experimental	  conditions	  for	  MS1.	  The	  nucleotide	  positions	  100	  –	  102	  are	  predicted	  to	  separate	  helix	  I	  from	  the	  pseudoknot	  domain	  in	  wildtype	  tTER.	  	  U102	  was	  moderately	  reactive	  in	  both	  free	  in	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solution	  and	  tTERT	  bound	  wild	  type	  tTER	  but	  became	  very	  reactive	  when	  bound	  by	  p65.	  	  U102	  was	  unreactive	  in	  both	  free	  in	  solution	  and	  p65	  bound	  MS1.	  	  Position	  A101	  was	  not	  determined	  for	  free	  in	  solution	  wildtype	  tTER	  but	  was	  unreactive	  in	  tTERT	  bound	  states.	  	  A101	  was	  moderately	  modified	  in	  p65	  bound	  wildtype	  (~0.6).	  	  MS1	  tTER	  position	  A101	  was	  unmodified	  in	  states	  where	  the	  p65	  protein	  was	  not	  present,	  but	  was	  very	  reactive	  when	  bound	  by	  the	  protein	  (~0.82).	  	  A100	  on	  the	  other	  hand	  went	  from	  unreactive	  to	  moderately	  reactive	  as	  wildtype	  bound	  the	  tTERT	  protein.	  	  While	  A100	  remained	  unreactive	  in	  the	  presence	  of	  p65	  for	  wildtype	  tTER	  (~	  0.3),	  A100	  changed	  from	  moderately	  to	  highly	  reactive	  as	  MS1	  bound	  p65(~	  0.5	  à	  1.0).	  	  	  Almost	  all	  of	  the	  wildtype	  nucleotides	  at	  positions	  10	  through	  19	  that	  are	  predicted	  to	  separate	  helices	  I	  and	  II	  were	  unreactive	  to	  NMIA	  or	  M7	  modification	  in	  the	  presence	  of	  tTERT,	  p65,	  or	  just	  free	  in	  solution.	  	  Only	  positions	  11,	  12,	  and	  14	  were	  moderately	  reactive	  when	  not	  bound	  by	  protein.	  	  However,	  we	  did	  not	  record	  data	  for	  these	  nucleotide	  positions	  in	  MS1	  tTER.	  	  We	  are	  unable	  to	  comment	  on	  the	  tTERT	  binding	  site	  of	  MS1	  mutant	  tTER.	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b. Helix	  II	  Because	  we	  were	  unable	  to	  quantify	  nucleotides	  upstream	  of	  position	  C39	  in	  MS1	  tTER,	  we	  are	  unable	  to	  comment	  on	  helix	  II	  in	  MS1	  mutant	  tTER.	  	  	  	  
c. Template	  Boundary	  Element	  SHAPE	  intensities	  in	  the	  TBE	  region	  (positions	  38-­‐42)	  of	  p65	  bound	  MS1	  tTER	  were	  consistent	  with	  a	  well-­‐structured	  region	  as	  all	  of	  the	  nucleotides	  observed	  in	  this	  region	  were	  unreactive.	  	  If	  you	  recall,	  SHAPE	  intensities	  in	  the	  TBE	  region	  (positions	  38-­‐42)	  of	  protein-­‐free	  wildtype	  tTER	  exhibited	  increasingly	  moderate	  reactivities	  as	  nucleotides	  approached	  the	  5’	  end	  of	  the	  template	  region	  at	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position	  43	  until	  U42	  displayed	  high	  reactivity	  (~	  0.85).	  	  Positions	  U38	  and	  C39	  were	  unmodified	  in	  tTERT	  bound	  states	  while	  A40	  was	  highly	  reactive	  (~	  1.1).	  	  Positions	  U41	  and	  U42	  maintained	  moderate	  reactivities	  in	  the	  presence	  of	  tTERT.	  	  All	  five	  nucleotides	  were	  unmodified	  by	  1M7	  in	  the	  presence	  of	  p65	  though	  and	  reversed	  the	  trend	  of	  increasingly	  moderate	  reactivities	  observed	  in	  free	  in	  solution	  tTER	  as	  nucleotides	  upstream	  of	  the	  template	  became	  increasingly	  protected	  from	  1M7	  as	  the	  sequence	  approached	  the	  5’	  end	  of	  the	  template.	  Positions	  A40	  and	  U42	  maintained	  unreactive	  2’	  hydroxyls	  in	  both	  states	  tested	  while	  U41	  was	  protected	  from	  modification	  in	  the	  presence	  of	  p65	  as	  nucleotides	  went	  from	  reactive	  (~	  1.4)	  to	  unreactive.	  	  
d. Template	  Region	  The	  template	  region	  of	  p65	  bound	  MS1	  tTER	  was	  highly	  structured	  as	  all	  but	  one	  position	  demonstrated	  low	  modification	  by	  1M7.	  	  The	  template	  nucleotides	  were	  mostly	  unmodified	  in	  solution	  state	  wildtype	  tTER	  as	  only	  positions	  A44	  and	  A50	  displayed	  moderate	  reactivities	  (~	  0.7).	  	  The	  same	  moderate	  modification	  pattern	  was	  observed	  in	  tTERT	  bound	  tTER	  as	  position	  A44	  decreased	  to	  about	  (~	  0.5)	  and	  position	  A50	  decreased	  to	  about	  (~	  0.6).	  	  Only	  position	  C43,	  which	  was	  not	  reported	  on	  in	  free	  in	  solution	  and	  tTERT	  bound	  wild	  type	  tTER,	  exhibited	  moderate	  modification	  in	  the	  presence	  of	  p65	  while	  all	  others	  were	  unreactive.	  	  	  	  	  MS1	  template	  nucleotides	  were	  all	  unreactive	  to	  1M7	  in	  the	  presence	  of	  p65	  except	  for	  A45,	  which	  showed	  moderate	  intensity	  (~	  0.6).	  	  SHAPE	  probing	  profiles	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of	  p65-­‐bound	  MS1	  and	  wildtype	  tTER	  were	  similar	  to	  each	  other,	  but	  they	  differed	  from	  protein-­‐free	  and	  tTERT-­‐bound	  MS1	  and	  wildtype	  profiles.	  	  	  The	  MS1	  and	  wild	  type	  p65	  bound	  secondary	  structural	  states	  resembled	  each	  other	  in	  the	  template	  region.	  	  MS1	  RNA	  bound	  by	  p65	  SHAPE	  intensities	  did	  not	  resemble	  solution	  state	  or	  tTERT	  bound	  wildtype	  tTER	  though.	  	  There	  was	  no	  higher	  modification	  observed	  at	  positions	  A44	  or	  A50	  in	  p65	  bound	  MS1.	  	  Although	  both	  of	  the	  p65	  bound	  sequences	  of	  tTER	  attain	  similar	  conformations,	  the	  secondary	  and	  tertiary	  structure	  of	  the	  template	  region	  in	  MS1	  is	  probably	  different	  from	  free	  in	  solution	  and	  reverse	  transcriptase	  bound	  wild	  type	  tTER.	  There	  was	  much	  more	  variability	  in	  the	  other	  template	  nucleotides	  as	  compared	  to	  wild	  type	  positions	  when	  MS1	  was	  free	  in	  solution	  however.	  	  We	  were	  unable	  to	  quantify	  positions	  43	  and	  45,	  but	  positions	  46	  –	  49	  were	  unmodified	  like	  in	  their	  wildtype	  counterparts.	  	  A44	  and	  A50	  were	  both	  highly	  reactive	  (~	  0.95	  and	  2.1	  respectively)	  while	  A51	  was	  only	  moderately	  modified	  (~	  0.6).	  	  	  MS1	  RNA	  that	  was	  bound	  by	  p65	  protein	  had	  a	  different	  SHAPE	  signature	  than	  that	  produced	  by	  any	  of	  the	  other	  wild	  type	  experimental	  conditions.	  	  There	  appeared	  to	  be	  characteristics	  of	  solution	  state	  and	  minimally	  active	  tTERT	  bound	  tTER	  present.	  	  Solution	  state	  wildtype	  characteristics	  were	  observed	  in	  the	  MS1	  positions	  46	  –	  49	  that	  remained	  unmodified	  upon	  binding	  p65.	  	  The	  tTERT	  bound	  characteristics	  were	  displayed	  in	  the	  relatively	  high	  intensities	  observed	  in	  positions	  A44	  and	  A50.	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e. Template	  Recognition	  Element	  The	  SHAPE	  profile	  of	  the	  TRE	  nucleotides	  in	  solution	  state	  MS1	  was	  consistent	  with	  formation	  of	  the	  wildtype	  misfolded	  solution	  state	  helix	  III	  and	  not	  consistent	  with	  being	  single	  stranded	  to	  position	  the	  template	  nucleotides	  into	  the	  tTERT	  active	  site.	  We	  were	  unable	  to	  quantify	  position	  C56	  in	  solution	  state	  MS1	  tTER.	  	  Positions	  55	  –	  67	  were	  found	  to	  be	  unmodified	  though.	  	  Positions	  68	  and	  54	  displayed	  high	  levels	  of	  1M7	  acylation	  adducts	  (~	  0.95	  and	  0.86	  respectively)	  while	  positions	  52	  and	  53	  were	  only	  moderately	  reactive	  (~	  0.49	  and	  0.55).	  	  The	  low	  SHAPE	  intensities	  from	  positions	  55	  –	  64	  were	  consistent	  with	  states	  containing	  the	  misfolded	  wildtype	  solution	  state	  helix	  III	  and	  not	  with	  states	  containing	  single	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stranded	  load	  bearing	  shafts	  as	  in	  the	  in	  vitro	  reconstituted	  tTER-­‐tTERT	  complex.	  	  We	  would	  have	  expected	  to	  observe	  more	  moderate	  to	  high	  levels	  of	  1M7	  modification	  instead	  of	  the	  lack	  of	  modification	  observed	  at	  positions	  65	  -­‐	  67	  if	  they	  were	  in	  a	  loop	  like	  in	  solution	  state	  wildtype	  tTER.	  	  The	  high	  SHAPE	  intensity	  observed	  at	  U68	  was	  consistent	  with	  it	  being	  unpaired.	  	  	  SHAPE	  intensities	  of	  MS1	  template	  recognition	  element	  nucleotides	  generally	  became	  less	  modified	  by	  1M7	  in	  the	  presence	  of	  p65.	  	  	  The	  template	  recognition	  element	  stretches	  from	  nucleotide	  positions	  52-­‐68	  in	  tTER.	  	  In	  solution	  state	  wild	  type	  tTER,	  A52	  marks	  the	  end	  of	  single	  stranded	  RNA	  with	  high	  rates	  of	  1M7	  modification	  from	  the	  template	  region.	  	  The	  beginning	  of	  misfolded	  helix	  III	  is	  marked	  by	  the	  low	  rates	  of	  1M7	  modification	  at	  A52	  that	  stretches	  all	  the	  way	  to	  moderate	  reactivities	  beginning	  at	  position	  A65.	  	  A	  predicted	  six-­‐member	  loop	  allows	  tTER	  to	  turn	  in	  such	  a	  way	  to	  close	  misfolded	  helix	  III	  and	  is	  signaled	  by	  the	  moderate	  reactivities	  from	  A65	  through	  A70.	  	  	  	  In	  tTERT	  bound	  wild	  type	  tTER,	  A52	  is	  only	  moderately	  modified	  and	  not	  highly	  reactive.	  	  Positions	  53	  –	  57	  remain	  unmodified	  as	  they	  were	  in	  solution	  state	  tTER	  and	  could	  provide	  structural	  rigidity	  to	  insert	  the	  template	  nucleotides	  into	  the	  tTERT	  active	  site.	  	  Positions	  57	  –	  61	  were	  moderately	  modified	  instead	  of	  unreactive	  to	  NMIA	  in	  tTERT	  bound	  tTER	  as	  were	  positions	  63	  -­‐	  68.	  	  Interestingly,	  C62	  remained	  unmodified	  in	  tTERT	  bound	  tTER.	  	  Moderate	  reactivities	  beginning	  at	  position	  65	  –	  70	  in	  solution	  state	  tTER	  signaled	  the	  misfolded	  helix	  III	  loop.	  	  Our	  3D	  model	  of	  tTERT	  bound	  tTER	  explains	  how	  the	  moderate	  intensities	  flanking	  C62	  are	  consistent	  with	  the	  nucleotides	  forming	  load-­‐bearing	  single	  stranded	  shafts	  around	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a	  restricted	  motion	  flexure	  bearing	  or	  living	  hinge	  in	  C62.	  	  p65	  bound	  wildtype	  tTER	  appeared	  to	  be	  consistent	  with	  the	  formation	  of	  solution	  state	  misfolded	  helix	  III	  as	  positions	  53	  –	  65	  were	  unmodified	  and	  66	  –	  68	  were	  moderately	  so.	  	  	  
	  
f. Helix	  IV	  Helix	  IV	  nucleotides	  generally	  became	  protected	  from	  1M7	  modification	  upon	  p65	  binding.	  	  Figure	  4.6	  shows	  that	  the	  SHAPE	  reactivity	  profile	  of	  MS1	  helix	  IV	  nucleotides	  was	  consistent	  with	  the	  previously	  determined	  structure.	  	  Stem	  loop	  IV	  was	  readily	  observed,	  as	  was	  the	  GA	  bulge	  and	  the	  helical	  content	  of	  the	  3’	  side	  of	  helix	  IV.	  	  Unlike	  in	  wildtype	  tTER,	  reduced	  acylation	  of	  bulged	  nucleotides	  at	  positions	  117	  and	  125-­‐127	  was	  not	  observed.	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g. Helix	  III	  The	  pseudoknot	  region	  begins	  at	  position	  A69	  and	  ends	  at	  position	  U99	  while	  the	  MS1	  mutant	  altered	  nucleotide	  positions	  70	  –	  73	  that	  are	  predicted	  to	  form	  the	  GC	  rich	  Helix	  IIIa	  of	  the	  pseudoknot.	  	  Native	  gel	  electrophoresis	  of	  free	  in	  solution	  MS1	  revealed	  a	  similar	  three-­‐dimensional	  conformation	  to	  wildtype	  sequence	  as	  evidenced	  by	  the	  small	  change	  in	  migration	  rates.	  	  Therefore,	  we	  would	  expect	  the	  SHAPE	  signatures	  of	  the	  respective	  pseudoknot	  regions	  to	  resemble	  each	  other.	  	  We	  found	  that	  solution	  state	  MS1	  had	  9	  positions	  between	  nucleotides	  69	  –	  99	  that	  were	  at	  least	  moderately	  modified	  by	  1M7	  (≥	  0.4)	  while	  wildtype	  had	  12	  positions	  with	  moderate	  reactivities.	  	  This	  suggested	  that	  a	  similar	  number	  of	  base	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pairs	  may	  have	  been	  made	  in	  both	  sequences.	  	  However,	  the	  identity	  of	  the	  moderate	  positions	  changed	  across	  sequences.	  	  Five	  of	  the	  nine	  moderately	  modified	  positions	  in	  MS1	  were	  also	  in	  the	  twelve	  moderate	  positions	  of	  wild	  type	  tTER.	  	  However,	  positions	  79,	  80,	  92,	  and	  93	  were	  moderately	  reactive	  in	  wild	  type	  and	  not	  so	  in	  MS1.	  	  Positions	  71	  –	  73	  and	  95	  in	  MS1	  were	  moderately	  modified	  but	  not	  so	  in	  wild	  type	  tTER.	  	  All	  other	  positions	  within	  the	  solution	  state	  pseudoknot	  domains	  agreed	  in	  their	  lack	  of	  modifications	  for	  both	  sequences.	  	  	  These	  observations	  suggested	  a	  secondary	  structure	  that	  was	  similar	  in	  the	  number	  of	  base	  pairs	  made,	  but	  different	  in	  the	  identity	  of	  base	  pairing	  partners.	  	  	  Solution	  state	  MS1	  did	  not	  exhibit	  SHAPE	  intensities	  that	  were	  consistent	  with	  base	  pairing	  in	  the	  altered	  nucleotides	  as	  they	  were	  all	  moderately	  modified	  (~0.5	  –	  0.84).	  	  The	  solution	  state	  MS1	  SHAPE	  signature	  was	  also	  inconsistent	  with	  solution	  state	  wildtype	  tTER.	  	  Lower	  intensities	  would	  be	  expected	  at	  positions	  C71	  and	  U73	  if	  they	  participated	  in	  base	  pairs	  with	  G64	  and	  U63	  (respectively)	  as	  they	  do	  in	  the	  misfolded	  helix.86,159	  	  	  	  MS1	  mutant	  RNA	  that	  was	  bound	  by	  p65	  displayed	  a	  SHAPE	  signature	  that	  differed	  from	  wildtype	  p65	  bound	  tTER.	  	  Both	  MS1	  and	  wild	  type	  tTER	  displayed	  low	  levels	  of	  modification	  in	  nucleotides	  between	  nucleotides	  69	  –	  77	  in	  the	  presence	  of	  p65.	  	  Twelve	  of	  the	  thirty	  helix	  III	  positions	  in	  MS1	  differed	  from	  corresponding	  wildtype	  positions	  when	  both	  sequences	  were	  in	  the	  presence	  of	  p65.	  	  Most	  of	  the	  discrepant	  SHAPE	  intensities	  were	  higher	  in	  wildtype	  p65	  bound	  helix	  III	  nucleotides	  than	  in	  MS1.	  	  Only	  G97	  was	  higher	  in	  MS1	  than	  in	  wildtype	  when	  tTERs	  were	  bound	  to	  p65.	  	  This	  discrepancy	  of	  SHAPE	  signatures	  suggested	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differing	  secondary	  structures	  between	  MS1	  and	  wildtype	  tTER	  in	  the	  presence	  of	  p65.	  
	  
4. MS2	  SHAPE	  Reactivities	  MS2	  tTER	  did	  not	  significantly	  change	  SHAPE	  intensities	  upon	  binding	  p65.	  	  Helix	  II	  was	  well	  formed	  as	  was	  helix	  IV.	  	  Decreased	  conformational	  flexibility	  was	  observed	  in	  the	  TBE	  and	  template	  regions	  as	  indicated	  in	  Figure	  4.8.	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a. Helix	  I	  	  The	  SHAPE	  reactivities	  of	  MS2	  helix	  I	  nucleotides	  were	  in	  agreement	  with	  the	  predicted	  structure	  of	  wild	  type	  tTER	  in	  both	  bound	  and	  protein	  free	  MS1	  as	  nucleotides	  103	  –	  107	  were	  generally	  not	  modified	  by	  1M7	  at	  all.	  	  Positions	  were	  negligibly	  more	  flexible	  in	  the	  presence	  of	  p65.	  	  Despite	  using	  an	  internal	  primer,	  we	  were	  unable	  to	  resolve	  nucleotides	  5’	  of	  nucleotide	  C39	  instead	  of	  U10	  as	  in	  wild	  type	  tTER.	  	  Therefore,	  we	  did	  not	  quantify	  bands	  corresponding	  to	  nucleotides	  4-­‐8	  that	  are	  predicted	  to	  form	  one	  half	  of	  the	  base	  pairs	  in	  helix	  I.	  	  The	  nucleotides	  108	  -­‐	  111	  that	  are	  predicted	  to	  separate	  helices	  I	  and	  IV	  in	  the	  wildtype	  sequence	  showed	  enhanced	  1M7	  modification	  upon	  binding	  p65	  in	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positions	  A110	  and	  A111.	  	  The	  other	  nucleotides	  that	  separate	  helix	  I	  from	  helix	  IV	  did	  not	  change	  much	  significantly	  upon	  binding	  p65.	  	  Nucleotide	  A108	  was	  unmodified	  in	  both	  free	  in	  solution	  and	  tTERT	  bound	  wildtype	  tTER	  as	  well	  as	  when	  wild	  type	  tTER	  was	  bound	  by	  p65.	  	  A108	  remained	  unmodified	  in	  both	  free	  in	  solution	  and	  p65	  bound	  MS2	  tTER.	  	  	  Like	  A108,	  G109	  was	  unreactive	  in	  all	  tested	  wild	  type	  conditions.	  	  Although	  G109	  in	  MS1	  was	  not	  modified	  by	  1M7	  in	  the	  presence	  of	  p65,	  G109	  was	  moderately	  modified	  (~0.5)	  when	  free	  in	  solution.	  	  Position	  A110	  was	  very	  reactive	  in	  both	  free	  in	  solution	  and	  tTERT	  bound	  wildtype	  tTER	  while	  only	  displaying	  moderate	  reactivity	  in	  p65	  bound	  states.	  	  A110	  went	  from	  unreactive	  in	  free	  in	  solution	  MS2	  (~0.1)	  to	  moderately	  reactive	  in	  p65	  bound	  states	  (~0.5).	  	  	  	  Position	  A111	  presented	  moderate	  1M7	  modification	  under	  all	  experimental	  conditions	  used	  for	  wildtype	  tTER	  and	  continued	  to	  present	  moderate	  modification	  under	  both	  experimental	  conditions	  for	  MS2.	  The	  nucleotide	  positions	  100	  –	  102	  are	  predicted	  to	  separate	  helix	  I	  from	  the	  pseudoknot	  domain	  in	  wildtype	  tTER.	  	  U102	  was	  moderately	  reactive	  in	  both	  free	  in	  solution	  and	  tTERT	  bound	  wild	  type	  tTER	  but	  became	  very	  reactive	  when	  bound	  by	  p65.	  	  U102	  was	  unreactive	  in	  both	  free	  in	  solution	  and	  p65	  bound	  MS2.	  	  Position	  A101	  was	  not	  determined	  for	  free	  in	  solution	  wildtype	  tTER	  but	  was	  unreactive	  in	  tTERT	  bound	  states.	  	  A101	  was	  moderately	  modified	  in	  p65	  bound	  wildtype	  (~0.6).	  	  MS2	  tTER	  position	  A101	  was	  unmodified	  in	  states	  where	  the	  p65	  protein	  was	  not	  present,	  but	  was	  highly	  reactive	  when	  bound	  by	  the	  protein	  (~1.35).	  	  A100	  on	  the	  other	  hand	  went	  from	  unreactive	  to	  moderately	  reactive	  as	  wildtype	  bound	  the	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tTERT	  protein.	  	  While	  A100	  remained	  unreactive	  in	  the	  presence	  of	  p65	  for	  wildtype	  tTER	  (~	  0.3),	  A100	  changed	  from	  moderately	  to	  highly	  reactive	  as	  MS2	  bound	  p65(~	  0.5	  à	  1.0)	  like	  in	  MS1	  tTER.	  	  	  Almost	  all	  of	  the	  wildtype	  nucleotides	  at	  positions	  10	  through	  19	  that	  are	  predicted	  to	  separate	  helices	  I	  and	  II	  were	  unreactive	  to	  NMIA	  or	  M7	  modification	  in	  the	  presence	  of	  tTERT,	  p65,	  or	  just	  free	  in	  solution.	  	  Only	  positions	  11,	  12,	  and	  14	  were	  moderately	  reactive	  when	  not	  bound	  by	  protein.	  	  However,	  MS2	  positions	  16	  and	  17	  both	  transitioned	  from	  moderately	  reactive	  (~0.7)	  to	  unreactive.	  	  Nucleotides	  15-­‐CAUU-­‐18,	  are	  predicted	  to	  form	  a	  tTERT-­‐binding	  site	  that	  acts	  in	  conjunction	  with	  the	  base	  of	  helix	  II	  and	  the	  template	  boundary	  element	  further	  downstream.55	  Moderate	  reactivities	  observed	  in	  the	  MS2	  tTERT	  binding	  site	  is	  consistent	  with	  1M7	  reporting	  on	  both	  reactive	  and	  unreactive	  tTER	  populations.	  	  The	  high	  affinity	  tTERT	  binding	  site	  could	  be	  oscillating	  between	  single	  stranded	  and	  base	  paired	  states	  as	  MS2	  bound	  p65.	  	  We	  are	  unable	  to	  comment	  on	  the	  tTERT-­‐binding	  site	  of	  MS2	  mutant	  tTER.	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b. Helix	  II	  As	  Figure	  4.10	  shows,	  MS2	  helix	  II	  appeared	  to	  be	  well	  formed	  in	  both	  free	  in	  solution	  and	  p65-­‐bound	  tTERs	  as	  the	  predicted	  helix	  II	  base	  pairs	  remained	  largely	  unmodified.	  Nucleotides	  19	  –	  25	  and	  31-­‐37,	  including	  the	  two	  adenine	  nucleotides	  A22	  and	  A34	  that	  were	  predicted	  to	  be	  unpaired,	  showed	  no	  significant	  changes	  in	  1M7	  intensities	  as	  the	  p65	  protein	  bound	  tTER.	  	  Stem	  loop	  II	  nucleotides	  26	  -­‐	  30	  were	  unreactive	  in	  the	  presence	  of	  p65	  but	  highly	  reactive	  when	  free	  in	  solution.	  	  Mirroring	  wildtype	  intensities,	  nucleotide	  A28	  showed	  the	  absolute	  largest	  decrease	  in	  SHAPE	  reactivity	  of	  any	  other	  tTER	  nucleotide	  when	  bound	  to	  p65,	  while	  U30	  showed	  the	  second-­‐largest	  decrease.	  	  	  
	   132	  
	  
c. Template	  Boundary	  Element	  SHAPE	  intensities	  in	  the	  TBE	  region	  (positions	  38-­‐42)	  of	  p65	  bound	  MS2	  tTER	  were	  consistent	  with	  a	  well-­‐structured	  region	  as	  all	  of	  the	  nucleotides	  observed	  in	  this	  region	  were	  unreactive	  as	  shown	  in	  Figure	  4.11.	  	  Positions	  C39	  and	  A40	  both	  went	  from	  moderately	  reactive	  to	  unreactive	  in	  the	  presence	  of	  p65	  (~	  0.6	  and	  0.4)	  in	  MS2.	  	  	  	  
d. Template	  	  The	  template	  region	  of	  p65	  bound	  MS2	  tTER	  was	  highly	  structured	  as	  all	  positions	  demonstrated	  low	  modification	  by	  1M7.	  	  Figure	  4.11	  shows	  MS2	  template	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nucleotides	  were	  mostly	  unmodified	  in	  solution	  state	  wildtype	  tTER	  as	  only	  positions	  A44,	  A50,	  and	  A51	  displayed	  moderate	  reactivities	  (~	  0.6,	  0.7,	  and	  0.55	  respectively).	  	  A	  similar	  moderate	  modification	  pattern	  was	  observed	  in	  tTERT	  bound	  wildtype	  tTER	  as	  position	  A44	  decreased	  to	  about	  (~	  0.5)	  and	  position	  A50	  decreased	  to	  about	  (~	  0.6).	  MS2	  resembled	  MS1	  and	  wild	  type	  tTER	  p65	  bound	  secondary	  structural	  states	  as	  all	  were	  unreactive.	  	  MS2	  RNA	  bound	  by	  p65	  SHAPE	  intensities	  did	  not	  resemble	  solution	  state	  or	  tTERT	  bound	  wildtype	  tTER	  though.	  	  There	  was	  no	  higher	  modification	  observed	  at	  positions	  A44	  or	  A50	  in	  p65	  bound	  MS2.	  	  Although	  all	  three	  of	  the	  p65	  bound	  sequences	  of	  tTER	  attain	  similar	  conformations,	  the	  secondary	  and	  tertiary	  structure	  of	  the	  template	  region	  in	  MS2	  is	  probably	  different	  from	  free	  in	  solution	  and	  reverse	  transcriptase	  bound	  wild	  type	  tTER.	  MS2	  RNA	  that	  was	  free	  in	  solution	  had	  a	  different	  SHAPE	  signature	  than	  that	  produced	  by	  any	  of	  the	  other	  wild	  type	  experimental	  conditions.	  	  There	  appeared	  to	  be	  characteristics	  of	  solution	  state	  and	  minimally	  active	  tTERT	  bound	  wildtype	  tTER	  present.	  	  Solution	  state	  wildtype	  characteristics	  were	  observed	  in	  the	  MS2	  positions	  45	  –	  49	  that	  remained	  unmodified	  upon	  binding	  p65.	  	  The	  tTERT	  bound	  characteristics	  were	  displayed	  in	  the	  relatively	  high	  intensities	  observed	  in	  positions	  A44,	  A50,	  and	  A51.	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e. TRE	  The	  SHAPE	  profile	  of	  the	  TRE	  nucleotides	  in	  solution	  state	  MS2	  shown	  in	  figure	  4.12	  was	  consistent	  with	  formation	  of	  the	  wildtype	  misfolded	  solution	  state	  helix	  III	  and	  not	  consistent	  with	  being	  single	  stranded	  to	  position	  the	  template	  nucleotides	  into	  the	  tTERT	  active	  site.	  	  	  Positions	  54	  –	  64	  were	  all	  unmodified	  by	  1M7	  in	  the	  absence	  of	  p65,	  suggesting	  these	  nucleotides	  were	  in	  a	  helical	  state.	  	  	  	  In	  the	  absence	  of	  p65,	  nucleotide	  positions	  66	  –	  68	  were	  consistent	  with	  states	  containing	  the	  misfolded	  wildtype	  solution	  state	  helix	  III	  and	  with	  states	  containing	  single	  stranded	  load	  bearing	  shafts	  as	  in	  the	  in	  vitro	  reconstituted	  tTER-­‐tTERT	  complex.	  	  As	  expected,	  more	  moderate	  to	  high	  levels	  of	  1M7	  modification	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were	  observed,	  consistent	  with	  these	  positions	  being	  in	  loop	  like	  in	  solution	  state	  wildtype	  tTER.	  	  The	  high	  acylation	  by	  1M7	  of	  these	  free	  in	  solution	  MS2	  nucleotides	  were	  also	  consistent	  with	  states	  containing	  single	  stranded	  load	  bearing	  shafts	  as	  in	  the	  in	  vitro	  reconstituted	  tTER-­‐tTERT	  complex.	  	  SHAPE	  intensities	  of	  MS2	  template	  recognition	  element	  nucleotides	  generally	  became	  less	  modified	  by	  1M7	  in	  the	  presence	  of	  p65,	  consistent	  with	  stabilization	  of	  the	  elongated	  helix	  formed	  by	  free	  in	  solution	  wildtype	  tTER.	  	  	  
	  
f. Helix	  IV	  Helix	  IV	  nucleotides	  appeared	  to	  occupy	  states	  that	  were	  not	  observed	  in	  corresponding	  positions	  in	  wildtype	  and	  MS1	  tTER.	  	  Helix	  IV	  MS2	  SHAPE	  intensities	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were	  not	  generally	  protected	  from	  1M7	  acylation	  upon	  binding	  p65	  as	  in	  wildtype	  and	  MS1.	  	  Rather,	  	  as	  shown	  in	  Figure	  4.13,	  SHAPE	  intensities	  of	  all	  helix	  IV	  nucleotides	  displayed	  similar	  levels	  of	  1M7	  modification,	  regardless	  of	  the	  presence	  of	  p65.	  	  Stem	  loop	  4	  and	  the	  GA	  bulge	  SHAPE	  intensities	  were	  not	  easily	  distinguishable	  from	  base	  pairs	  predicted	  to	  base	  pair.	  	  	  Like	  in	  MS1,	  but	  unlike	  wildtype	  tTER,	  reduced	  acylation	  of	  bulged	  nucleotides	  at	  positions	  117	  and	  125-­‐127	  was	  not	  observed.	  
	  
g. Helix	  III	  The	  pseudoknot	  region	  begins	  at	  position	  A69	  and	  ends	  at	  position	  U99	  while	  the	  MS2	  mutant	  altered	  nucleotide	  positions	  83	  –	  87	  that	  are	  predicted	  to	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form	  the	  GC	  rich	  Helix	  IIIa	  of	  the	  pseudoknot.	  	  Native	  gel	  electrophoresis	  of	  free	  in	  solution	  MS2	  revealed	  a	  three-­‐dimensional	  conformation	  that	  differed	  greatly	  from	  the	  wildtype	  sequence	  as	  evidenced	  by	  the	  large	  change	  in	  migration	  rates	  (see	  Figure	  4.1).	  	  Therefore,	  we	  expected	  the	  SHAPE	  signatures	  of	  the	  respective	  pseudoknot	  regions	  to	  differ	  from	  each	  other.	  	  	  Solution	  state	  MS2	  did	  not	  exhibit	  SHAPE	  intensities	  that	  were	  consistent	  with	  base	  pairing	  in	  the	  altered	  nucleotides	  as	  all	  nucleotides	  except	  for	  position	  84	  exhibited	  moderate	  reactivities	  (see	  Figure	  4.14).	  	  Only	  eight	  of	  the	  free	  in	  solution	  MS2	  helix	  III	  nucleotides	  between	  positions	  69	  –	  99	  were	  unmodified	  by	  1M7.	  	  This	  contrasted	  MS1	  and	  wildtype	  helix	  III	  nucleotides	  as	  most	  of	  their	  solution	  state	  nucleotides	  were	  not	  acylated	  by	  1M7.	  	  All	  but	  9	  and	  12	  nucleotide	  positions	  in	  MS1	  and	  wildtype	  tTER	  (respectively)	  displayed	  low	  SHAPE	  intensities.	  	  The	  high	  SHAPE	  intensities	  observed	  in	  MS2	  helix	  III	  nucleotides	  suggested	  a	  state	  that	  had	  more	  conformational	  flexibility	  than	  both	  MS1	  and	  wildtype	  tTER.	  	  The	  increased	  conformational	  entropy	  in	  MS2	  helix	  III	  nucleotides	  as	  evidenced	  by	  the	  generally	  enhanced	  1M7	  modification	  at	  these	  positions	  was	  bolstered	  by	  native	  gel	  electrophoresis	  of	  MS2	  as	  it	  migrated	  slower	  than	  all	  sequences	  tested	  (see	  Figure	  4.1).	  	  The	  propensity	  for	  MS2	  helix	  III	  nucleotides	  to	  have	  more	  conformational	  flexibility	  than	  both	  MS1	  and	  wildtype	  tTERs	  and	  to	  interact	  with	  the	  polyactylamide	  matrix	  more	  often	  than	  the	  other	  tTER	  sequences	  could	  explain	  why	  protein	  free	  MS2	  migrates	  slower	  than	  protein	  free	  MS1	  and	  wildtype	  tTERs.	  	  	  MS2	  mutant	  RNA	  that	  was	  bound	  by	  p65	  also	  displayed	  a	  SHAPE	  signature	  that	  was	  different	  from	  wildtype	  and	  MS1	  p65	  bound	  tTER.	  	  The	  moderate	  to	  high	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levels	  of	  1M7	  modification	  of	  MS2	  helix	  III	  nucleotides	  was	  inconsistent	  with	  both	  MS1	  and	  wild	  type	  tTER	  that	  displayed	  low	  levels	  of	  modification	  in	  nucleotides	  between	  nucleotides	  69	  –	  84	  in	  the	  presence	  of	  p65.	  	  G85	  was	  moderately	  reactive	  in	  wildtype	  and	  unreactive	  in	  MS1.	  	  Positions	  86	  –	  89	  had	  similar	  SHAPE	  reactivities.	  	  	  	  	  	  MS2	  secondary	  structure	  of	  helix	  III	  nucleotides	  was	  probably	  similar	  to	  wildtype,	  although	  MS2	  displayed	  generally	  higher	  SHAPE	  intensities	  than	  wildtype	  positions.	  	  All	  but	  seven	  MS2	  Helix	  III	  nucleotides	  had	  the	  same	  classification	  of	  SHAPE	  intensity	  as	  wildtype	  in	  the	  presence	  of	  p65.	  	  MS2	  positions	  69,	  80,	  81,	  87,	  88,	  93,	  and	  97	  were	  generally	  acylated	  more	  by	  1M7	  than	  wildtype	  tTER.	  	  Only	  position	  88	  had	  a	  higher	  SHAPE	  intensity	  in	  wildtype	  tTER	  than	  in	  MS2.	  	  Conversely,	  16	  of	  30	  MS2	  helix	  III	  residues	  had	  higher	  SHAPE	  intensities	  than	  the	  corresponding	  MS1	  intensities.	  	  In	  fact,	  only	  position	  A89	  in	  MS1	  helix	  III	  had	  a	  higher	  rate	  of	  1M7	  modification	  than	  MS2.	  	  The	  higher	  intensities	  in	  MS2	  helix	  III	  may	  be	  indicative	  of	  higher	  conformational	  entropy	  than	  in	  wildtype	  and	  MS1	  helix	  III	  conformations.	  	  MS2	  probably	  has	  a	  different	  conformation	  than	  wildtype	  and	  MS1	  tTERs	  in	  both	  the	  free	  in	  solution	  and	  p65	  bound	  states.	  	  	  	  Only	  one	  MS2	  position	  had	  the	  same	  classification	  of	  SHAPE	  intensity	  as	  wildtype	  in	  the	  presence	  of	  p65.	  	  Position	  79	  was	  moderately	  reactive	  in	  both	  sequences.	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5. MS1	  /	  MS2	  SHAPE	  reactivities	  In	  general,	  MS1	  /	  MS2	  SHAPE	  intensities	  were	  reduced	  in	  the	  presence	  of	  p65.	  	  However,	  we	  were	  unable	  to	  quantify	  nucleotide	  positions	  upstream	  of	  position	  10	  and	  downstream	  of	  position	  102.	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a. Helix	  II	  As	  Figure	  4.16	  shows,	  MS1	  /	  MS2	  helix	  II	  did	  not	  appear	  to	  be	  as	  well	  formed	  in	  both	  free	  in	  solution	  and	  p65-­‐bound	  tTERs.	  	  The	  predicted	  helix	  II	  base	  pairs	  were	  moderately	  reactive	  in	  the	  absence	  of	  p65	  and	  unreactive	  in	  the	  presence	  of	  p65.	  	  Only	  nucleotide	  position	  A28	  was	  significantly	  altered	  in	  the	  presence	  of	  p65	  as	  it	  transitioned	  from	  moderately	  reactive	  to	  unreactive.	  	  Stem	  loop	  II	  nucleotides	  26	  –	  30	  did	  not	  display	  SHAPE	  intensities	  above	  “unreactive”	  whether	  in	  the	  presence	  or	  absence	  of	  p65.	  	  	  Nucleotides	  19	  –	  25	  and	  31-­‐37,	  including	  the	  two	  adenine	  nucleotides	  A22	  and	  A34	  that	  were	  predicted	  to	  be	  unpaired,	  showed	  no	  significant	  changes	  in	  1M7	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intensities	  as	  the	  p65	  protein	  bound	  tTER	  except	  for	  position	  20.	  	  Stem	  loop	  II	  nucleotides	  26	  -­‐	  30	  were	  unreactive	  in	  the	  presence	  of	  p65	  but	  more	  reactive	  when	  free	  in	  solution.	  	  Mirroring	  wildtype	  intensities,	  nucleotide	  A28	  showed	  the	  absolute	  largest	  decrease	  in	  SHAPE	  reactivity	  of	  any	  other	  tTER	  nucleotide	  when	  bound	  to	  p65.	  	  
	  
b. Template	  Boundary	  Element	  SHAPE	  intensities	  in	  the	  TBE	  region	  (positions	  38-­‐42)	  of	  p65	  bound	  MS1	  /	  MS2	  tTER	  were	  consistent	  with	  a	  well-­‐structured	  region	  as	  all	  of	  the	  nucleotides	  observed	  in	  this	  region	  were	  unreactive	  as	  shown	  in	  Figure	  4.17.	  	  Positions	  38	  –	  41	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were	  all	  moderately	  reactive	  in	  the	  absence	  of	  p65.	  	  Other	  positions	  were	  unreactive	  when	  free	  in	  solution.	  	  All	  TBE	  positions	  became	  unreactive	  upon	  binding	  p65.	  	  	  	   c. Template	  The	  template	  region	  of	  p65	  bound	  MS1	  /	  MS2	  tTER	  was	  highly	  structured	  as	  all	  positions	  demonstrated	  low	  modification	  by	  1M7.	  	  Figure	  4.17	  shows	  four	  of	  nine	  MS1	  /	  MS2	  template	  nucleotides	  were	  at	  least	  moderately	  modified	  when	  free	  in	  solution.	  	  Positions	  44,	  48,	  and	  49	  all	  displayed	  moderate	  intensities	  in	  the	  absence	  of	  p65.	  	  Position	  50	  was	  however	  highly	  modified	  when	  protein	  free.	  	  	  	  MS1	  /	  MS2	  resembled	  MS1,	  MS2,	  and	  wild	  type	  tTER	  p65	  bound	  secondary	  structural	  states	  as	  all	  templates	  were	  unmodified	  by	  1M7.	  	  	  MS1	  /	  MS2	  RNA	  bound	  by	  p65	  SHAPE	  intensities	  did	  not	  resemble	  solution	  state	  or	  tTERT	  bound	  wildtype	  tTER	  however.	  	  There	  was	  no	  higher	  modification	  observed	  at	  positions	  A44	  or	  A50	  in	  p65	  bound	  MS1	  /	  MS2.	  	  Although	  all	  four	  of	  the	  p65	  bound	  sequences	  of	  tTER	  attain	  similar	  conformations,	  the	  secondary	  and	  tertiary	  structure	  of	  the	  template	  region	  in	  MS2	  is	  probably	  different	  from	  free	  in	  solution	  and	  reverse	  transcriptase	  bound	  wild	  type	  tTER.	  MS1	  /	  MS2	  tTER	  that	  was	  free	  in	  solution	  had	  a	  different	  SHAPE	  signature	  than	  that	  produced	  by	  any	  of	  the	  other	  wild	  type	  experimental	  conditions.	  	  There	  appeared	  to	  be	  characteristics	  of	  solution	  state	  and	  minimally	  active	  tTERT	  bound	  wildtype	  tTER	  present.	  	  Solution	  state	  wildtype	  characteristics	  were	  observed	  in	  the	  MS2	  positions	  45	  –	  49	  that	  remained	  unmodified	  upon	  binding	  p65.	  	  The	  tTERT	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bound	  characteristics	  were	  displayed	  in	  the	  relatively	  high	  intensities	  observed	  in	  positions	  A44,	  C48,	  C49,	  and	  A50.	  	  	  
	  
d. TRE	  The	  SHAPE	  profile	  of	  the	  TRE	  nucleotides	  in	  solution	  state	  MS1	  /	  MS2	  was	  consistent	  with	  being	  single	  stranded	  to	  position	  the	  template	  nucleotides	  into	  the	  tTERT	  active	  site	  and	  not	  consistent	  with	  the	  wildtype	  solution	  state	  helix	  III.	  	  Figure	  4.	  18	  shows	  that	  about	  half	  of	  MS1	  /	  MS2	  TRE	  positions	  (52,	  55,	  56,	  58,	  and	  60	  –	  64)	  were	  unmodified	  in	  the	  absence	  of	  p65.	  	  The	  other	  nucleotide	  positions	  exhibited	  moderate	  to	  high	  SHAPE	  intensities.	  	  	  We	  expected	  to	  observe	  every	  nucleotide	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position	  between	  54	  and	  64	  to	  be	  unmodified	  in	  the	  absence	  of	  p65	  if	  those	  nucleotides	  were	  in	  a	  helical	  state	  as	  in	  the	  wildtype	  solution	  state	  helix	  III.	  	  In	  the	  absence	  of	  p65,	  nucleotide	  positions	  65	  –	  68	  were	  mostly	  consistent	  with	  states	  containing	  the	  misfolded	  wildtype	  solution	  state	  helix	  III.	  	  As	  expected,	  moderate	  to	  high	  levels	  of	  1M7	  modification	  were	  observed	  in	  all	  of	  these	  nucleotide	  positions,	  except	  for	  position	  68	  that	  was	  unmodified	  by	  1M7.	  	  The	  moderate	  activities	  were	  consistent	  with	  these	  nucleotides	  being	  in	  a	  loop,	  as	  predicted	  in	  wildtype	  solution	  state	  tTER.	  	  	  	  MS1	  /	  MS2	  SHAPE	  intensities	  when	  bound	  by	  p65	  were	  consistent	  with	  solution	  state	  wildtype	  helix	  III	  as	  positions	  54	  –	  64	  were	  all	  unmodified	  by	  1M7	  in	  the	  presence	  of	  p65.	  	  However,	  only	  MS1	  /	  MS2	  positions	  67	  and	  68	  were	  moderately	  reactive	  in	  the	  presence	  of	  p65.	  	  We	  expected	  to	  observe	  moderate	  to	  high	  SHAPE	  intensities	  in	  positions	  65	  –	  70	  if	  the	  wildtype	  solution	  state	  helix	  III	  persisted	  in	  p65	  bound	  MS1	  /	  MS2.	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e. Helix	  III	  The	  pseudoknot	  region	  begins	  at	  position	  A69	  and	  ends	  at	  position	  U99	  while	  the	  MS1	  /	  MS2	  mutant	  altered	  nucleotide	  positions	  70	  –	  73	  and	  83	  –	  87	  that	  are	  predicted	  to	  form	  the	  GC	  rich	  Helix	  IIIa	  of	  the	  pseudoknot.	  	  Native	  gel	  electrophoresis	  of	  free	  in	  solution	  MS1	  /	  MS2	  revealed	  a	  three-­‐dimensional	  conformation	  that	  differed	  greatly	  from	  the	  wildtype	  sequence	  as	  evidenced	  by	  the	  large	  change	  in	  migration	  rates	  (see	  Figure	  4.1).	  	  Therefore,	  we	  expected	  the	  SHAPE	  signatures	  of	  the	  respective	  pseudoknot	  regions	  to	  differ	  from	  each	  other.	  	  	  There	  was	  little	  appreciable	  difference	  between	  the	  SHAPE	  intensities	  of	  free	  in	  solution	  and	  p65	  bound	  MS1	  /	  MS2	  nucleotides.	  	  MS1	  /	  MS2	  SHAPE	  intensities	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were	  most	  consistent	  with	  a	  pseudoknotted	  helix	  III	  in	  both	  protein	  free	  and	  p65	  bound	  states.	  	  Helix	  IIIa	  nucleotides	  were	  mostly	  unmodified	  as	  only	  free	  in	  solution	  positions	  85	  and	  86	  had	  moderate	  reactivities.	  	  Positions	  76	  –	  82	  that	  comprise	  one	  half	  of	  helix	  IIIb	  base	  pairs	  were	  mostly	  unmodified	  by	  1M7.	  	  Only	  free	  in	  solution	  positions	  79	  and	  80	  and	  p65	  bound	  79	  –	  81	  displayed	  moderate	  reactivities.	  	  The	  other	  half	  of	  helix	  IIIb	  nucleotides	  all	  displayed	  at	  least	  moderate	  reactivities,	  which	  was	  inconsistent	  with	  these	  nucleotides	  participating	  in	  base	  pair	  interactions.	  	  Interestingly,	  many	  of	  those	  nucleotides	  that	  are	  predicted	  to	  be	  single	  stranded	  in	  the	  pseudoknotted	  state	  displayed	  moderate	  to	  high	  SHAPE	  intensities.	  	  Only	  p65	  bound	  positions	  74	  and	  75	  and	  free	  in	  solution	  position	  75	  were	  unmodified	  by	  1M7.	  	  MS1	  /	  MS2	  helix	  III	  nucleotides	  were	  the	  most	  consistent	  with	  being	  pseudoknotted	  of	  all	  of	  the	  sequences	  tested.	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6. Mutant	  SHAPE	  Reactivity	  Comparison	  
a. SHAPE	  Reactivities	  of	  Free	  in	  Solution	  Mutant	  RNAs	  	  SHAPE	  intensities	  in	  helices	  I,	  II,	  IV,	  and	  the	  TBE	  of	  free	  in	  solution	  MS1,	  MS2,	  and	  MS1	  /	  MS2	  mutant	  tTERs	  were	  all	  consistent	  with	  wildtype	  secondary	  structure	  predictions	  made	  in	  chapter	  II	  as	  nucleotides	  remained	  unchanged	  by	  the	  mutations	  of	  the	  tTER	  pseudoknot	  region	  nucleotides.	  	  Figure	  4.20	  shows	  that	  when	  the	  free	  in	  solution	  mutant	  SHAPE	  intensities	  are	  subtracted	  from	  wildtype	  intensities	  at	  each	  nucleotide	  position,	  helices	  I,	  II,	  and	  IV	  secondary	  structures	  are	  not	  significantly	  altered	  by	  the	  mutations.	  	  However,	  figure	  4.20	  also	  shows	  that	  helix	  loop	  II,	  the	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template	  region	  and	  adjacent	  nucleotides,	  as	  well	  as	  the	  pseudoknot	  region	  have	  unique	  SHAPE	  profiles	  for	  each	  sequence.	  	  	  
	  	  
b. SHAPE	  Reactivities	  Of	  P65	  Bound	  Mutant	  Rnas	  Figure	  4.21	  shows	  that	  when	  the	  p65	  bound	  mutant	  SHAPE	  intensities	  are	  subtracted	  from	  wildtype	  intensities	  at	  each	  nucleotide	  position,	  helices	  I,	  II,	  and	  IV	  secondary	  structures	  are	  not	  significantly	  altered	  by	  the	  mutations.	  	  There	  was	  not	  an	  appreciable	  difference	  in	  p65	  bound	  SHAPE	  intensities	  for	  nearly	  all	  nucleotide	  positions,	  regardless	  of	  tTER	  sequence.	  	  Figure	  4.21	  also	  shows	  that	  the	  only	  region	  that	  displayed	  variable	  1M7	  modification	  rates	  was	  helix	  III.	  	  It	  is	  evident	  that	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mutating	  helix	  IIIa	  nucleotides	  drastically	  alters	  the	  conformation	  of	  the	  entire	  helix	  III.	  	  	  
	  	  
7. Secondary	  Structural	  Predictions	  
a. MS1	  The	  Fold	  program	  produced	  four	  predictions	  based	  upon	  solution	  state	  MS1	  SHAPE	  restraints.	  	  We	  concentrated	  on	  the	  only	  one	  containing	  the	  base	  pairs	  predicted	  for	  helix	  II.	  	  That	  prediction,	  which	  we	  call	  MS1fold,	  formed	  helices	  I,	  II,	  and	  IV	  as	  predicted.106,127,158	  However,	  a	  base	  pair	  pattern	  unique	  from	  solution	  state,	  tTERT	  bound,	  and	  p65	  bound	  was	  predicted	  in	  the	  pseudoknot	  domain	  as	  shown	  in	  Figure	  4.22.	  	  The	  twelve	  base	  pairs	  made	  in	  the	  MS1	  pseudoknot	  region	  
	   150	  
was	  the	  identical	  number	  of	  base	  pairs	  made	  in	  wild	  type	  solution	  state	  tTER.	  	  This	  explains	  the	  similar	  migration	  rates	  through	  non-­‐denaturing	  polyacrylamide	  gel	  matrices.	  	  The	  different	  base	  pair	  pattern	  could	  also	  explain	  the	  small	  difference	  in	  observed	  migration	  rates	  between	  the	  two	  sequences,	  as	  the	  structure	  formed	  in	  solution	  state	  MS1	  may	  be	  slightly	  more	  compact	  than	  misfolded	  wildtype	  helix	  III.	  	  Both	  the	  ProbKnot	  and	  the	  ShapeKnots	  program	  produced	  identical	  predictions	  as	  the	  Fold	  program.	  	  The	  Fold	  program	  again	  produced	  four	  predictions	  based	  upon	  p65	  bound	  MS1	  SHAPE	  restraints.	  	  Again,	  we	  concentrated	  on	  the	  only	  one	  containing	  the	  base	  pairs	  predicted	  for	  helix	  II.	  	  This	  prediction	  was	  again	  distinct	  from	  all	  previous	  wildtype	  predictions	  as	  well	  as	  the	  solution	  state	  MS1	  predicted	  structure	  as	  shown	  in	  Figure	  4.22.	  	  We	  did	  not	  use	  the	  prediction	  produced	  by	  the	  ProbKnot	  program	  because	  it	  did	  not	  produce	  a	  secondary	  structure	  with	  helix	  II	  formed.	  	  The	  
ShapeKnots	  program	  did	  produce	  a	  helix	  II	  containing	  structure,	  but	  it	  also	  predicted	  long-­‐range	  base	  pairing	  interactions	  between	  nucleotides	  in	  the	  template	  recognition	  element	  and	  stem	  loop	  IV.	  	  Our	  3D	  model	  does	  not	  allow	  this	  type	  of	  interaction	  nor	  has	  it	  been	  predicted	  in	  any	  of	  the	  literature	  to	  our	  knowledge.	  	  We	  feel	  that	  the	  RNAstructure	  program	  was	  unable	  to	  correctly	  predict	  p65	  bound	  MS1	  secondary	  structure.	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b. MS2	  The	  Fold	  program	  produced	  two	  identical	  predictions	  based	  upon	  SHAPE	  intensities.	  	  Helices	  I,	  II,	  and	  IV	  base	  pairs	  were	  predicted	  to	  form	  in	  both	  protein	  free	  and	  p65	  bound	  MS2.	  	  A	  base	  pair	  pattern	  in	  helix	  III	  unique	  to	  MS2	  was	  predicted	  for	  protein	  free	  and	  p65	  bound	  MS2.	  	  There	  was	  no	  difference	  in	  base	  pair	  patterns	  predicted	  for	  free	  in	  solution	  and	  p65	  bound	  MS2.	  	  This	  lack	  of	  secondary	  structural	  change	  further	  bolsters	  our	  hypothesis	  that	  p65	  does	  not	  change	  the	  secondary	  structure	  of	  tTER	  upon	  binding.	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c. MS1	  /	  MS2	  The	  Fold	  program	  predicted	  two	  base	  pair	  patterns	  for	  MS1	  /	  MS2.	  	  The	  free	  in	  solution	  MS1	  /	  MS2	  base	  pair	  pattern	  predicted	  included	  those	  base	  pairs	  predicted	  to	  exist	  in	  helix	  IIIa.	  	  However,	  none	  of	  the	  helix	  IIIb	  base	  pairs	  were	  predicted	  for	  free	  in	  solution	  MS1	  /	  MS2.	  	  The	  p65	  bound	  base	  pair	  pattern	  predicted	  of	  MS1	  /	  MS2	  differed	  from	  the	  free	  in	  solution	  pattern.	  	  Helix	  II	  and	  III	  base	  pairs	  in	  MS1	  /	  MS2	  differed	  from	  any	  base	  pair	  pattern	  predicted	  in	  this	  study.	  	  The	  lack	  of	  a	  well-­‐formed	  helix	  II	  was	  not	  supported	  by	  SHAPE	  intensities.	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Discussion	  Mutating	  pseudoknot	  nucleotides	  definitely	  altered	  the	  secondary	  structure	  of	  tTER	  as	  evidenced	  by	  native	  gel	  electrophoresis	  and	  SHAPE	  directed	  structural	  predictions.	  	  Native	  gel	  electrophoresis	  migration	  rates	  of	  mutant	  tTER	  sequences	  reflected	  altered	  pseudoknot	  structures	  in	  Figure	  4.1.	  	  Unique	  SHAPE	  probing	  profiles	  of	  mutant	  RNAs	  in	  Figures	  4.20	  and	  4.21	  indicated	  structural	  changes	  were	  localized	  to	  the	  pseudoknot	  region	  only.	  	  	  RNAstructure	  did	  not	  accurately	  predict	  the	  pseudoknot	  structure	  characteristic	  of	  active	  telomerase	  or	  the	  elongated	  helix	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III	  characteristic	  of	  protein-­‐free	  tTER.	  	  It	  was	  clear	  that	  mutating	  pseudoknot	  nucleotides	  prevented	  the	  base	  pair	  configurations	  predicted	  in	  Figure	  3.2.	  	  	  	  	  
CONCLUSIONS	  
	  	   The	  combination	  of	  SHAPE,	  RNAstructure,	  and	  previous	  biophysical	  studies	  has	  proven	  to	  be	  a	  productive	  in	  generating	  models	  of	  telomerase	  assembly.	  	  	  	  We	  found	  that	  the	  secondary	  structure	  of	  the	  pseudoknot	  region	  of	  tTER	  was	  dynamic	  in	  Chapters	  II	  and	  III.	  	  In	  Chapter	  IV,	  we	  also	  found	  that	  mutating	  the	  pseudoknot	  nucleotides	  disrupted	  helix	  III	  base	  pairs	  and	  telomerase	  activity	  but	  did	  not	  alter	  binding	  affinity	  of	  p65	  for	  helix	  IV.	  	  Binding	  of	  p65	  to	  the	  helix	  IV	  GA	  bulge	  helps	  to	  loosen	  the	  free	  in	  solution	  structure	  helix	  III	  by	  increasing	  entropy	  in	  torsion	  angles	  of	  nucleotide	  positions	  69-­‐99.	  	  The	  tTERT	  protein	  presumably	  recognizes	  and	  tightly	  binds	  the	  template	  boundary	  element	  to	  promote	  the	  final	  reorganization	  of	  the	  structure	  to	  the	  pseudoknot,	  freeing	  the	  template	  recognition	  element	  and	  the	  template	  for	  primer	  recognition	  and	  binding	  as	  shown	  in	  figure	  4.24.	  	  This	  thesis	  describes	  our	  ever-­‐expanding	  understanding	  of	  the	  role	  that	  non-­‐coding	  RNAs	  play	  in	  cellular	  biochemistry.155,157	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